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Chapter 1
Introduction and outline of the thesis
When cure is no longer possible, cancer patients enter the palliative phase in which 
several treatment options may be available. In this setting, anti-cancer drugs may prolong 
life while maintaining or sometimes improving quality of life (QoL). In addition, when 
systemic treatment is not available, palliative care of cancer-related symptoms may be of 
benefit. Currently available systemic treatment options consist of conventional cytotoxic 
therapy, hormonal therapy, immunotherapy and the so-called targeted therapies. 
Targeted therapy concerns the administration of a relatively new class of drugs that are 
specifically directed against one or more well-defined molecular targets that are relevant 
for carcinogenesis, cell cycle regulation, tumor progression, metastasis, tumor angio-
genesis and/or apoptosis. Today, the most successful drugs in this class are directed 
against the vascular endothelial growth factor (receptor) (VEGF(R)), the epidermal growth 
factor receptor (EGFR), the mammalian target of rapamycin’ (mTOR), BRAF, epidermal 
growth factor receptor 2 protein (HER2), platelet derived growth factor (PDGF), mitogen/
extracellular signal-regulated kinase (MEK), extracellular signal regulated kinase (ERK), 
anaplastic lymphoma kinase (ALK), c-kit  and cytotoxic T-Lymphocyte antigen 4 (CTLA-4). 
Although their mechanism of action is more tumor-specific compared to cytotoxic 
chemotherapy, treatment with targeted drugs is still associated with adverse events (AEs). 
The etiology of many of these AEs has not been clarified, which complicates their 
treatment. Since AEs may compromise the QoL of a patient, and targeted drugs may be 
indicated for a prolonged period of time (sometimes years), increased knowledge on this 
topic is urgently required. Adequate management of treatment-related AEs is therefore 
very important to allow patients the maximal benefit of treatment. 
In oncology clinical trials the incidence and severity of AEs is usually assessed by the 
treating medical oncologist with the use of the National Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI CTCAE) and graded in a score from I (mild) 
to V (death related to the AE). However, provider-reported ratings may not accurately or 
consistently represent the full effect of an AE on a patient, particularly when the AE is 
subjective, such as with fatigue, nausea or pain.1,2 Furthermore, reporting of AEs within a 
clinical trial is typically based on the incidence, and not on the duration of symptoms. In 
contrast to CTCAE assessment, patient-reported outcomes may provide a more detailed 
understanding of symptom data and their effects on functioning and well-being, including 
their development and impact over time.2
In this thesis we focus on three targeted drugs: sunitinib, sorafenib and cediranib. These 
drugs are directed against the VEGF receptor and are VEGF receptor tyrosine kinase 
inhibitors (VEGFR TKIs). Sunitinib and sorafenib are registered as mono-therapy for the 
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palliative treatment of several cancer types such as metastatic renal cell carcinoma 
(mRCC). Sunitinib is also registered for gastrointestinal stromal tumors (GIST), and 
neuroendocrine tumors of the pancreas (pancreasNET), sorafenib for the treatment of 
hepatocellular cancer (HPC) and differentiated thyroid cancer. Cediranib has anti-tumor 
activity as mono therapy or in combination in many cancers but is not yet registered. 
Aim of this thesis
The aim of this thesis is to provide better insight in treatment-related aspects of VEGFR 
TKIs like diarrhea, cognitive- and immune functioning, to assess the effects of these drugs 
on patient-reported outcomes as fatigue, QoL and depression, and to explore the 
palliative effects of a VEGFR TKI on malignant effusions. 
In Chapter 2 an introduction on targeted therapy is presented. Their mechanism of 
action, possible interactions with other drugs, and the toxicity are described. Furthermore 
the management of two frequently occurring side effects, i.e., hypertension during anti 
VEGF(R) therapy and skin toxicity induced by anti-EGFR therapy, is discussed.
 
Fatigue depression and QoL
Fatigue is one of the most frequently reported AEs of VEGF TKIs. Fatigue, even of low 
grade (1 or 2), may have a huge impact on the QoL. The incidence of fatigue in patients 
using sunitinib in phase I studies was 70% and was often dose limiting.3 and in phase II-III 
studies 27% - 51%.4,5 The causes of fatigue in patients with cancer are multifactorial and 
inter-related, although the precise underlying pathophysiology of the development of 
fatigue has yet to be elucidated.6 The pathophysiology of VEGFR TKI related fatigue 
remains unclear and is poorly understood.7 In Chapter 3 the incidence, cause and course 
of self-reported fatigue in patients before, during and after treatment with the VEGFR 
TKIs sunitinib and sorafenib, and its relation with QoL and depression is described. 
Additionally, the predictive value of self-reported fatigue, QoL and depression scores on 
progression free survival (PFS) and overall survival (OS) are explored. 
Cognitive functioning
Cognitive complaints have been reported in cancer patients treated with chemotherapy, 
as established by objective neuropsychological assessment.8 The effects of drugs like the 
VEGFR TKIs on cognitive functioning have not been studied previously. The VEGF pathway 
plays an important role in the biology of the central nervous system. Angiogenetic factors, 
especially VEGF, are involved in neurogenesis, neuroprotection and the pathogenesis of 
stroke, Alzheimer’s disease and motor neuron disease.9 Many VEGFR TKI-treated patients 
report problems with concentration and decreased memory function. In Chapter 4 two 
14
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patients are presented who developed a psychosis during sunitinib use. No studies have 
been performed on less severe cognitive impairments using validated neuropsychological 
tests during VEGFR TKI treatment. We hypothesized that cognitive dysfunctioning during 
VEGF inhibition is a substantial and underreported problem. For this reason we conducted 
a cross-sectional study to examine cognitive functioning and self-reported cognitive 
complaints during VEGFR TKI treatment (Chapter 5).
Diarrhea
All VEGFR TKIs may cause diarrhea. Diarrhea (grade 1-4) was observed in 53% of the 
patients treated with sunitinib, which was of grade 3 severity (CTCAE) in 5% of the 
patients.5 Diarrhea negatively influences the QoL. This is obvious for severe diarrhea, but 
also mild but chronic complaints can lead to social invalidity due to frequent urge to go to 
the bathroom, flatulence, or abdominal cramps. Diarrhea may necessitate dose reductions 
or interruptions, which may compromise the efficacy of treatment. Adequate treatment 
and prevention of diarrhea is therefore of utmost importance. However, in spite of its 
frequent occurrence, the etiology and pathophysiological mechanisms that lead to VEGFR 
TKIs treatment-related diarrhea have not yet been clarified. In Chapter 6 we described a 
patient who developed a severe exacerbation of Crohn`s disease during treatment with 
sunitinib. This patient was one of the reasons to start an explorative study with endoscopy 
of the upper and lower gastrointestinal tract, in patients with diarrhea during treatment 
with VEGFR TKIs, of which the results are reported in Chapter 7.
Malignant ascites and pleural effusion
Malignant ascites and pleural effusion are challenging clinical problems in cancer patients 
which have a major impact on QoL, especially when standard anti-cancer therapies are 
not available or no longer feasible. Although paracentesis, diuretics and shunting are 
commonly used treatments for malignant ascites, the evidence for their efficacy is weak 
and no data from prospective randomized trials are available.10 Therefore there is a need 
for more effective palliative treatments of malignant effusions. We observed that 
malignant effusions sometimes decreased during treatment with a VEGFR TKI. In addition, 
preclinical and clinical studies have shown that malignant effusion may be associated 
with high levels of VEGF in peripheral blood and malignant effusions.11,12 As a result we 
conducted a randomized phase II study with cediranib, to determine the effect and safety 
of cediranib as palliative treatment of malignant ascites or pleural effusion. The results 
are outlined in Chapter 8.
Influenza vaccination
To maintain QoL, efforts should be made to reduce comorbidities whenever possible. 
Prevention of a severe influenza infection by vaccination contributes to preserving QoL. 
15
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In cancer patients treated with chemotherapy, vaccination has shown to be safe, but 
during chemotherapy suboptimal antibody responses and in some studies even an 
absence of responsiveness have been reported.13 No data were available about the safety 
and efficacy of influenza vaccination in cancer patients treated with sunitinib or sorafenib. 
Data from, mainly animal, studies have shown that both sunitinib and sorafenib have 
effects on the immune system with varying clinical consequences.14,15 The way by which 
these agents affect the immune response to influenza vaccination is unknown. In Chapter 9 
we explored the antibody and cellular immune response on influenza vaccination in 
patients during treatment with sunitinib or sorafenib. In Chapter 10 a summary, general 
discussion and future perspectives are described.
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Chapter 2
Introduction
 
The therapeutic arsenal for the treatment of cancer is changing rapidly, in particular 
because the development of new class of drugs which are commonly being referred to as 
targeted therapies. These drugs have shown efficacy in several types of cancer, and the 
indication for their use is increasing rapidly.
Cancer develops through a multi-step carcinogenesis process which involves genetic 
aberrations and deregulation of pathways. Circulating cytokines, hormones and growth 
factors control the proliferation, differentiation, angiogenesis, apoptosis, function and 
mobility of the cell. Growth factors bind to their respective receptors on the cell surface 
which results in the transduction of the signal to the intracellular part by tyrosine kinase 
proteins. Depending on the signal a variety of processes that are relevant for cell growth 
and survival are initiated, such as angiogenesis, proliferation, apoptosis and metastasis.
Targeted therapies
Targeted therapies are characterized by having one or more well defined molecular 
targets that are relevant for carcinogenesis, cell cycle regulation, tumour progression, 
metastasis, tumour angiogenesis and/or apoptosis. Targeted therapies can be divided 
into two groups (see table 1): the monoclonal antibodies, binding to the extracellular part 
of the receptor or their ligand, and the small molecules, which inhibit the tyrosine kinase 
activity of the intracellular part of the receptor. Current targets of monoclonal antibodies 
include the vascular endothelial growth factor (VEGF) or its receptor (VEGFR), the 
epidermal growth factor receptor (EGFR), and the epidermal growth factor receptor 2 
protein (HER2/neu). Pathways/receptors affected by the tyrosine kinase inhibitors include 
VEGFR, EGFR, RAS/RAF/MEK/ERK, C-kit, flt-3, and the platelet-derived growth factor 
receptor (PDGFR). 
Toxicity of targeted therapies
Table 1 provides a list of the most commonly observed or severe toxicities of selected 
targeted agents which are currently being used in the clinic. The aetiology of many of 
these side effects, and the management of these events is mainly based on empirical 
findings. Some of these, such as diarrhoea and nausea, may be handled as occurring by 
conventional cytotoxic agents. In order to minimize side effects, one should be aware that 
many of these agents are metabolised in the liver by the CYP3A4 cytochrome P450 enzyme 
system (Table 1). 
Managing toxicities of targeted therapies
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Many other drugs are substrates (metabolized in the liver by CYP3A4), inducers or 
inhibitors or mixed inhibitors/inducers of the CYP3A4 enzyme. Drugs metabolized by the 
CYP3A4 enzyme system may compete with each other, leading to increased plasma 
concentrations of one or both drugs. Drugs known to induce CYP3A4 levels may decrease 
therapeutic levels of the targeted therapy. Examples of CYP3A4 inducers are 
carbamazepine, dexamethasone, phenobarbital, rifampycin, and St. John’s Wort. Drugs 
that inhibit CYP3A4 enzyme activity include cimetidine, claritromycin, cyclosporine, 
fluconazole, fluoxetine, omeprazole, ranitidine and grapefruit juice. For a more detailed 
list of CYP3A4 inducers and inhibitors see Deininger et al.1 Only a few pharmacokinetic 
drug interaction studies have been performed, and the preference for use of drugs 
without influence on the CYP3A4 enzyme in combination with imatinib, gefitinib, erlotinib, 
sunitinib and sorafenib is therefore mostly based on theoretical grounds. 
We will discuss the management of two common side effects of targeted therapy, 
hypertension and skin rash.
Managing hypertension in anti-VEGF(R) therapy
The mechanism of VEGF inhibition-related hypertension is not clearly understood, but a 
decreased production of nitric oxide has been proposed.2 Symptomatic cardiovascular 
toxicity related to hypertension in studies with bevacizumab, sunitinib and sorafenib is 
uncommon, but serious events have been reported with low frequency (<1%) such as 
hypertensive crisis, cerebrovascular events, myocardinfarct and the reversible posterior 
leukoencephalopathy syndrome (RPLS).3,4 Because of this as well as the fact that results 
from long-term follow-up after VEGF inhibition are not yet available, the management of 
hypertension is important.
A calcium channel blocker is a likely first choice to treat VEGF(R) targeting related 
hypertension because of its vasodilating effects. In the pivotal study in colorectal cancer 
by Hurwitz and colleagues.5 hypertension was controllable in all patients and no 
complications of hypertension were reported. Importantly, discontinuation of 
bevacizumab for hypertension was not required in any patient. There are no such studies 
with sunitinib or sorafenib, and their interactions with the CYP3A4 enzyme may pose a 
problem when used in combination with other drugs. Since calcium channel blockers are 
substrates of the CYP3A4 enzyme, amlodipine may be the drug of choice in this class of 
agents since it has a low interaction of CYP3A4. Angiotensin-converting enzyme inhibitors 
and diuretics have no interaction with CYP3A4. When beta blockers are used, atenolol is 
preferred due to its lack of metabolization in the liver. 
Before initiation of anti-VEGF therapy the baseline blood pressure should be recorded as 
reference value. When the diastolic blood pressure increases ≥ 20 mm Hg above baseline 
value or when blood pressure exceeds 150/100 mm Hg (grade 1 according to CTC), 
bevacizumab should be withheld and antihypertensive treatment should be initiated. A 
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possible treatment plan for hypertension is as follows. In case of insufficient effect (i.e. 
blood pressure not below CTC grade I), one should proceed to the next step: 
Step 1: start amlodipine 5 mg/day (when a calcium channel blocker is contraindicated, 
start atenolol 50 mg/day; Step 2: increase the amlodipine dose to 10 mg/day (when 
calcium channel blocker is contraindicated go to step 3); Step 3: add lisinopril 5 mg/day; 
Step 4: increase the lisinopril dose to 10-20 mg/day; Step 5: add hydrochlothiazide 25 mg/
day or start atenolol 50 mg/day. 
The decision to stop administering or decrease the dose of sunitinib or sorafenib at this 
moment depends on the blood pressure and possible accompanying symptoms and 
reaction on the treatment of the anti-hypertensive drugs. Bevacizumab administration is 
usually only resumed when blood pressure has decreased to values below CTC grade 1. 
Dose reductions of bevacizumab are currently not recommended. Anti-VEGF therapy 
should be permanently discontinued in any patient who experiences symptomatic 
cardiovascular toxicity resulting from hypertension. 
Managing skin toxicity induced by anti-EGFR therapy
Anti-EGFR therapies (cetuximab, panitumumab, erlotinib and gefitinib) are associated 
with various cutaneous side-effects like rash, hair modifications, paronychial inflammation 
and xerosis.6 These side-effects are the most common adverse events associated with 
these agents and occur in more than 50% of the patients.6 The rash is situated primarily 
on the face, neck and upper torso and is characterized by inter- and intrafollicular 
papulopustules, and usually occurs during the first 2 weeks of treatment.7 There appears 
to be a relationship with the occurrence of this toxicity and clinical efficacy. 
The terminology for these skin reactions varies greatly (rash, acne, acne form skin 
reaction, folliculitis, maculopapular skin rash etc).The aetiology of the skin toxicity is still 
unclear.6-8 EGFR is expressed and activated in many skin cells with the strongest 
expression in proliferating undifferentiated keratinocytes located in the basal epidermal 
layer and the outer root sheath of hair follicles.9 EGFR inhibition disturbs the balance 
between proliferation and differentiation of keratinocytes.9-11 Abnormal expression is 
implicated in epithelial tumour formation12 and epidermal hyper proliferation disorders 
such as psoriasis.13 
No evidenced-based recommendations for managing rash are currently available.7 
Emollients are advised to prevent and alleviate the skin dryness, and the rash may be 
covered with makeup.8 A possible treatment plan for acne form rash CTC grade ≤ 2 is as 
follows. If results are insufficient one should proceed to the next step. Step 1: topical 
antibiotics like erythromycin, clindamycin or metronidazole; Step 2: systemic antibiotic 
therapy with minocycline 100 mg/day; Step 3: topical retinoids (0,02% tretinoin cream) 2 
times/day. In the case of a CTC grade 3 folliculitis, the EGFR inhibitor should be interrupted 
until CTC ≤ grade 2. If a Staphylococcus aureus infection is confirmed, or a clinical 
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diagnosis of impetigo is made, consider topical mupirocin (BactrobanR). Pruritis may be 
treated with an oral antihistamine. For the treatment of non-folliculitis rash topical 
steroids (0.05% betamethasone cream) can be helpful.6 
Registered targeted therapies for solid tumours in 2015 in the Netherlands
Since 2007 there is an explosive development ongoing in the area of targeted therapies. 
Today many monoclonal antibodies and tyrosine kinase inhibitors are available and two 
protein kinase inhibitors. In Table 2 an overview is given of all drugs registered in The 
Netherlands in 2015 for solid tumors and their indication. 
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Abstract
Background
Fatigue is one of the most frequently reported side effects of the vascular endothelial 
growth factor receptor tyrosine kinase inhibitors (VEGFR TKIs). Aim of the study was to 
explore the incidence and course of self-reported fatigue, and its relation with QoL, 
depression and its possible predictive value for treatment outcome. 
Methods
A prospective trial was conducted in 74 patients starting on VEGFR TKIs. During the study 
3 questionnaires were completed by the patients: one day before start of treatment 
(baseline), 4 weeks after start, then every 3 months, on the day patients discontinued 
treatment, and 1 and 4 weeks later. Fatigue was measured by the Checklist Individual 
Strength (CIS20r), the European Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire (EORTC-QLQ-C30) for QoL and the Beck’s depression 
inventory for primary care (BDI-PC) for depression. 
Results
At baseline 36% of the patients were severely fatigued, and these patients had a lower 
QoL, more cancer related symptoms, more feelings of depression, less physical activity 
and more problems with role- emotional- and social functioning. After 16 weeks, 28 weeks 
and 1 week after discontinuation of treatment, 46%, 19% and 90%, respectively, of the 
patients were severely fatigued. Severe fatigue, depression and a low global QoL at 
baseline were predictive for time on treatment. Severe fatigue and depression were also 
predictive for overall survival. 
Conclusions
The high incidence of severe fatigue, depression and low QoL before, during and after 
treatment with VEGFR TKIs, legitimates attention from all health care professionals 
towards these symptoms. 
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Introduction
In the palliative phase several systemic treatment options are nowadays available for 
cancer patients. The goal of this treatment is to prolong survival, while maintaining or 
even improving quality of life is of equal importance. Targeted therapy concerns the 
administration of a class of drugs that are specifically directed against one or more well-
defined molecular targets in cancer cells. Today, the most effective drugs in this class are 
directed against the vascular endothelial growth factor receptor (VEGFR), the epidermal 
growth factor receptor (EGFR), the mammalian target of rapamycin inhibitors (mTORi) 
and BRAF. Many new drugs are becoming rapidly available against new targets or a 
combination of targets. Although their action is more tumor-specific compared to 
cytotoxic chemotherapy, treatment with targeted drugs is still associated with adverse 
events (AEs). Since treatment with targeted therapy is a chronic treatment, adequate 
management of AEs is very important in order to allow prolonged treatment and to 
minimize a decline in QoL. 
In oncologic trials the severity of AEs is usually assessed by the treating physician using 
the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI 
CTCAE). However, provider-reported ratings may not accurately or consistently depict the 
full effect of an AE on a patient, particularly when the AE is subjective, such as fatigue, 
nausea or pain.1,2 Furthermore, reporting of AEs from a clinical trial is typically based on 
overall frequency, neglecting the time course. In contrast to CTCAE assessment, patient-
reported outcomes may provide a more detailed understanding of symptom data and 
their effects on functioning and well-being, including their development and impact over 
time.1
Fatigue is a symptom that is frequently reported in cancer patients and it may adversely 
impact QoL because its effects on physical functioning, social functioning, activity level 
and emotional well-being.3 The causes of fatigue in patients with cancer are multifactorial 
and inter-related, although the precise underlying pathophysiology of the development 
of fatigue has yet to be elucidated.4 Fatigue can arise as a result of the cancer itself or as 
a side effect of cancer treatment. However, it is also possible that fatigue is a symptom of 
depression, and, alternatively, prolonged fatigue in itself can lead to depression.5 
Fatigue is also one of the most frequently reported AEs of the so-called receptor tyrosine 
kinase inhibitors (VEGFR TKIs) sunitinib and sorafenib, two oral targeted drugs directed 
against the VEGF receptor.6 Both drugs are registered as monotherapy for the palliative 
treatment of several cancer types like metastatic renal cell carcinoma (mRCC). The 
incidence of fatigue (assessed with NCI CTCAE) in patients using sunitinib in phase I 
studies was approximately 70% and often dose limiting,7 and occurred in phase II-III 
studies between 27% - 51%.8,9 In a phase III placebo-controlled trial of sorafenib the 
incidence of fatigue in the sorafenib group was 37% and in the placebo group 28%.10 
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The aim of this study was to assess the incidence and course of self-reported fatigue in 
patients before, during and after treatment with the VEGFR TKIs sunitinib and sorafenib 
and its relation with QoL, cancer related symptoms and depression. Furthermore we 
aimed to get more insight in the cause of fatigue in this patient group, by exploring 
several psychological, demographic and physical variables. 
Additionally, since self-reported pretreatment QoL in several advanced solid tumors and 
in mRCC patients on sorafenib and sunitinib appeared to be predictive for progression 
free survival (PFS)11,12 and even overall survival (OS),13,14 we also explored the predictive 
value of self reported fatigue and depression scores. 
Methods
Participants and procedure 
Patients with mRCC, gastrointestinal stromal tumors (GIST) and hepatocellular cancer 
(HPC) in whom treatment with the VEGFR TKIs sunitinib or sorafenib was planned were 
prospectively followed. Patients were recruited in 3 hospitals. Eligible patients were at 
least 18 years old. Patients with prior treatment with sunitinib, sorafenib or bevacizumab 
within 7 days of registration were excluded. We planned to include 100 patients, due to 
slower than expected inclusion, we closed the study after 74 patients. The study was 
approved by the Medical Ethics Review Committee Region Arnhem-Nijmegen and all 
participants gave written informed consent. This study was registered at ClinicalTrials.
gov, number NCT00979329.
Treatment 
Sunitinib was administered at a dose of 50 mg once daily for 4 weeks, followed by 2 weeks 
of rest, and sorafenib at 400 mg twice daily in 6-week cycles. Dose reductions and delays 
were applied according to standard practice. Treatment was continued until progressive 
disease or unacceptable toxicity.
Data collection
During the study 3 self-report questionnaires were send to patients at regular intervals by 
mail, or handed out by the treating physician, at baseline, 4 weeks after the start of 
treatment, thereafter every 3 months until the end of treatment, on the day of treatment 
discontinuation, and finally 1 and 4 weeks after treatment discontinuation. A baseline 
questionnaire for demographic characteristics was included. Patients completed the 
questionnaires one day before the start of VEGFR TKI (baseline). 
Extra blood samples were collected at the same time points as the questionnaires. These 
blood samples were analyzed for hematology, clinical biochemistry, thyroid function, 
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levels of testosterone and sex hormone binding globulin (SHBG). Free testosterone was 
calculated from the testosterone and SHBG values.15 Plasma levels of VEGF were measured 
at baseline by a specific ELISA as previously described.16,17
Questionnaires
Fatigue was measured by the subscale fatigue severity of the Checklist Individual Strength 
(CIS20r), Fatigue severity was measured on a 7-point Likert scale over the last 14 days. A 
score of ≥ 35 on this subscale indicates severe fatigue, representing two times the 
standard deviation above the mean score of healthy controls.18 For quality of life (QoL), 
the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life 
Questionnaire (EORTC-QLQ-C30 version 3) was used.19 The EORTC-QLQ-C30 consists of 30 
items, the raw EORTC-QLQ-C30 scores were transformed to a 0-100 scale.19,20 For the five 
functioning scales and the global QoL a higher score represents a better level of 
functioning and quality of life. For the symptom-oriented scales and items, a higher score 
corresponds to a higher level of symptoms. A mean change in scores of 10 points or more 
may be regarded as clinically significant.21 
Depression was measured by Beck’s depression inventory for primary care (BDI-PC). This 
7-item self-report instrument composed of cognitive and affective symptoms. A BDI-PC 
cut-off score of ≥4 was found to correctly classify patients as being diagnosed with or 
without a major depression disorder in 82% of the time.22
Statistical analysis 
For the questionnaires, total and subscale scores were according to their manuals. 
Descriptive statistics were calculated. Paired sample t-test, the Wilcoxon ranked t-test, Mc 
Nemar test, Chi-square and analyses of variance (ANOVA) were performed to analyze 
differences between groups. Pearson’s and Spearman’s correlation coefficients (r) were 
computed to examine relationships between the outcome of the questionnaires and 
biomarkers or patient characteristics. The biomarkers were assessed for (log-) normality. 
Survival analyses were done with the Kaplan-Meier test. All analyses were done in SPSS 
version 20.0 and a P value of < 0.05 was considered significant. 
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Figure 1. Flow chart patients in the first 28 weeks of the study
Figure 1. Flow chart patients in the first 28 weeks of the study  
 
 
 
  
Assessed for eligibility and signed 
informed consent N=76 
2 patients never started sunitinib or sorafenib due 
to complication and progression of disease 
After 16 weeks still in study N=47 (63.5 %) 
(mRCC N=44, HCC N=0, GIST N=3) 
Sunitinib N=39 (83.0 %) sorafenib N=8 ( 17.0 %) 
16 weeks Questionnaires filled in N=38 (80.9 %) 
 
After 4 weeks still in study N=65 (87.8 %) 
(mRCC N=61, HCC N=1, GIST N=3) 
Sunitinib N=55 (84.6 %) sorafenib N=10 (15.4 %) 
4 weeks Questionnaires filled in N=55 (84,6 %) 
 
Start QOL study N=74 (100 %) 
(mRCC N=69, HCC N=2, GIST N=3) 
Start with sunitinib N= 61 (82.4 %) 
Start with sorafenib N=13 (17.6 %) 
Baseline Questionnaires filled in N=67 (90.5%) 
 
 
 
 
 
9 (12.2%) patients stopped (1 HCC, 8 mRCC) 
Due to toxicity N=5 
Due to progression N=4 
18 (24.3%) patients stopped (1 HCC, 17 mRCC)  
Due to toxicity N=6 
Due to progression N=10 
Other N=2 (operation for tumor resection N=1, 
radiotherapy N=1) 
 
ra 
21 (28.4 %) patients stopped (20 mRCC, 1 GIST)  
Due to toxicity N=5 
Due to progression N=13 
Other (operation for nefrectomie N=1, CVA N=1, 
Myocardinfarct N=1) 
After 28 weeks still in study N=26 (35.1 %) 
(mRCC N=24, HCC N=0, GIST N=2) 
Sunitinib N=22 (84.6 %) sorafenib N=4 (15.4 %) 
28 weeks Questionnaires filled in N= 22 (84.6 %) 
 
Baseline scores of this group 
CIS-FAT ≥ 35: n=24 
BDI Total ≥ 4: n=12 
 
 
Baseline scores of this group 
CIS-FAT ≥ 35: n=22 
BDI Total ≥ 4: n=6 
 
Baseline scores of this group 
CIS-FAT ≥ 35: n= 17 
BDI Total ≥ 4: n=4 
 
Baseline scores of this group  
CIS-FAT ≥ 35: n=4 
BDI Total ≥ 4: n=1 
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Results
Between May 2008 and December 2010 a total of 74 patients were enrolled into the study. 
The baseline demographic and clinical characteristics of the study sample are summarized 
in Table 1. Nineteen (26%) patients received prior anti-VEGF treatment of whom 7 (10%) 
patients in the last month prior to the start of the study. The baseline self-report 
questionnaires were returned by 65 (91%) of patients. During the treatment the 
questionnaire compliance remained above 80% (Figure 1). At treatment discontinuation, 
the questionnaire compliance was low (between 19% and 30%). The results of the 
questionnaires are presented in Table 2. 
At the time of data analysis in January 2015, 3 patients (1 GIST, 2 mRCC) were still on the 
treatment and 9 (12%) patients were still alive (2 GIST, 7 mRCC). An overview of the 
patients during the first 28 weeks of the study and their compliance to the questionnaires 
is shown in Figure 1. 
Fatigue at baseline and its relation with QoL, cancer related symptoms and 
depression
At baseline severe fatigue was present in 24 (36%) of the patients (Table 2) and (12) 18% 
of the patients were depressed (BDI score of ≥4) (Table 2); of these 12 patients, 8 (7%) felt 
also severely fatigued. In Table 3 the non-severely fatigued patients are compared to the 
severely fatigued patients on baseline characteristics and results of the BDI and EORTC 
QLQ-C30. Fifty-five percent of the women felt severely fatigued and 32% of the men 
(P=0.144).
No difference in baseline levels of fatigue, global QoL or depression were found between 
patients who had an anti-VEGF treatment before start of the study and patients who 
never had an anti-VEGF treatment (28.8 vs. 29.5; P=0.605, 66.2 vs. 63.8; P=0.550, and 1.39 
vs. 2.0; P=0.107, respectively). The three patients who had only 7 or 8 days between a 
former anti-VEGF TKI treatment and start of the study, due to rapid progressive disease, 
were all severely fatigued at baseline, had a low global QoL score (33.3, 33.3 and 56 
respectively) but were not depressed. 
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Table 1. Baseline demographic and clinical characteristics (n=74)
Characteristics no %
Sex
Male / Female 58/16 78.4 / 21.6
Age mean (y) 59.2
Range 23 - 78
Mean Education (SD) 3 (1.8)
Paid work (yes) 30 44.1
Retired 26 29.9
Karnofsky Performance Score
90 - 100 26 35.2
80 24 32.4
70 21 28.4
60 3 4.1
Tumor
Hepatocellular carcinoma (HCC) 2 2.7
Gastro intestinal stromal tumor (GIST) 3 4.1
Renal cell carcinoma (mRCC) 69 93.3
Clear cell mRCC 59 86
Metastatic sites 
1 9 12.2
2 23 31.1
>2 41 55.4
Brain metastasis 6 8.1
Median duration of disease in years (range) 1.7 (0 - 19)
Median duration of metastatic disease in years (range) 0.7 (0 - 10.6)
No systemic treatment before entering the study 47 64
Haemoglobin level
Normal
low
 
18
51
 
24.3
68.9
Albumin 
Normal ≥ 35 g/l
Low < 35 g/l
 
38
32
 
51.4
43.2
Corrected calcium
Normal < 2.65 mmol/l
High ≥ 2,65 mmol/l
 
46
23
 
62.2
31.1
CRP 
Normal < 10 mg/l
High ≥ 10 mg/l
 
18
45
 
24.3
60.8
VEGF ng/ml median (SD) n=53  1.46 (0.53)
Free calculated testosterone (only in men) median (SD) pmol/l n=41 180 (62.7)
Vitamin B12 pmol/l median (SD) n=62 287 (201) 
Only mRCC patients 
MSKCC prognostic risk factors 
Low risk (0)
Intermediate risk (1)
Poor risk (2, 3) 
Unknown 
 
7
19
41
2
 
10.2
27.5
59.4
2.8
 
Normal values for free calculated testosterone: 120 – 630 pmol/l 
Normal values for Vitamin B12 160 – 750 pmol/l
MSKCC Memorial Sloan-Kettering Cancer Center (low Karnofsky performance status (<80%) low Haemoglobin (males: < 
14 g/dl or < 8.7 mmol/l, females < 12,0 g/dl or < 7,5 mmol/l), high corrected calcium (> 10 mg/dl or > 2,5 mmol/l), low 0, 
intermediate 1, poor 2-3 risk factors)29
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Table 2. Results from the CIS20r, the global QoL and the BDI-PC questionnaire mean values (with SD)
CIS20r Global QoL BDI
Variable N CIS-Fatigue 
(SD)
CIS-Fatigue ≥35 
Severe Fatigue 
N(%)
Global QoL 
(SD) 
BDI-total 
(SD)
BDI-total ≥ 4 
(depressed) 
N (%)
Baseline 66 29.3 (13.8) 24.0 (36) 64.4 (21.9) 1.8 (2.1) 12 (18)
Week 4 54 31.3 (12.3) 22.0 (41 ) 65.6 (14.8) 1.5 (2.0) 6 (11)
P- value* 0.004 0.344 0.210 0.558 1.0
Week 16 37 32.3 (12.8) 17.0 (46 ) 64.5 (18.3) 1.4 (1.6) 4 (11)
P- value* 0.004 0.065 0.065 0.910 1.0
Week 28 21 27.8 (11.5) 4.0 (19) 67.1 (20.3) 0.9(1.3) 1 (5)
P- value* 0.136 1.0 0.377 0.804 1.0
Stop 13  41.0 (10.9) 10.0 (77) 53.9 (14.7) 2.8 (1.9) 5 (42)
P- value* 12 0.011 0.031 0.016 0.400 0.500
1 week after stop 19 46.7 (10.0) 17.0 (90) 40.9 (21.1) 3.3 (2.6) 9 (45)
P- value* 0.000 0.002 0.003 0.081 0.031
4 weeks after stop 20 42.1 (14.2) 14.0 (70) 38.5 (22.7) 2.8 (2.0) 6 (30)
P- value* 0.000 0.008 0.001 0.050 0.250
 
 
* P value compared to baseline with the Wilcoxon ranked test or the Mc Nemar test
For the CIS20R and for the BDI-PC a higher score corresponds to a higher level of symptoms. For the global QoL: a higher 
score represents a better level of functioning.
Predictive value of baseline scores of fatigue, global QoL and depression for 
time on treatment and survival
There was a significant difference in the median time that patients stayed on treatment 
when comparing the non-severely fatigued patients to the severely fatigued patients at 
baseline (6.4 and 2.9 month; P=0.002, respectively) (Figure 2). The same pattern was seen 
for the median OS:13.8 months in patients without severe fatigue at baseline vs. 9.7 
months with severe fatigue (P=0.001) (Figure 2). In addition, patients with a global QoL 
score at baseline above the median of 66.7 (n=29) stayed longer on treatment compared 
to the group (n=38) with a score of 66.7 or lower (7.7 vs. 3.5 months, respectively, P=0.001). 
No difference in median OS was found between these latter groups (14.8 vs. 11.7 months, 
respectively, P=0.067). Depression also was a predictor for the time that patients stayed 
on treatment and the OS. Patients who were not depressed at baseline stayed longer on 
treatment and had a better OS compared to the depressed patients (5.6 vs. 3.0 months; 
P=0.008, and 14.8 vs. 7.3 months, P=0.001, respectively) (Figure 2). 
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Figure 2a. The predictive value of the baseline scores of CIS-fatigue, global QoL, and depression on 
treatment duration
   
                      
      
P=0.002 
P=0.001 
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Fatigue during treatment and its relation with QoL, cancer related symptoms 
and depression
In the first 4 weeks of the study, 9 (12%) patients discontinued treatment (Figure 1), 5 due 
to toxicity (one grade 4 allergic reaction on sorafenib; one grade 3 hypertension; one 
colon perforation due to diverticulitis; one colon perforation due to a second primary 
tumor of the colon, and one acute decompensated heart failure. The longer patients 
stayed in the study the greater the chance to stop due to progression instead of toxicity. 
After 4 and 16 weeks, a significant increase in fatigue was observed compared to baseline 
(Table 2). The percentage of severely fatigued patients raised, although not more patients 
met the criterion for severe fatigue compared to baseline. In the period from baseline to 
4 weeks, 14% of the patients changed from not-severely fatigued to severely fatigued, and 
6% from severely fatigued to not-severely fatigued. After 4 weeks on the VEGFR TKIs 32 
(49%) patients experienced no severe fatigue and 22 (41%) patients severe fatigue. The 
comparison of these two groups on patients and QoL aspects and depression are 
presented in Table 4. 
The highest fatigue levels were observed in week 16 of treatment: 6 of the 17 patients 
(35%) who experienced severe fatigue at week 16 discontinued treatment before week 28. 
Comparing the severely fatigued patients to the non-severely patients at 16 weeks in the 
same way as in Table 3, a lower global QoL, worse social function and more complaints of 
dyspnoea in the severely fatigued patients were the only differences (data not shown).
P=0.008 
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Figure 2b. The predictive value of the baseline scores of CIS-fatigue, global QoL and depression on OS
   
           
P=0.001 
P=0.067 
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Of the 26 patients who were still on treatment after 28 weeks, only 4 (19%) reported 
severe fatigue and had no change compared to baseline in any of the QoL aspects except 
for diarrhea, and only 5% felt depressed. The mean fatigue scores of patients still on 
treatment at 28 weeks at baseline, 4, 16 and 28 weeks were 23.5 (SD 12.2), 26.6 (SD 12.3), 
28.8 (12.3) and 26.8 (11.0), respectively.
This increase of fatigue was significant at week 16 (P=0.030). In addition, these patients 
had significantly less complaints of depression, a better global QoL, and a lower CRP and 
ESR at baseline compared to the other patients (data not shown). Of the 13 patients who 
were still on treatment after one year 2 patients (15%) were severely fatigued. 
P=0.001 
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Table 3. Comparing the non-severely fatigued patients to the severely fatigued patients on baseline 
characteristics and results of BDI and QLQ-C30
Non-severely fatigued 
patients (n=42) 
Mean (SD)
Severely fatigued 
patients (n=24) 
Mean (SD)
P- value
Age (y) 61.6 (8.5) 56.1 (11.2) 0.029
Education 3.1 (1.8) 3.1 (1.5) 0.543
Karnofsky PS 82.4 (8.5) 77.5 (11.1) 0.050
Time since diagnosis of cancer (months) 54.2 (55.3) 17.7 (19.6) 0.003
Time since metastatic disease (months) 28.6 (32.1) 10.7 (13.3) 0.011
VEGF level 1.6 (0.5) 1.4 (0.6) 0.272
Corrected calciuma 0.9 (0.1) 1.0 (0.1) 0.031
Albumine 36.3 (5.7) 32.7 (7.1) 0.026
Hb 7.6 (1.2) 7.0 (1.0) 0.037
ANCa 1.6 (0.5) 1.7 (0.5) 0.265
CRPa 2.9 (1.4) 3.8 (1.2) 0.020
ESRa 3.2 (1.1) 3.8 (1.0) 0.080
Free calculated testosteron (only men) 180.5 (56.8) 166.7 (73.7) 0.531
LDHa 6.0 (0.3) 6.1 (0.3) 0.437
Vitamin B12a 5.7 (0.5) 5.8 (0.7) 0.427
TSHa 0.3 (0.8) -0.04 (1.6) 0.251
BDI 1.24 (1.6) 2.83 (2.4) 0.002
EORTC QLQ-C30
Global QoL 74.0 (17.6) 47.6 (19.1) 0.000
Phyisical functioning 85.0 (16.2) 59.1 (26.8) 0.000
Role functioning 73.0 (28.5) 45.7 (37.3) 0.002
Emotional functioning 81.1 (19.8) 64.6 (21.7) 0.003
Cognitive functioning 91.3 (13.9) 86.8 (20.3) 0.293
Social functioning 87.7 (22.1) 61.1 (27.2) 0.000
Fatigue 21.2 (17.5) 53.1 (23.0) 0.000
Nausea/vomiting 6.0 (18.0) 16.7 (25.1) 0.051
Pain 15.1 (23.2) 34.0 (36.1) 0.012
Dyspnoe 11.1 (17.5) 23.2 (25.5) 0.028
Insomnia 14.3 (22.3) 11.6 (19.1) 0.626
Apetite loss 13.0 (27.8) 26.1 (30.1) 0.084
Constipation 2,3 (8.6) 17.6 (26.7) 0.006
Diarrhea 7.1 (7.3) 12.5 (23.7) 0.296
Financial Problems 6.3 (19.8) 6.9 (17.0) 0.902
 
For the BDI and the symptom scales of the EORTC QLQ-C30 a higher score corresponds to a higher level of symptoms. 
For the global QoL and the functional scales of the EORTC QLQ-C30 a higher score represents a better level of functioning. 
a calculated with the logarithmic values
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Discontinuation of treatment 
Reasons for discontinuation of treatment were toxicity (n=17, 26%), progression (n=39, 
60%), or other, (n=9, 14%). The median time on treatment with the VEGFR TKI was 4.8 
months (range 0.2 – 77.7 months), and the median overall survival (OS) was 12.7 months 
(range 0.4 – 79.1 months). Twenty-two patients (30%) received subsequent systemic 
treatment. The reason that patients stopped treatment had no influence on the time that 
they stayed in the study, nor on OS, or OS after discontinuation of treatment (data not 
shown). 
Only 13 patients completed the questionnaire on the last day of treatment, and 21 
patients the questionnaire one week after treatment discontinuation. In order to assess 
if these patients were representative for the overall study group we compared the 
baseline characteristics of these 21 patients to the group (n=53) that did not complete the 
questionnaires after discontinuation. No differences were observed in CIS-Fatigue, BDI, 
global QoL, PS, age, OS or median duration of (metastatic) disease before start of the 
study (data not shown). However, the patients that completed the questionnaires after 
discontinuation of treatment, remained in the study for a shorter period of time (1.4 vs. 
3.5 months, P=0.018) and stopped more frequently due to toxicity (48% vs. 28%) than due 
to disease progression (38% vs. 59%). There was no significant difference in median OS 
after discontinuation treatment between patients who filled in the stop questionnaires 
and patients who didn’t filled in (7.7 vs. 3.8 months respectively, P=0.079).
Fatigue after discontinuation of treatment and its relation with QoL, cancer 
related symptoms and depression
At treatment discontinuation and in the following weeks 70% – 90% of the patients felt 
severely fatigued. (Table 2). One week after discontinuation of treatment, more complaints 
of fatigue were strongly correlated to a lower global QoL (r=-0.559, P=0.006), a lower 
physical- and emotional functioning (r=-0.707 P=0.000, r=-0.739, respectively, P=0.000), 
and more depression (r=0.552, P=0.008). No correlations were found between fatigue 
severity and the cancer related symptoms (data not shown). Of the physical and 
demographic characteristics only a higher CRP was correlated to fatigue (r=0.650, P=0.012 
one week after TKI discontinuation, and r=0.501, P=0.034 four weeks after TKI 
discontinuation). Higher corrected calcium levels were correlated with fatigue at 4 weeks 
after TKI discontinuation (r=0.499 P=0.041). 
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Table 4. Comparing the non-severely fatigued patients to the severely fatigued patients after 4 weeks 
treatment, on baseline characteristics, blood values at 4 weeks and results of BDI and QLQ-C30 at 4 
weeks. 
Non-severely fatigued 
patients (n= 32)  
Mean (SD)
Severely fatigued 
patients (n=22)  
Mean (SD)
P- value
Age (y) 59.0 (9.6) 59.2 (10.0) 0.942
Education 3.2 (1.8) 3.5 (1.9) 0.651
Karnofsky PS 82.2 (7.5) 80.1 (11.0) 0.621
Time since diagnosis of cancer (months) 47.1 (57.6) 32.1 (36.6) 0.283
Time since metastatic disease (months) 21.8 (30.2) 21.0 (27.1) 0.922
VEGF level (ng/mL) 1.5 (0.5) 1.5 (0.6) 0.839
Corrected calciuma (mmol/L) 0.9 (0.6) 0.9 (0.6) 0.450
Albumine (g/dL) 34.0 (6.7) 33.1 (6.1) 0.615
Hb (mmol/L) 7.8 (0.9) 7.4 (1.1) 0.119
ANCa (109/L) 1.0 (0.4) 1.1 (0.4) 0.134
CRPa 3.3 (1.2) 3.7 (0.9) 0.254
ESRa (mm/uur) 3.2 (0.71) 3.5 (1.0) 0.402
LDHa (U/L) 6.1 (03) 6.3 (0.2) 0.149
Vitamin B12a (pmol/L) 5.7 (0.4) 6.0 (0.7) 0.105
TSHa (mE/L) 0.8 (0.9) 0.8 (1.3) 0.903
BDI 1.19 (1.6) 1.6 (2.1) 0.404
EORTC QLQ-C30
Global QoL 72.9 (12.4) 55.3 (12.2) 0.000
Phyisical functioning 82.5 (15.4) 62.7 (20.7) 0.000
Role functioning 72.4 (27.0) 43.2 (28.9) 0.000
Emotional functioning 81.5 (13.7) 82.2 (13.9) 0.858
Cognitive functioning 92.7 (12.7) 91.7 (14.3) 0.779
Social functioning 84.4 (16.4) 71.2 (30.5) 0.045
Fatigue 26.4 (16.2) 53.0 (18.8) 0.000
Nausea/vomiting 7.8 (14.0) 17.4 (20.2) 0.044
Pain 13.5 (22.6) 27.3 (23.3) 0.035
Dyspnoe 12.5 (16.4) 31.8 (28.1) 0.002
Insomnia 14.6 (23.9) 16.7 (26.7) 0.765
Apetite loss 15.6 (25.4) 34.8 (33.3) 0.020
Constipation 15.2 (22.4) 22.2 (38.5) 0.501
Diarrhea 14.6 (20.6) 21.2 (30.1) 0.340
Financial Problems 8.3 (16.9) 19.7 (38.6) 0.107
For the BDI and the symptom scales of the EORTC QLQ-C30 a higher score corresponds to a higher level of symptoms. 
For the global QoL and the functional scales of the EORTC QLQ-C30 a higher score represents a better level of functioning. 
a calculated with the logarithmic values
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Discussion
To our knowledge this is the first prospective study that explores self-reported fatigue 
and its relation with QoL, cancer related symptoms and depression before, during and 
after treatment with the VEGFR TKIs sunitinib and sorafenib. 
The results of our study show that even before start of the treatment a high number of 
patients turned out to be severely fatigued. Severely fatigued patients had a lower QoL, 
more cancer related symptoms, more feelings of depression, less physical activity and 
more problems with role- emotional- and social functioning. We have no data of other 
studies on fatigue incidence measured by the CIS20r in patients before VEGFR TKI 
treatment. However the high prevalence of severe fatigue that we found at baseline is in 
concordance with results of other studies that used the CIS20r. In cancer patients even 
before start of a curative treatment 24% felt severe fatigue.23 
Previous studies have not provided clear answers on the possible relationship between 
psychological and physiological factors and their contribution to the development of 
fatigue in cancer patients yet.4,24,25 We found that severely fatigued patients were 
younger, had more physical symptoms, had signs of more disease activity (higher CRP and 
corrected Calcium, lower Hb) and a shorter time from diagnosis to metastasis and from 
diagnosis to start of treatment in the study. We did not observe an effect of prior anti-
VEGF treatment before start of the study on fatigue, global QoL or depression at baseline. 
This and the other results of our study suggest that severe fatigue at baseline, but also a 
low global QoL and depression mainly reflect disease activity. This is supported by our 
finding that severe fatigue, depression, and low global QoL at baseline, were predictive 
for a shorter time on treatment. Severe fatigue and depression at baseline were also 
predictive for a shorter OS. 
We observed a significant increase in fatigue at 4 and 16 weeks of treatment. In agreement 
with our findings at baseline, severely fatigued patients had a lower global QoL at 4 weeks 
and were less physical active and had more cancer related symptoms compared to the 
non-severely fatigued patients. However, in contrast to baseline no differences were 
found between those groups on depression score, and demographic or physical variables. 
At 16 weeks the differences between these two patient groups were even smaller. These 
results are in accordance with data from a recently published meta-analysis of randomized 
controlled trials on TKIs and mTOR which investigated the relative risk (RR) of fatigue 
during treatment.26 The type of drug (VEGFR TKI vs. mTOR), line of therapy, age, type of 
tumor and median duration of therapy did not affect the risk of fatigue. 
Our findings suggest that VEGFR TKIs have a small but significant negative impact on 
fatigue mostly during the first months of treatment, but also that cancer itself contributes 
most to the prevalence of severe fatigue. This early and transient increase of fatigue may 
be a treatment effect induced by tumor necrosis and accompanying cytokine release. In 
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accordance to this hypotheses we found that the prevalence of severe fatigue (19%) and 
depression (5%) at 28 weeks was low and the global QoL above the median. Probably 
because after 28 weeks only a selection of fit and responding patients were still on 
treatment. In a study on cognitive functioning in mRCC patients, longer treatment on 
VEGFR TKIs was also associated with less complaints of severe fatigue.27 Results of a 
retrospective analysis of a phase III trial (sunitinib vs. interferon-α as first line treatment 
in mRCC patients) showed a comparable pattern.3 In this study the drop out percentage 
of patients was also high, after 3 months, only 50% of the patients were still on treatment 
and after 6 months only 18%.9
Although our data at this time point are limited, these patients appear to be representative 
for the overall study population, except that patients that filled in the questionnaires 
stayed shorter in the study and stopped more frequently due to toxicity instead of 
progression. At treatment discontinuation and in the following weeks, a significant 
increase in fatigue was observed, with 70% – 90% of patients being severely fatigued. 
Fatigue was related to a decline in global QoL, physical- , role- social functioning and an 
increase in depression, but not to cancer related symptoms. Whether disease progression, 
treatment effect, or both play a causative role in the observed increase in fatigue, 
depression and worsening of QoL at the end of treatment remains unclear. Of the physical 
and demographic characteristics after discontinuation of treatment, only elevated CRP- 
and corrected calcium values correlated to more complaints of fatigue, which may suggest 
a role for tumor progression. Lastly, psychological aspects cannot be excluded since 
discontinuation of treatment can bring uncertainty about the future for patients. 
In conclusion, the results of our study contribute to further knowledge on the mechanisms 
of fatigue and its relation to QoL, disease-related symptoms and depression in cancer 
patients treated with VEGFR TKIs. Our data may be of value for health care professionals 
in the interpretation of these symptoms. Assessment of all patients before start of VEGFR 
TKI treatment with the CIS20r, BDI and EORTC QlQ-C30 should be considered to identify 
severely fatigued and depressed patients. This may allow the selection of patients suitable 
for physical activity programs and evidence-based psychological interventions for 
fatigue28 and depression to improve QoL. Additionally, these baseline values might help 
to predict OS and the time patients will stay on treatment and therefore may be helpful 
to inform and select patients before start of a VEGFR TKI treatment to set realistic 
expectations.
We strongly recommend to incorporate similar investigations in future clinical studies 
with VEGFR TKIs, by which our results could also be validated. 
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Abstract
The vascular endothelial growth factor (VEGF) receptor inhibitor sunitinib is a first-line 
treatment in most patients with metastatic renal cell carcinoma. No psychiatric adverse 
events have previously been reported. We describe two patients with psychotic symptoms, 
during treatment with sunitinib. Possible mechanisms of sunitinib-induced psychosis are 
discussed. 
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Introduction
The vascular endothelial growth factor (VEGF) receptor inhibitor sunitinib is a first-line 
treatment in patients with metastatic renal cell carcinoma1,2. The most frequent adverse 
events include diarrhea, fatigue, nausea, stomatitis, vomiting, hypertension, hand–foot 
syndrome, skin rash and hematological events2-7. Two articles reported neurological events 
due to sunitinib8,9, describing one patient with reversible posterior leukoencephalopathy 
and three patients with preexisting cerebrovascular changes who develop reversible 
cognitive disorders9. We describe the cases of two patients who developed psychotic 
symptoms during treatment with sunitinib.
Case 1
A 62-year-old male underwent tumor nephrectomy in 2007, because of clear cell carcinoma. 
At 10 months of routine follow-up, CT scanning showed mediastinal and retroperitoneal 
lymphadenopathy. He started with sunitinib, 50 mg once daily, in a 4-weeks-on–2-weeks-off 
schedule, without concurrent medication. After 10 days he was admitted to an affiliated 
hospital because of visual and auditory hallucinations, without any other abnormalities 
on psychiatric and neurological examination. There was a mild fever (temperature=38°C); 
laboratory test results revealed leucopenia (2.9×109/L), thrombocytopenia (100×109/L) 
and dehydration (creatinine: 150 μmol/L; urea nitrogen: 9.1 mmol/L). Results of chest 
radiography and MRI of the cerebrum were normal. The symptoms were interpreted as a 
toxic psychosis with hallucinations, due to sunitinib. Sunitinib was discontinued and intra-
venous saline and haloperidol, 1 mg twice daily, were started. Hallucinations disappeared 
within 48 h of treatment. Leucopenia and thrombocytopenia resolved within a week. 
Sunitinib was not reinstituted because of fast tumor progression. 
Case 2
A 63-year-old male patient with clear cell renal carcinoma underwent a tumor nephrectomy 
and was treated with interferon-α after local recurrence. He was enrolled in a Phase II 
study because of mediastinal lymph node metastases and treated with sunitinib 50 mg 
orally once daily. Two months later, amlodipine 5 mg was started because of hypertension. 
As he developed a hand–foot syndrome (Grade 2), sunitinib was decreased to 37.5 mg. 
After 18 months of sunitinib treatment psychotic symptoms occurred. On admission to the 
university clinic, the patient presented with paranoid delusions and visual hallucinations, 
depressed mood and minor sleep disturbances. Psychiatric and neurological examination 
showed no further abnormalities. He used the following co-medication: tolbutamide, 
atenolol, amlodipine and haloperidol. Laboratory tests showed slightly elevated lactate 
dehydrogenase (569 U/L) and low sodium (127 mmol/L; urine osmolality: 406 msmol/kg; 
urine sodium: 58 mmol/L). Fluid restriction increased sodium to normal levels within 48 h. 
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MRI of the cerebrum showed two small, old ischemic lesions in the left parietal cortex and 
the right cerebellum. The symptoms were interpreted as a toxic psychosis due to sunitinib. 
Sunitinib was discontinued; haloperidol 2 mg twice daily was started and later replaced 
with risperidone 2 mg once daily. The patient improved within 5 days after discontinuation 
of sunitinib. Sunitinib was reinstituted at a lower dose of 25 mg once daily, 10 days after 
remission of psychiatric symptoms, with co-administration of risperidone. After 2 years, 
the patient was still free of psychiatric symptoms. 
Discussion
We described the cases of two patients who developed psychotic symptoms during 
treatment with sunitinib. These symptoms were interpreted as a neuropsychiatric adverse 
reaction to sunitinib, in the absence of other likely causes. The cases lacked neurological 
symptoms such as described by van Veldt et al.9, i.e., cognitive disorders, gait disorder 
and parkinsonism. Considering a causal relation between the occurrence of a psychotic 
episode and the use of a drug requires a temporal association, i.e., occurrence of the 
event after initiation of treatment, disappearance after cessation of treatment and 
reappearance after readministration of the drug. Moreover, other likely causes of 
psychotic symptoms should be excluded. Psychotic symptoms developed within 2 weeks 
of treatment with sunitinib in the first patient and after 18 months in the second. The 
latter being less common in drug-induced psychotic symptoms. Van der Veldt et al.9 
described one case in which neurological symptoms occurred 6 months after initial 
treatment with sunitinib. Sunitinib is metabolized in the liver, mainly by the CYP3A4 
enzyme. CYP3A4 inhibitors increase sunitinib plasma levels, with an increased risk of 
adverse events10. The second patient used amlodipine, a mild CYP3A4 inhibitor11,12, and 
developed a hand-foot syndrome within 2 months of co-administration of amlodipine. 
Inhibition of CYP3A by amlodipine may have contributed to the development of psychotic 
symptoms 6 months later. All psychotic features disappeared within 1 week after 
discontinuation of sunitinib (half-life elimination: 80 – 110 h). Recurrence of symptoms 
after re-challenge with sunitinib would further establish causality. One case of recurrence 
of cognitive symptoms and behavioral changes after re-challenge with sunitinib was 
described elsewhere9. Re-administration at a lower dose, with concomitant use of an 
antipsychotic, as in the second case appears to be a safe option. Other possible causes of 
psychosis in patients treated with sunitinib, such as brain metastases and reversible 
posterior leukoencephalopathy, as well as contribution of metabolic disorders, such as 
hypothyroidism or cobalamin deficiency, were excluded. Delirium was excluded because 
of the absence of typical fluctuations in consciousness and orientation deficits. Yet, 
dehydration, leucopenia, low platelets and mild fever in Case 1 and hyponatremia in Case 
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2 might have contributed to the psychotic episode. This is a limitation that should be 
taken into account. The psychotic symptoms described here and the previous report on 
neurological symptoms clearly constitute distinct neuropsychiatric phenomena. Yet, they 
may be different presentations of the same underlying pathophysiology. Animal studies 
have shown that sunitinib passes the blood–brain barrier, affecting angiogenesis and 
vessel permeability in the brain13. The development of cerebral inflammation and 
edema14, or decreased blood flow9, has been suggested to induce regional brain 
dysfunction and neuropsychiatric symptoms. A more tentative explanation would be 
based on the influence of VEGF on synaptic activity and neuronal development15-19. It has 
been shown that VEGF levels are decreased in the prefrontal cortex of schizophrenia 
patients and antipsychotics increase brain VEGF levels20-23. Sunitinib may cause psychosis 
in ways similar to those observed in schizophrenia, by inhibition of VEGF receptors. 
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Abstract
Background
Impairment of cognitive functioning has been reported in several studies in patients 
treated with chemotherapy. So far, no studies have been published on the effects of the 
vascular endothelial growth factor receptor (VEGFR) inhibitors on cognitive functioning. 
We investigated the objective and subjective cognitive function of patients during 
treatment with VEGFR tyrosine kinase inhibitors (VEGFR TKI).
Methods
Three groups of participants, matched on age, sex and education, were enrolled; 1. 
metastatic renal cell cancer (mRCC) or GIST patients treated with sunitinib or sorafenib 
(VEGFR TKI patients n=30); 2. patients with mRCC not receiving systemic treatment 
(patient controls n=20); 3. healthy controls (n=30). Sixteen neuropsychological tests 
examining the main cognitive domains (intelligence, memory, attention and concentration, 
executive functions and abstract reasoning) were administered by a neuropsychologist. 
Four questionnaires were used to assess subjective cognitive complaints, mood, fatigue 
and psychological wellbeing.
Results
No significant differences in mean age, sex distribution, education level or IQ were found 
between the three groups. Both patient groups performed significantly worse on the 
cognitive domains Learning & Memory and Executive Functions (Response Generation 
and Problem Solving) compared to healthy controls. However only the VEGFR TKI patients 
showed impairments on the Executive subdomain Response Generation. Effect sizes of 
cognitive dysfunction in patients using VEGFR TKI were larger on the domains Learning & 
Memory and Executive Functions, compared to patient controls. Both patients groups 
performed on the domain Attention & Concentration the same as the healthy controls. 
Longer duration of treatment on VEGFR TKI was associated with a worse score on Working 
Memory tasks.
Conclusions
Our data suggest that treatment with VEGFR TKI has a negative impact on cognitive 
functioning, specifically on Learning & Memory, and Executive Functioning. We propose 
that patients who are treated with VEGFR TKI are monitored and informed for possible 
signs or symptoms associated with cognitive impairment.
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Introduction
Cognitive complaints have been reported in cancer patients treated with chemotherapy, 
which has been confirmed by objective neuropsychological assessment.1-3 Several candi-
date mechanisms have been suggested, such as direct neurotoxic effects of chemotherapy, 
oxidative damage, immune dysregulation, microemboli and genetic predisposition.4 To 
date no studies have been published on the effects of targeted drugs, such as the vascular 
endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR TKI) sunitinib and 
sorafenib on cognitive functioning. The vascular endothelial growth factor (VEGF) plays an 
important role in the biology of the central nervous system. Angiogenetic factors, especially 
VEGF, are involved in neurogenesis, neuroprotection and the pathogenesis of stroke, 
Alzheimer’s disease and motor neuron disease.5 In patients with Alzheimer’s disease the 
mean serum VEGF concentration is significantly lower than in healthy controls and the 
lower the VEGF level the higher the risk for Alzheimer’s disease6. Results of research with 
rodents indicate that VEGF expression in the hippocampus is a mediator of the effects of 
the environment on neurogenesis and cognition, learning and memory.7,8
Besides VEGF, cytokines are also involved in the functioning of the central nervous 
system4. Several studies have reported a relationship between cognitive impairment and 
cytokine levels.4, 9-12 Higher interleukin-6 (IL-6) levels were associated with cognitive 
impairments on the domain Executive Functions, whereas higher IL-8 levels were 
associated with better Memory performance. IL-6, IL-1 receptor antagonist and tumor 
necrosis factor alpha (TNF-α) levels were related to ratings of fatigue.12
Only two case reports have been published on neurobehavioral dysfunction during 
treatment with sunitinib, but these did not include standardized neuropsychological 
assessment tools.13,14 The first paper describes three patients with preexisting 
cerebrovascular changes who developed severe cognitive and behavioral disorders 
during sunitinib treatment, which normalized within one week after discontinuation of 
sunitinib.13 The second paper reports two patients who developed severe psychotic 
symptoms in the course of sunitinib treatment which also disappeared after cessation of 
the drug.14 No studies have been performed however, examining milder forms of cognitive 
impairments using validated neuropsychological tests during VEGFR TKI treatment.
This prompted us to examine cognitive functioning and assess subjective cognitive 
complaints in patients using the VEGFR TKI sunitinib or sorafenib. Since objective cognitive 
dysfunction has also been reported in untreated cancer patients,12,15-17 patient controls 
were included. We conducted a cross sectional study with three study groups: patients 
with metastatic renal cell cancer (mRCC) or gastrointestinal stromal tumors (GIST) treated 
with the VEGFR TKI sunitinib or sorafenib, patients with mRCC without systemic treatment 
and healthy controls.
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Patients and Methods
Participants and procedure
Thirty patients with mRCC or GIST treated with sunitinib or sorafenib for at least 8 weeks 
(VEGFR TKI patients), as well as 20 patients with mRCC, not receiving systemic treatment 
and previously not treated with a VEGFR TKI (patient controls), were selected to participate 
in this cross sectional study. Furthermore, 30 healthy controls were included as reference 
group from the same socioeconomic background in order to match patients and controls 
on four important characteristics (age, sex, estimated IQ and level of education), which in 
itself affect cognitive performance, and cannot be properly adjusted for statistically. 
Patients were recruited through their treating specialist; controls were recruited among 
the acquaintances of the patients and by advertisements in local papers. Eligibility criteria 
included: age ≥18 years, Karnofsky Performance Status (KPS) ≥70 and fluent in the Dutch 
language. Participants were excluded if they had been treated with systemic chemotherapy 
or interferon alpha (IFN-α) or IL-2 during the last 12 months, had general anesthetics in 
the last 3 months, were known with brain metastasis, brain injury, cognitive disorders, or 
psychiatric or anti-epileptic drug use. Age, sex, level of education using a 7 point scoring 
system (1: less than primary school, 7: university degree)18 and estimated IQ were used 
for matching purposes. The study was approved by the Medical Review Ethics Committee 
Region Arnhem-Nijmegen and all participants gave written informed consent.
Neuropsychological tests and self-report questionnaires
An extensive neuropsychological assessment, duration approximately 90 minutes, was 
administered by a trained neuropsychologist. The assessment consisted of 12 sensitive 
Dutch versions of widely used and well-validated tests covering the major cognitive 
domains, that is, Learning & Memory, Attention & Concentration, and Executive Functions. 
Tests in each domain were selected on the basis of cognitive theory and clinical validation 
studies and covered all relevant subdomains.19 First, within the domain Learning & 
Memory, Working Memory was assessed by the subtests Digit Span Backwards and Letter-
Number Sequencing of the WAIS-III;19 Episodic Memory was measured using the Rey 
Auditory Verbal Learning Test (RAVLT)19 and the subtest Story Recall of the Rivermead 
Behavioural Memory Test (RBMT)19 and Semantic Memory was assessed by the Semantic 
Fluency Test (animal/profession naming).19 As part of the domain Attention & 
Concentration, Sustained Attention was assessed using the d2 Test,20  Alertness (attention 
span) was measured by the WAIS-III Digit Span Forward19 and the subtest Alertness from 
the computerized TAP 2.1.21 In the domain Executive Functions the Controlled Oral Word 
Association Test (COWAT)19 was used to measure Response Generation. Response 
Inhibition was tapped by the Stroop Color-Word test (interference score),19 Mental 
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Flexibility by the subtest Flexibility of the TAP 2.120 and Problem Solving by the Brixton 
Spatial Anticipation Test19 and Raven’s Advanced Progressive Matrices (Set I).19 To 
estimate the level of premorbid intelligence the Dutch version of the National Adult 
Reading Test (NART)19 was administered. Moreover, self-report questionnaires were 
administered to assess psychological well-being (Symptom Checklist–Revised; SCL-
90-R),22 everyday cognitive failures (Cognitive Failures Questionnaire; CFQ),23  mood (Beck 
Depression Inventory–Second Edition; BDI-II)24 and fatigue (Checklist Individual Strength; 
CIS20r).25
Biomarkers
In the patient groups, blood samples were obtained on the day of the neuropsychological 
assessment. Blood samples were analyzed for a full blood count, liver and renal function, 
and levels of testosterone, sex hormone binding globuline (SHBG), estradiol, albumin, 
vitamin B12, thyroid function, glucose C-reactive protein (CRP), erythrocyte sedimentation 
rate (ESR) and lactate dehydrogenase (LDH). Free testosterone was calculated from the 
testosterone and SHBG values26. Plasma VEGF–and serum cytokine levels were measured. 
Levels of VEGF were measured by a specific ELISA as previous described27,28. We used the 
Th1/Th2 11plex kit (eBioscience) according to the manufacturer’s protocol to measure 
cytokines levels. The minimum detectable concentrations were estimated to be 4.2 pg/ml 
for IL-1β, 16.4 pg/ml for IL-2, 20.8 pg/ml IL-4, 1.6 pg/ml IL-5, 1.2 pg/ml IL-6, 0.5 pg/ml IL-8, 
1.9 pg/ml IL-10, 1.5 pg/ml IL-12 (p70), 3.2 pg/ml TNF-α, 2.4 pg/ml TNF-β and 1.6 pg/ml 
interferon gamma (IFN-γ). Results were expressed as percentage of detectable values and 
as median values in both patient groups.
Statistical analyses
All neuropsychological tests were scored according to their manuals. For data reduction 
purposes and to enhance the comparability of cognitive (sub)domains, standardized 
z-scores were computed using the raw test results. All analyses were performed on these 
(sub)domain scores. The performances on the individual (sub)tests are presented for 
descriptive purposes only. For the self-report questionnaires, total and subscale scores 
were calculated using their manuals. Overall between-group analyses were performed 
using multivariate analysis of variance (general linear model) with Fisher’s post-hoc t-tests 
or nonparametric tests for nominal or ordinal variables (sex distribution and education 
level). The biomarkers were assessed for (log-)normality and t-tests were used to compare 
patient groups when applicable. Pearson’s correlation coefficients (r) were computed to 
examine relationships between cognitive performance and self-report measures on one 
hand and the biomarkers on the other. Analyses were conducted using SPSS 18.0 for 
Windows (SPSS, Chicago, IL).
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Results
Participants
Between August 2009 and May 2011 a total of 80 patients and controls were enrolled. 
Within the VEGFR TKI group, 26 patients had a diagnosis of mRCC and 4 of GIST. Three 
patients in the VEGFR TKI group and 4 in the patient controls had been treated in the past 
(>1 year before) with a combination of IFN-α, IL-2 and 5FU. One patient in the VEGFR TKI 
group and 2 patients in the patient control group had previously been treated with IFN-α 
monotherapy. During the study 23 patients were treated with sunitinib and 7 with 
sorafenib. The median duration of treatment with VEGFR TKI at the time of the 
neuropsychological assessment was 20 months (range 2-55). Most patients on sunitinib 
were on a continuous schedule (n=14), while the others were treated on a 4 weeks on and 
2 weeks off schedule. The dose ranged from 25 mg continuously to 50 mg 4 weeks on and 
2 weeks off. Sorafenib dosing was continuously with a total daily dose of 800 mg in most 
patients.
Neuropsychological tests
All participants were able to complete all neuropsychological tests and self-report 
questionnaires. Participants characteristics (age, sex distribution, estimated IQ and 
education level) were equally distributed among the 3 groups (Table 1), indicating that the 
groups were well-matched. Significant differences between the groups were found on the 
domains Learning & Memory (F(2,77) = 8.2, P=0.001) and Executive Functions (F(2,77) =4.5, 
P=0.014). No significant differences were demonstrated for the domain Attention & 
Concentration (F(2,77) =1.7, P=0.20). Post-hoc comparisons showed that, compared to the 
healthy controls, the VEGFR TKI patients performed worse on the domain Learning & 
Memory (P=0.0001) and Executive Functions (P=0.005) (Table 2). The patient controls also 
performed worse than healthy controls on Learning & Memory (P=0.019) and Executive 
Functions (P=0.049). No significant differences were found between the VEGFR TKI and 
the patient controls on the domains Learning & Memory (P=0.24) and Executive Functions 
(P=0.55). Figure 1 shows that the magnitude of the effects were largest in the VEGFR TKI 
patients.
Subsequently, analyses were performed between the three groups, on the cognitive 
subdomains for the significant domains Learning & Memory and Executive Functions 
(Table 2). With respect to the domain Learning & Memory, between-group differences 
were observed on Episodic Memory (F(2,77) =6.7, P=0.002) and Semantic Memory (F(2,77) 
=8.1, P=0.001), no differences were found on Working Memory (F(2,77) =2.1, P=0.13). Post-
hoc comparisons showed that both the VEGFR TKI patients and the patient controls 
performed worse than healthy controls on Episodic Memory (P=0.001 and P=0.03) and 
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Semantic Memory (P< 0.0001 and P=0.004). Within the domain Executive Functions, 
between-group differences were found on Problem Solving (F(2,77) =3.5, P=0.037) and 
Response Generation (F(2,77) =3.2, P=0.047), no differences were found on Inhibition 
(F(2,77) =0.04, P=0.96 and Mental Flexibility (F(2,77) =2.2, P=0.12). Post-hoc comparisons 
showed that the VEGFR TKI patients performed worse than healthy controls on both 
Problem Solving (P=0.02) and Response Generation (P=0.02). The patient controls 
performed worse on Problem Solving (P=0.04) compared to the healthy controls. In the 
VEGR TKI group, longer treatment on VEGFR TKI was associated with a worse score on 
Working Memory tasks (r=-0.461, P=0.012).
Table 1. Characteristics of the study groups
Patients 
VEGFR TKI (n = 30)
Patient Controls 
(n = 20)
Healthy Controls 
(n = 30)
P
Characteristics
Age, years
Mean 60 62 58 0.456e
Range 38-81 30-75 45-73
Sex (%)
Male 27 (90) 15 75 26 (87) 0.329f
Female 3 (10) 5 25 4 (13)
Median education level (SD)d 4 (1.21) 5 (1.12) 5 (0.80) 0.546g
Estimation IQ (SD) 102.30 (10.37) 106.20 (10.55) 106.37 (8.09)
Median free testosteronec pmol/L  
(IQR 25-75)
165.00 (129.5-238.00) 237.50 (200.75-299.25) - - 0.005a
Median estradiol pmol/l† (IQR 25-75) 48.00 (42-55) 78.50 (78.5-112.5) - - 0.000a
Median albumin g/l (IQR 25-75) 39.00 (34.50-40.25) 37.50 (35.25-40.00) - - 0.599a
Median CRP mg/l (IQR 25-75) 10.00 (4.00-21.75) 5.00 (4.00-38.25) - - 0.849a, b
Median absolute neutrophil count 
109 /l (IQR 25-75)
2.95 (2.08-3.66) 3,89 (3.43-5.64) - - 0.009a
Median ESR mm/hour (IQR 25-75) 20.00 (8.75-34.50) 19.00 (7.00-31.00) - - 0.767a, b
Median glucose mmol/l (IQR 25-75) 5.6 (4.9-5.98) 5.8 (5.35-7.55) - - 0.010a
Median TSH mE/l (IQR 25-75) 2.29 (1.49-3.63) 1.12 (0.78-2.04) - - 0.003a, b
Median LDH U/l (IQR 25-75) 463.50 (402.25-526.50) 346.50 (314.50-458.00) - - 0.008a, b
Median VEGF ng/ml (IQR 25-75) 1.62 (1.09-2.18) 1.48 (1.21-2.00) - - 0.221a
 
a T-test between the two patients groups; b calculated with the logaritmic values;
c calculated free testosterone only in men, reference value for men: 120-630 pmol/l, †estradiol level only in men, reference 
value 75-220 pmol/l. Abbreviations: SD = Standard deviation; IQR = inter quartile range 25e and 75e percentile; ESR = 
erythrocyte sedimentation rate; CRP = C-reactive protein; LDH = lactate dehydrogenase; VEGF = vascular endothelial 
growth factor.
d Education levels as assessed using 7 categories in accordance with the Dutch educational system (1 = less than primary 
school; 7 = academic degree); eANOVA; fChi-square test; dKruskal-Wallis Test.
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Figure 1. Cognitive domain scores
The cognitive domain scores (standardized Z values) for the patients using VEGFR TKI, the patient controls and the 
healthy controls. Post-hoc t-tests, patient groups compared to healthy controls: *P<0.05, **P<0.01, ***P<0.001.
Self-report questionnaires
With respect to the self-report questionnaires, significant between-group differences 
were found on psychological well-being as measured with the SCL-90-R (Table 3) (F(2,77) 
=7.5, P=0.001), mood scores as assessed with the BDI-II (Table 3) (F(2,77) =12.9, P=0.000) 
and fatigue measured with the CIS20r (Table 3) (F(2,77) =7.2, P=0.001). No between-group 
differences were found on experienced cognitive failures in daily functioning assessed 
with the CFQ (Table 3) (F(2,77) =0.7, P=0.50). Post-hoc comparisons showed that on 
psychological well-being the VEGFR TKI patients reported more feelings of anxiety 
(P=0.005), depressive symptoms (P<0.0001), somatic symptoms (P<0.0001) and subjective 
cognitive complaints (P=0.002), as well as an overall heightened level of distress (P=0.001) 
compared to the healthy controls. The patient controls reported more symptoms than 
healthy controls on the subscales anxiety (P=0.034), depressive symptoms (P=0.003), 
somatic symptoms (P=0.029), subjective cognitive complaints (P=0.005), and the total 
distress scale (P=0.004).
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Table 2. Cognitive subdomain scores and raw neuropsychological test scores
 
Patients VEGFR TKI Patient Controls Healthy Controls
Mean SD Mean SD Mean SD
Learning & Memory
Working Memory −0.26 0.93 0.11 0.95 0.19 0.79
     Digit Span Backwards WAIS-III 5.67 1.77 6.40 1.98 6.37 1.75
     Letter-Number Sequencing WAIS-III 9.47 2.27 10.15 2.08 10.50 1.59
Episodic Memory −0.31*** 0.89 −0.11* 0.74 0.38 0.56
     RAVLT Total Score 33.70 8.01 37.55 8.25 39.77 5.76
     RAVLT Delayed Recall 5.87 2.57 7.00 2.32 7.37 2.50
     RAVLT Delayed Recognition 26.33 3.02 27.70 1.59 28.03 1.45
     RBMT Story (Immediate Recall) 9.62 2.75 9.42 3.14 11.75 2.51
     RBMT Story (Delayed Recall) 8.43 3.51 7.85 3.30 10.38 2.56
Semantic Memory −0.36*** 0.97 −0.26** 0.89 0.53 0.88
     Semantic Fluency (Animal) 22.47 5.49 22.95 4.39 26.73 5.22
     Semantic Fluency (Profession) 16.30 4.65 16.80 5.19 20.70 4.21
Attention & Concentration
Alertness −0.17 0.88 0.17 0.68 0.06 0.59
     Digit Span Forwards WAIS-III 8.23 2.05 9.20 1.94 8.47 1.28
     TAP 2.1 Alertnessa 256.28 51.96 248.40 35.52 240.75 27.45
Sustained Attention −0.22 0.93 0.18 1.16 0.10 0.94
     d2 Test 138.63 30.93 151.60 38.33 149.03 31.25
Executive Functions
Response Generation −0.26* 0.91 −0.13 1.23 0.35 0.83
     Letter Fluency (COWAT) 32.97 9.28 34.25 12.58 39.17 8.46
Response Inhibition −0.04 1.05 0.01 1.05 0.04 0.95
     Stroop Color Word Test (Interference)a 0.70 0.30 0.73 0.47 0.65 0.21
Mental Flexibility −0.29 0.98 0.11 1.13 0.22 0.88
     TAP Flexibility (Alternation)a 900.37 353.23 824.40 405.37 732.03 177.52
Problem Solving −0.19* 0.88 −0.18* 0.85 0.31 0.74
     Raven APM (Set I) 8.00 2.23 8.10 2.02 9.50 1.93
     Brixton Spatial Anticipation Test 36.97 6.06 36.90 6.31 38.83 5.43
Cognitive subdomain scores (standardized Z-scores, mean + SD) and raw neuropsychological test scores (mean + SD) for 
the patients using VEGFR TKI, the patient controls and the healthy controls. Higher scores indicate a better performance 
except where noted. Post-hoc t-tests, patient groups compared to healthy controls, for the cognitive subdomain scores: 
* P<0.05, ** P<0.01, *** P<0.001. a Higher scores reflect a worse performance. Abbreviations: RAVLT = Rey Auditory 
Verbal Learning Test; RBMT = Rivermead Behavioural Memory Test; WAIS-III = Wechsler Adult Intelligence Scale–Third 
Edition; TAP = Test for Attentional Processing; Raven APM = Raven Advanced Progressive Matrices.
Mood scores as assessed with the BDI-II (Table 3) were higher in the VEGFR TKI group 
(P<0.0001) and the patient controls (P=0.002) compared to healthy participants. Seven 
(23%) VEGFR TKI patients, 2 (10%) patient controls and none of the healthy volunteers had 
scores above the cut-off value of 16 indicative for a depressive disorder that has been 
validated on advanced cancer patients29. Moreover, the VEGFR TKI patients and the 
patient controls experienced more fatigue than healthy controls on the CIS20r (P=0.000 
and P=0.025 respectively) (Table 3). No significant differences between the two patient 
groups were found on any of the self-report questionnaires or subscales (Table 3). In the 
VEGR TKI group, longer treatment on VEGFR TKI was associated with less complaints of 
fatigue (CIS20r total score r=-0.404, P=0.030).
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Table 3. Self-reported psychological well-being, subjective cognitive complaints, depressive symptoms 
and level of fatigue
Patients VEGFR TKI Patient Controls Healthy Controls
Mean SD Mean SD Mean SD
SCL-90-R
     Anxiety 13.07** 3.10 12.75* 3.06 11.10 1.71
     Depression 23.87*** 6.31 22.55** 5.32 18.20 2.68
     Sleep Disturbance 4.93 2.57 5.00 2.03 4.10 1.40
     Agoraphobia 7.90 2.01 8.10 2.20 7.40 0.77
     Somatization 19.23*** 5.73 17.40* 6.07 14.17 3.18
     Cognitive-Performance Difficulty 14.77** 4.68 14.75** 4.82 11.43 2.13
     Interpersonal Sensitivity and Paranoid 
Ideation
20.90 3.63 22.50 5.69 20.87 3.15
     Anger-Hostility 6.90 1.27 6.90 1.12 6.43 0.86
     Total score 123.10*** 24.13 121.80** 26.81 103.67 11.88
CFQ
     Total score 93.37 13.20 89.55 10.13 91.80 9.64
BDI-II
     Total score 9.87*** 5.76 8.25** 5.78 3.60 2.98
CIS20r
     Total score 67.67*** 26.75 61.05* 21.11 46.60 16.24
Self-reported psychological well-being, subjective cognitive complaints, depressive symptoms and level of fatigue (mean 
+ SD) for the patients using VEGFR TKI, the patient controls and the healthy controls. Post-hoc t-tests, patient groups 
compared to healthy controls: * P<0.05, ** P<0.01, *** P<0.001. Abbreviations: SCL-90-R = Symptom Checklist-Revised; 
CFQ = Cognitive Failures Questionnaire; BDI-II = Beck Depression Inventory-Second Edition; CIS-20-R = Checklist Individual 
Strength-Revised.
Biomarkers
Between the two patients groups no significant differences were found in hemoglobin 
level, leucocytes and platelet counts, liver and renal function, electrolytes, HbA1c, vitamin 
B12 (data not shown), albumin CRP, ESR and VEGF levels (Table 1). In the VEGFR TKI 
patients group the calculated free testosterone- and estradiol values, absolute neutrophil 
counts and glucose levels were significantly lower, and the Thyrotropin (TSH) and LDH 
levels were higher compared to the patient controls (Table 1). No consistent correlations 
were found between the results of hematology- and chemistry-blood tests and the 
neuropsychological tests or the self-report questionnaires (data not shown). Only in the 
VEGFR TKI patients were higher ESR levels associated with worse scores on the main 
cognitive domains Learning & Memory, Attention & Concentration and Executive Functions 
(Table 4). CRP levels (Table 4) and higher neutrophils (data not shown) in this group were 
also negatively correlated with the domain score Learning & Memory. In the VEGFR TKI 
patients higher ESR, CRP and LDH levels were associated with higher scores on the BDI-II, 
indicating more depressive symptoms. No correlations were found between the free 
testosterone- or estradiol levels and the results on the neuropsychological tests or the 
self-report questionnaires (data not shown).
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In both patient groups, the VEGF levels were not associated with the results on the 
cognitive domain scores or fatigue (CIS20r) (Table 4). Only in the patient control group 
higher VEGF levels were associated with less complaints on mood (BDI-II), psychological 
well-being (SLC-90-R) and cognitive failure in daily functioning (CFQ) (Table 4).
We were able to analyze serum cytokine levels in 29 VEGFR TKI patients and 18 patient 
controls. In both groups no detectable levels of IL-5 and IL-6 were found in any of the 
patients, and IL-2 and TNF- α levels were only sporadically detected (data not shown). The 
IL-8 level was detectable in 80% (n=23) of the VEGFR TKI group and in 67% (n=12) of the 
patient controls and no difference was found in IL-8 levels between the patient groups. 
We found no correlations between the serum IL-8 level and the scores on the 
neuropsychological tests or the self-report questionnaires.
No correlations were found between the duration of treatment with VEGFR TKI and 
biomarker concentrations (data not shown) or the results of the neuropsychological tests 
and the self-report questionnaires, except for the results on the subdomain Working 
Memory and the CIS20r.
Discussion
This study is the first to examine cognitive functioning and subjective cognitive complaints 
in cancer patients during treatment with the VEGFR TKI sunitinib or sorafenib. We found 
that these patients performed worse on the cognitive domains Learning & Memory 
(Episodic-and Semantic Memory) and Executive Functions (Response Generation and 
Problem Solving) compared to healthy controls. Furthermore, a longer duration of VEGFR 
TKI treatment was associated with worse functioning on Working Memory tasks. Patient 
controls also showed impairments on the neuropsychological tests concerning Learning 
& Memory (Episodic- and Semantic Memory). However, in contrast with the VEGFR TKI 
patients, they showed impairment only on the subdomain Problem Solving but not on 
Response Generation. Our data suggest that effect sizes of cognitive dysfunction in 
patients using VEGFR TKI are larger on the domains Memory & Learning and Executive 
Functions, compared to patient controls. Although we found no significant differences in 
the results of the neuropsychological tests between the VEGFR TKI patients and the 
patient controls, possibly due to the smaller group size of the patient control group.
Since both patient groups performed on the domain Attention & Concentration the same 
as the healthy controls, the observed deficits in the other domains are not due to worse 
attention and concentration.
On self-reported psychological well-being, subjective cognitive complaints, depressive 
symptoms and fatigue, both patient groups reported significantly more complaints 
compared to the healthy controls. Although the VEGFR TKI patients showed more cognitive 
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impairments on the domain Executive Functions, both patient groups reported equal 
levels of psychological and somatic complaints on the self-report questionnaires. 
Moreover, the non-significant, yet slightly higher scores on depressive symptoms and 
fatigue of the VEGFR TKI patients do not explain the lower scores on the memory and 
executive functioning tests. That is, no differences were found between the patient 
groups and the healthy control group on attention and concentration tasks, which are 
typically susceptible for mood disturbances and fatigue.19
We did not observe any consistent correlations between self-reported cognitive 
complaints and neuropsychological measures neither in patients, nor in healthy controls 
(data not shown), as is observed in patients treated with chemotherapy.9,30,31
We chose to perform a cross sectional study design, which is frequently used in 
neuropsychology, as this could give an indication if cognitive functioning was indeed 
decreased. Our study design included two relevant and well matched control groups and 
the results were not confounded by practice effects through repeated testing. 
Furthermore, the in vitro rodent data demonstrated that VEGF plays a role in cognitive 
functioning.7,8 The complaints of VEGF TKI treated patients about cognitive functioning 
and the result of this study support the necessity for a longitudinal study on cognitive 
functioning in these patients.
We included both patients on sunitinib and sorafenib. As both sunitinib and sorafenib 
inhibit the VEGFR2,32,33 and we presumed that the cognitive functioning would be 
influenced by blocking this pathway, there was no reason to exclude one of both 
angiogenesis inhibitors. We did not perform a MRI of the brain before inclusion but 
Included patients did not have symptomatic brain metastases. Therefore, we may have 
missed asymptomatically brain metastases, although there is no reason to expect that 
this was different between the two patient groups.
In our study we explored factors possibly influencing cognitive functioning in cancer 
patients and specifically in patients during VEGFR TKI treatment. We demonstrated that 
male patients on treatment with sunitinib or sorafenib had lower free testosterone levels 
compared to patient controls, possibly due to the treatment. However we observed no 
relation between these sex hormones and cognitive functioning. Previous studies 
correlating cognitive functioning with testosterone levels in hypogonadal men and studies 
on androgen-ablation therapy have produced inconsistent results.34,35
In contrast to others,12 we found no correlation between serum IL-8 concentrations and 
objective or subjective cognitive functioning. In mRCC patients elevated levels of serum 
IL-6 and IL-8,36-38 neutrophil counts and LDH39 have been identified as markers of a 
systemic inflammatory response and predictors of worse prognosis. In the VEGFR TKI 
patients we found that higher levels of ESR, CRP and neutrophils were associated with 
worse objective cognitive functioning, and higher levels of ESR, CRP en LDH with depressive 
symptoms. Especially the ESR level seems relevant as it showed correlations with all 
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cognitive domains. Our data suggest that markers of systemic inflammatory response, 
probably as a symptom of tumor progression, are correlated with worse cognitive 
performance and more depressive feelings in patients treated with VEGFR TKI. This is 
consistent with the work of others who found that higher CRP levels were associated with 
depression and worse cognitive functioning.40,41
Recently a review was published addressing the role of VEGF in the brain and the role of 
VEGF inhibitors on cognitive impairment. Ng et al. concluded that VEGF plays an important 
role in the Central Nervous System such as neurogenesis and neuroprotection, and that 
studies suggest that VEGF may affect cognitive functioning through its effects on 
neurogenesis, cerebral blood flow and modulation of long-term potentiation.42 We 
demonstrated no differences in plasma VEGF concentration between the two patient 
groups, and no influence of VEGF levels on cognitive functioning was observed. However, 
in the VEGFR TKI group the intracellular effect of VEGF is prevented by receptor blockade, 
and therefore VEGF plasma concentrations are not reflecting the intracellular 
concentrations and effects of VEGF in this group. A possible explanation for the difference 
in cognitive functioning between the two patient groups is that, as a result of blocking the 
cerebral VEGF receptor through the VEGFR TKI, the capacity of neuronal repair and 
neurogenesis and learning is decreased. Furthermore, in the patient controls we found a 
strong negative correlation between subjective complaints and VEGF concentration, 
suggesting that VEGF indeed is important for psychological well-being.
In summary, our data suggest that treatment with VEGFR TKI has a negative impact on 
cognitive functioning, and that subjective complaints can be corroborated by objective 
neuropsychological testing. However this should be confirmed in a longitudinal study. 
Our results also warrant further studies on the underlying mechanism of the impairment 
of cognitive functioning during VEGF TKI therapy for example with functional imaging 
such as dynamic MRI imaging.
We propose that patients who are treated with VEGFR TKI are monitored and informed for 
possible signs or symptoms associated with cognitive impairment.
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Abstract
Sunitinib is a multiple tyrosine kinase inhibitor of the vascular endothelial growth factor 
and platelet-derived growth factor pathway and inhibits angiogenesis, cell proliferation, 
and tumor cell invasion, and stimulates apoptosis. Treatment with sunitinib in first-line 
metastatic renal cell carcinoma improves progression-free survival and overall survival 
compared with interferon-a. Crohn’s disease is characterized by chronic immune-mediated 
intestinal inflammation. Although the exact pathogenesis of Crohn’s disease remains un-
known, the involvement of angiogenesis is acknowledged. It is unknown whether sunitinib 
interferes with the natural course of Crohn’s disease. 
We describe a patient with metastatic renal cell carcinoma and a history of Crohn’s disease 
who was treated with sunitinib and developed a severe exacerbation of Crohn’s disease. 
After rechallenge with sunitinib, a second exacerbation occurred. 
We therefore conclude that angiogenesis inhibitors should be administered with care in 
patients with a history of Crohn’s disease. 
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Introduction
Targeted therapies, such as sunitinib, have considerably improved outcomes for patients 
with metastatic renal cell carcinoma (mRCC). Sunitinib is a multiple tyrosine kinase 
inhibitor of the vascular endothelial growth factor (VEGF) and platelet-derived growth 
factor (PDGF) pathway and inhibits angiogenesis, cell proliferation, and tumor cell 
invasion, and stimulates apoptosis. Treatment with sunitinib in first-line mRCC improves 
progression-free survival and overall survival compared with interferon-a.1 Crohn’s 
disease is characterized by chronic immune mediated intestinal inflammation. Mucosal 
healing in Crohn’s disease depends in part on angiogenesis and cell proliferation. It is 
unknown whether sunitinib interferes with the natural course of Crohn’s disease. We 
describe a patient with mRCC and a history of Crohn’s disease who was treated with 
sunitinib and developed an exacerbation of Crohn’s disease. This case report raises 
important questions about the management of patients with a history of Crohn’s disease 
and concurrent treatment with an angiogenesis inhibitor. 
Case report
A 57-year-old man with a diagnosis of clear renal cell carcinoma with metastasis in lung, 
pleura, and lymph nodes started treatment with sunitinib 37.5 mg once daily for 4 weeks 
on/2 weeks off. This lower than normal dose was chosen because the patient also was 
known to have Crohn’s disease since 2 years and was treated with mesalazine 4.5 g since. 
Initially, the diagnosis was made by means of sigmoidoscopy, until the splenic flexure, 
where the colon showed a cobble stone effect and ulcera. Pathology results at that time 
showed severe transmural inflammation, without histologic signs of ischemia. At the start 
of sunitinib therapy, his Crohn’s disease was in clinical remission. Colonoscopy showed a 
single ulceration in the sigmoid amidst normal mucosa and a short section with 
inflammation in the colon descendens. The remaining colon and terminal ileum were 
normal. Sunitinib treatment was well tolerated and increased to 50 mg once daily in the 
second cycle. During the third week of this cycle, he developed watery, bloody stools, 
abdominal cramping, weight loss, and fever. Laboratory values included C-reactive 
protein 170 mg/l (normal <5mg/l), leukocytes 3.5 x 109/l (normal 3.5–11 x 109/l), with 74% 
neutrophils and 12% lymphocytes. Stool cultures including Clostridium difficile and PCR 
for cytomegalovirus were negative. Colonoscopy indicated an edematous mucosa with 
deep, large ulcers in the entire colon and also a few ulcers in the ileum. Histology of 
colonic biopsies showed strong crypt deformation and inflammation with influx of 
lymphocytes. The ileum biopsies showed inflammation in the lamina propria with erosions 
of the epithelial cell layer and crypt abscesses. This was compatible with reactivation of 
Crohn’s disease. The patient was admitted to the hospital, sunitinib was discontinued, 
and treatment with oral prednisone 30 mg once daily was started. Clinical remission was 
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achieved within 1 week. Within 2 months, the prednisone was gradually tapered. Because 
of progression of the mRCC, he then started everolimus 10 mg once daily, an mTOR 
inhibitor. During this treatment, he maintained remission of his Crohn’s disease. 
Unfortunately, after 6 months, progressive mRCC recurred and sunitinib was restarted in 
a continuous dosing schedule of 37.5 mg a day. However, after 3 months, he was admitted 
to the hospital because of diarrhea with severe rectal blood loss. A colonoscopy until the 
cecum showed aphthous ulcers throughout the entire colon. Pathology results were 
compatible with an exacerbation of Crohn’s disease with mild crypt deformation and 
inflammation with infiltration of lymphocytes. Sunitinib was definitely withdrawn, 
budesonide was started, and the patient received a blood transfusion. No systemic 
treatment was restarted and the patient died of progressive mRCC 5 months later. No 
post-mortem examination was performed. 
Discussion 
This is the first case report describing a patient with a history of Crohn’s disease who 
started sunitinib treatment for mRCC and developed two episodes of exacerbation of his 
Crohn’s disease following initiation of sunitinib. 
Crohn’s disease is a chronic, relapsing, inflammatory disease that may be localized in any 
part of the digestive tract and affects the entire intestinal wall. Although the exact 
pathogenesis of Crohn’s disease remains unknown, the involvement of angiogenesis is 
acknowledged [2–4]. Danese et al.2 showed that increased micro vessel density is present 
in tissue involved in active inflammation because of Crohn’s disease and colitis ulcerosa 
but not in normal tissue. Treatment with the antiangiogenic compound ATN-161 decreased 
the micro vessel density,4,5 the associated tissue histopathology,4 and the disease activity 
index5 in experimental mouse models (CD4+CD45RBhigh T-cell transfer model4 and 
interleukin 10 –/ – model5). In patients, it has been shown that levels of VEGF-A and its 
receptor VEGFR-2 are increased in patients with inflammatory bowel disease.3,6 VEGF-A 
promotes intestinal angiogenesis and inflammation and is thereby a mediator of 
inflammatory bowel disease. Agents that block VEGF-A signaling might reduce intestinal 
inflammation.3 Indeed, two patients with Crohn’s disease were treated for a simultaneously 
residing colorectal cancer with bevacizumab, a VEGF-antibody, and did not experience an 
exacerbation of the Crohn’s disease during treatment.7 However, also a patient is 
described who developed a segmental colitis associated with diverticulosis after therapy 
with bevacizumab.8 Also, thalidomide has effectively been used as therapy in Crohn’s 
disease.9,10 Besides its immunomodulatory effect through inhibition of tumor necrosis 
factor-a production, thalidomide has also been shown to have antiangiogenic properties.11,12 
However, whether the positive effect of thalidomide on disease activity in Crohn’s disease 
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is attributable to antiangiogenic properties or to immunomodulatory effects has yet to be 
elucidated. 
The PDGF pathway also plays a role in Crohn’s disease activity.13,14. Accordingly, there is 
a case report of a long-standing remission of Crohn’s disease achieved during therapy 
with imatinib,15 which inhibits PDGF. Sunitinib is an inhibitor of both VEGF and PDGF and 
might therefore have a positive effect on the course of Crohn’s disease. However, in this 
case, sunitinib treatment was complicated by an exacerbation of pre-existent Crohn’s 
disease and a rechallenge resulted in a second exacerbation. Also, Loriot et al.16 described 
a case of exacerbation of hemorrhagic colitis in a patient receiving sunitinib and sorafenib. 
We therefore conclude that angiogenesis inhibitors should be administered with care in 
patients with a history of Crohn’s disease. The awareness of a possibly higher risk of a 
Crohn’s disease exacerbation during treatment with sunitinib or other VEGF inhibitors 
can guide physicians and patients with both Crohn’s disease and mRCC in optimizing 
palliative treatment.
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Abstract
Background
Diarrhea is a frequently occurring adverse event during treatment with vascular 
endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR TKIs) and is mostly 
accompanied by abdominal cramps, flatulence and pyrosis. These complaints impair 
quality of life and lead to dose reductions and treatment interruptions. It is hypothesized 
that the diarrhea might be due to ischemia in bowel mucosa or inflammation, but the 
exact underlying pathophysiological mechanism of the diarrhea is still unknown. We 
aimed at exploring the mechanism for diarrhea in these patients by thorough endoscopic 
and histological assessment. 
Materials and methods
Endoscopies of the upper and lower gastrointestinal(GI) tract in ten patients with 
metastatic renal cell carcinoma (mRCC) who developed diarrhea during treatment with 
VEGFR TKIs were performed. 
Results
Ten patients were included. The results showed endoscopically normal mucosa in the 
lower GI tract in seven patients without signs of ischemic colitis or inflammation. 
Gastroduodenoscopy revealed gastro-esophageal reflux disease, bulbitis and/or 
duodenitis with ulcers in eight patients. In three selected patients with bulbitis/duodenitis 
additional video capsule endoscopy was performed but revealed no additional intestinal 
abnormalities.
Conclusions
We observed frequent mucosal abnormalities in the upper GI tract in VEGFR TKI treated 
mRCC patients with diarrhea. Although these abnormalities provide insufficient 
explanation for the occurrence of diarrhea, we suggest to perform routine upper GI 
endoscopy in VEGFR TKI treated patients with GI complaints.
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Introduction
Tyrosine kinase inhibitors (TKIs) of the vascular endothelial growth factor receptors 
(VEGFR), such as sunitinib, sorafenib and pazopanib, have improved survival in patients 
with metastatic renal cell carcinoma (mRCC). These drugs showed to increase progression 
free survival and stabilization of the disease compared to interferon alpha1,2 or placebo.3,4 
VEGFR TKIs inhibit angiogenesis, cell proliferation and tumor cell invasion. In general, 
VEGFR TKIs are tolerated reasonably well, but diarrhea is a frequently reported side-
effect1,3-7 which may persist for a prolonged period of time. In 53% of 375 patients treated 
with sunitinib diarrhea was observed and in 5% of cases it was severe, defined as grade 3 
diarrhea according to the common terminology criteria for adverse events (CTCAE).1  A 
phase III study with pazopanib reported similar percentages, 52% of patients having 
diarrhea which was severe diarrhea in 4%.4 
Diarrhea negatively influences the quality of life due to flatulence, cramps, urge and fecal 
incontinence. Furthermore, diarrhea can necessitate dose reductions or interruptions, 
potentially leading to less effectiveness of treatment. Therefore, it is of utmost importance 
to understand, treat and if possible prevent VEGFR TKI- induced diarrhea.
Despite its frequent occurrence, the etiology and pathophysiological mechanisms that 
lead to diarrhea in patients treated with VEGFR TKIs have not been clarified yet. Several 
potential causes for diarrhea in these patients have been previously suggested. VEGFR 
TKIs do not exclusively inhibit the vasculature of tumors, but also have their effect on the 
blood supply of healthy organs. Cases have been published in which ischemic colitis and 
perforation have been reported after treatment with bevacizumab and VEGFR TKIs.8-12 
Chronic low-grade ischemia can also occur and lead to chronic symptoms. We hypothesized 
that ischemic conditions in the bowel mucosa might lead to the diarrhea in patients 
treated with VEGFR TKIs. Second, it is known that angiogenesis is involved in the 
pathogenesis of inflammatory bowel diseases.13,14 It may be that inflammation has a role 
in the pathogenesis of the diarrhea. 
In order to explore possible causes of diarrhea in patients who developed diarrhea during 
treatment with a VEGFR TKI, including intestinal ischemia and mucosal inflammation, we 
performed an endoscopy of the upper and lower gastrointestinal (GI) tract.
Material and Methods
Ten consecutive patients on VEGFR TKI treatment for mRCC who developed diarrhea of 
any grade according to the common terminology criteria of adverse events (CTC AE)15 
were asked for participation in this study. Diarrhea was defined as the sudden deviation 
of normal bowel movements, with a higher frequency of bowel movements (at least three 
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times a day), a larger quantity and feces containing more water than before. Patients with 
a known history of bowel diseases such as inflammatory bowel disease, lactose intolerance 
or celiac disease were excluded. Patients using laxatives on a regular basis were also 
excluded. 
The medical ethical committee of our institute (nr 2011/151) approved this study. After 
providing written informed consent, a thorough history was taken, covering all aspects of 
diarrhea and accompanying GI complaints in relation to treatment with the VEGFR TKI. In 
all patients, both a sigmoidoscopy and gastroduodenoscopy were performed. At least two 
biopsies from stomach, duodenum and sigmoid each were taken on formalin and liquid 
nitrogen and stored on -20°C until analysis. In case of macroscopic abnormalities targeted 
additional biopsies were taken. A pathologist with expertise in GI diseases (IN) assessed 
all biopsies in a systematic way. In the context of the “ischemic” hypothesis, additional 
immunohistochemical stainings on stomach, duodenal and sigmoid biopsies for CD31 
(marker for endothelial cells), D2-40 (marker for lymphatic endothelial cells) and VEGFR2 
(the receptor that mediates almost all of the known cellular responses to VEGF)  were 
done. Stainings for cytomegalovirus and helicobacter pylori were performed to rule out 
an infectious cause.  
Results
Patients
Ten patients with clear cell mRCC were enrolled between November 2011 and March 
2013. Patient characteristics are described in Table 1. Nine patients were treated before 
study entry with sunitinib for a median duration of 11 months. One patient was on 
treatment with cediranib 30 mg once daily in a phase I study since 62 months. The median 
duration of therapy before occurrence of the diarrhea was 5 months (range 1-14 months), 
including four patients complaining of diarrhea since the first cycle. Patients complained 
about frequent bowel movements, median 4 to 5 times a day, typically starting in the late 
afternoon or early after dinner and occurring within a short time interval e.g. two or three 
times in 30 minutes time (Table 2). Seven patients also reported nocturnal bowel 
movements necessitating passing stools at night. Five patients reported fecal incontinence. 
In eight patients, the diarrhea was accompanied with abdominal cramps and/or flatulence. 
Patients did not report undigested food, blood or mucus in the stools, nor did they 
describe the typical findings of steatorrhoe (pale, greasy, voluminous stools). Seven 
patients used loperamide chronically to control their complaints. All patients changed 
their food and drinking habits in an attempt to diminish the complaints: milk products, fat 
and spicy food were banned from the menu, with variable results. 
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Table 1. Patient characteristics
  
Pt 
nr
TKI Dosage Age 
(year)
Sex BMI Duration 
of 
treatment 
(months)
Start of 
diarrhea 
(months of 
treatment)
Concomitant medication
1 sunitinib 37.5 mg 
CDD
63 M 26.4 12 7 amlodipine, loperamide
2 sunitinib 37.5 mg 
CDD
59 F 24.1 36 3 atenolol, levothyroxine, 
loperamide
3 sunitinib 50 mg 4/2 47 M 26.4 17 7 amlodipine, atenolol, lisinopril, 
loperamide, omeprazole
4 sunitinib 37.5 mg 
CDD
58 M 23.9 11 7 amlodipine, levothyroxine, 
lisinopril, loperamide, 
pantoprazole
5 cediranib 30 mg 
CDD
66 M 25.0 62 14 amlodipine, doxycyclin, 
levothyroxine, loperamide
6 sunitinib 50 mg 4/2 61 M 27.4 7 1 amlodipine, ASA, 
hydrochlorothiazide
7 sunitinib 25 mg 
CDD
60 M 43.7 10 1 amlodipine, atenolol
8 sunitinib 37.5 mg 
CDD
65 M 28.1 10 7 ASA, furosemide, isosorbide 
mononitrate, lisinopril, 
loperamide, metformin, 
nebivolol, oxycodone, 
pantoprazole, simvastatin
9 sunitinib 37.5 mg 
4/2
61 M 28.1 26 1 ASA, atorvastatin, 
chlortalidone, clopidogrel, 
diazepam,  isosorbide 
mononitrate, loperamide, 
losartan, metoprolol, 
pantoprazole
10 sunitinib 37.5 mg 
CDD
50 M 25.7 9 1 none
 
Abbreviations: pt nr patient number; TKI tyrosine kinase inhibitor; CDD continous daily dosing; 4/2 four weeks on two 
weeks off; M male; F female, BMI body mass index; ASA acetylsalicylic acid
Table 2. Patients’ complaints of diarrhea and other gastrointestinal adverse events
Patient Frequency During night Cramps Flatulence Pyrosis
1 4-5 Y N Y N
2 5-6 Y N Y N
3 4 Y Y Y Y
4 5-6 Y Y N Y
5 3-4 N N Y N
6 4 N N N Y
7 2-4 N N N N
8 5-6 Y Y Y Y
9 >7 Y Y Y Y
10 3 Y Y Y Y
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Endoscopy: macroscopic findings
In half of the patients the sigmoidoscopy showed macroscopic abnormalities with swollen 
mucosa, a polyp in the rectum, impression from outside accompanied by an ulcer, 
teleangiectasias and diverticulosis all occurring once (Table 3). With gastroduodenoscopy 
macroscopic abnormalities were found in eight out of ten patients (Table 3). Five patients 
had gastro esophageal reflux disease (GERD) and four patients had endoscopic signs of 
bulbitis/duodenitis with ulcers. In one patient with a long history of heartburns and a 
family history of reflux esophagitis, a carcinoma in situ of the esophagus was found, 
which was treated subsequently by endoscopic mucosal resection. 
Endoscopy: microscopic findings
The microscopic findings of the biopsies in patients by sigmoidoscopy and 
gastroduodenoscopy are shown in Table 3. Biopsies of the sigmoid showed abnormalities 
in three patients: a hyperplastic polyp, localization of RCC in the submucosa/lamina 
propria and aspecific abnormalities in architecture with focal bleeding. In three patients 
the staining for VEGFR2 showed an increase of VEGFR2 in the epithelium and subepithelium 
of the sigmoid.
In biopsies of stomach and duodenum, six cases of chronic inflammation were found 
(60%), three cases of active inflammation, intestinal metaplasia and angiodysplasia (30%) 
and two cases of proton pump inhibitor effect, reactive gastropathy and infection with 
helicobacter pylori each (20%). Stainings for CMV, D2-40 and CD31 were normal in all 
patients. 
Additional tests 
When we found the mucosal abnormalities such as ulcers and erosions, in the duodenum 
and bulbus of four patients, we hypothesized that this might explain the diarrhea and 
subsequently, three patients underwent a video capsule endoscopy (VCE) in order to 
assess the entire small intestine. 
In two patients small angiodysplasias, superficial erosive lesions and microscopic 
haemorrhages  were observed in the entire small intestine. In one patient the lesions 
were mostly localized in the most distal part of the small intestine and also in the right-
sided colon. No ulcers were observed. In the last patient only very few superficial erosions 
were seen. 
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Discussion
Diarrhea is a frequently occurring adverse event of treatment with VEGFR TKI, which 
could lead to dose interruptions or reductions and diminish quality of life. The endoscopies 
performed in our study showed no definitive evidence for ischemia or inflammation as 
the cause of the diarrhea. Unexpectedly, we found focal mucosal abnormalities such as 
erosions and ulcers in esophagus, stomach and duodenum in the majority of patients. 
Despite the high prevalence of the diarrhea in patients with VEGFR TKI and the negative 
consequences on quality of life, research focusing on the cause of this adverse effect is 
scarce. As far as we know, no other prospective studies in which endoscopy was performed 
had been published before. Thus far, only a retrospective case series was published in 
which colonoscopy was performed in patients treated with bevacizumab, which showed 
bowel mucosa changes consistent with ischemic colitis. However, these patients had 
severe anal pain and bowel perforation[8]. 
The first hypothesis of ischemia is supported by preclinical research in mice by Kamba et 
al.16 which showed that capillaries of healthy tissue in adult mice regressed in reaction to 
anti-VEGF therapy. After anti-VEGF therapy for 2-3 weeks, 20-46% of capillaries in the 
microvilli in the small intestine regressed. In our study, neither endoscopic evaluation 
showed macroscopic signs of ischemia, nor did  (immune)histological examination. The 
results of this study also did not give any indication that inflammation is involved in the 
pathogenesis of diarrhea. Biopsies of the sigmoid were almost exclusively normal as well 
as the macroscopic pictures were. Histology of biopsies of the upper GI tract showed 
signs of focal chronic and acute inflammation. However, the VCE, performed in three 
patients, showed only limited and patchy abnormalities in the small intestine. Since the 
predominantly occurrence of abnormalities in the upper GI tract, this is not a plausible 
explanation for the diarrhea.
A study performed by Mir et al. did show that the diarrhea and hypophosphatemia which 
developed in eight patients treated with sorafenib was due to a pancreatic exocrine 
dysfunction.17 Pancreatic exocrine dysfunction leads to malabsorption, as well as other 
disorders such as celiac disease, lactose intolerance and short bowel syndrome. A 
malabsorption syndrome could explain the macrocytosis, vitamin B12 deficit18,19 and 
weight loss despite a normal caloric intake which often develops in patients who are 
treated with VEGFR TKIs. Because of the nature of this study, we were not able to 
investigate non-mucosal diseases such as pancreatic exocrine dysfunction. This should be 
the scope of new studies. 
In this study, five out of ten patients showed signs of GERD. In addition, one patient was 
diagnosed with a carcinoma in situ of the esophagus. Three patients used acetylsalicylic 
acid (ASA), which is a known risk factor for the development of gastric and esophageal 
mucosal injury.20 However, two of these patients also used a proton pump inhibitor in 
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combination with ASA to protect their mucosa for the detrimental effects. In this study, 
seven patients had a body mass index (BMI) above 25 (see Table 1) and were thus 
overweight, which is also a known risk factor for GERD. However, one of the patients with 
a healthy weight suffered from GERD, whereas the patient with very severe obesity did 
not have any abnormalities. Four of the five patients with GERD were symptomatic and 
complained of pyrosis, which started since the initiation of treatment with the VEGFR TKI. 
Because of the non-prospective nature of our study, a causal relationship between the 
reflux disease and the use of VEGFR TKI could not be evaluated.  
In conclusion, this study did not support an ischemic or inflammatory cause as the 
underlying pathophysiological mechanism for diarrhea in patients treated with VEGFR 
TKIs. However, as an unexpected result, we found mucosal abnormalities such as erosions 
and ulcers in esophagus, stomach and duodenum in the majority of patients. Based on 
these results, we recommend routine gastroduodenoscopy in patients treated with VEGFR 
TKIs who report gastrointestinal symptoms, in order to timely diagnose and treat these 
abnormalities. 
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Abstract 
Background
Malignant ascites and pleural effusion are challenging clinical problems, with a major 
impact on quality of life. We conducted a randomized phase II trial to assess the palliative 
value of cediranib, an oral vascular endothelial growth factor tyrosine kinase inhibitor 
(VEGF TKI).
Methods
After a baseline paracentesis or thoracentesis (on day 0), patients with symptomatic 
malignant ascites and/or pleural effusion were randomized between immediate treatment 
with cediranib (Immediate Cediranib) or delayed treatment with cediranib (Delayed 
Cediranib) on day 29, or after a new puncture was needed. The primary objective of the 
study was the puncture-free survival, defined as the time from study start (day 1) to the 
first need for paracentesis or thoracentesis, or time to death, whichever event occurred 
first.
Results
 Twelve patients were enrolled. The median puncture-free survival was 45 days (range 10 
- 368) in the Immediate Cediranib patients and 7 days (range 4 - 13) in the Delayed 
Cediranib patients (P=0.011). The change in puncture-free interval (the puncture-free 
survival after study start minus the puncture-free interval before study start) increased 
with a median of 31 days in the Immediate Cediranib patients and shortened with a 
median of 3 days in the Delayed Cediranib patients (P=0.015). The most common adverse 
events were fatigue and anorexia. 
Conclusions
Cediranib increased the puncture free-survival and puncture free-interval with an 
acceptable toxicity profile. This is the first study in which an oral VEGFR TKI showed 
beneficial palliative effects in patients with malignant effusions. 
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Introduction 
Malignant ascites and malignant pleural effusion are challenging clinical problems in 
cancer patients, which have a major impact on quality of life, especially when standard 
anti-cancer therapies are not available or no longer feasible. Ovarian- and gastrointestinal 
cancers are the most common causes of malignant ascites, while1 lung and breast cancer 
are the most common causes of malignant pleural effusion.2 In a survey among 209 
patients with malignant ascites, 58% of patients had ascites-related symptoms. The most 
frequently occurring symptoms were abdominal swelling, abdominal pain, nausea, 
anorexia, vomiting, fatigue, dyspnea and early saturation with eating.1 The main 
complaints of pleural effusion are dyspnea, cough, and chest pain.3 The prognosis of 
malignant ascites or pleural effusion is poor with a median survival of only 5.7 and 4 
months, respectively.1,3 Although paracentesis, diuretics and shunting are commonly 
used procedures as treatment for malignant ascites, the evidence for their efficacy is 
weak and no prospective randomized trials have been performed.4 For malignant pleural 
effusion thoracentesis, chemical and mechanical pleurodesis, pleural catheter drainage 
and pleuroperitoneal shunting are treatment options; however there is no universally 
accepted standard approach3, and the results are often temporary. Repeated paracentesis 
or thoracentesis increases the risk of infection, perforation of abdominal organs or the 
lung, bleeding, and therefore the risk of hospitalization in a group of patients who are in 
the palliative phase of their disease. Therefore, there is a need for an effective palliative 
treatment that provides symptomatic relief from ascites and pleural effusions and that is 
associated with limited toxicity. 
Preclinical and clinical studies have shown that malignant effusion is associated with high 
levels of vascular endothelial growth factor (VEGF) in serum/plasma as well as in malignant 
effusions.5-7 VEGF in malignant pleural effusion and ascites appears to be biologically 
active as demonstrated by its stimulating effect on endothelial cell proliferation.8 
Cediranib (AZD2171) is an oral VEGF receptor tyrosine kinase inhibitor (VEGFR TKI) with an 
inhibitory effect on all three VEGF receptors (VEGFR-1, 2 and -3).9 Cediranib has been 
shown to have anti tumor acitivity as monotherapy in several cancers and the 
recommended dose is 45 mg once daily.10,11 Common adverse events include hypertension, 
fatigue, diarrhea and hoarseness.12 
We conducted a single center randomized phase II study of cediranib to determine the 
effect and safety of cediranib as palliative treatment of malignant ascites or pleural 
effusion. 
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Methods
Patients
Eligible patients had symptomatic malignant ascites and/or pleural effusion, due to a 
histological proven solid malignancy which was refractory to standard anti-tumor therapy 
or for which no standard therapy existed. Patients were ≥18 years with a Karnofsky 
performance score of ≥50. Patients had adequate hematologic, renal and hepatic 
functions. Excluded were patients with a pleural or peritoneal tap, with a history of poorly 
controlled hypertension or with a resting blood pressure >150/100, with a prolonged QTc, 
or significant hemorrhage in the previous 3 months. Written informed consent was 
obtained before entering the study. 
Study design
This was an open label, single center, randomized phase II study. Patients were randomized 
1:1 between “immediate treatment” with cediranib (Immediate Cediranib) on day 1, or 
“delayed treatment” with cediranib (Delayed Cediranib) on day 29, or after a subsequent 
puncture was required, whichever came first. All patients received best supportive care. 
The primary objective of this study was to determine the effects of cediranib as palliative 
treatment of malignant ascites or pleural effusion, by assessment of the puncture-free 
survival, defined as the time from study start (day 1) to the first need for paracentesis or 
thoracentesis, or time to death, whichever event occurred first. The decision to perform 
a paracentesis or thoracentesis was taken on the basis of the symptoms of the patient 
and the amount of malignant effusion at that moment. The secondary objectives of this 
study were: 1. the change in puncture-free interval defined as the difference between the 
puncture free survival and the puncture free interval before start of the study (in days); 2. 
the puncture free survival after starting cediranib, defined as the time to first need for 
paracentesis or thoracentesis or time to death (whichever event occurred first) after 
starting cediranib (in day); 3. to assess the tolerability of cediranib in a palliative end-
stage disease; and 4.to determine the overall survival (OS). 
This study was registered at ClinicalTrials.gov, number NCT01262612.
Treatment plan and dose modification
Patients were planned to start with the study at the time they needed a new paracentesis 
or thoracentesis due to increasing fluid accumulation and symptoms. The day that the 
patient underwent the paracentesis or thoracentesis was day 0 of the study. During every 
paracentesis or thoracentesis as much as possible effusion was removed. The starting 
dose of cediranib was 30 mg orally once daily. Special in this study was the possibility to 
decrease (to minimal 15 mg once daily) or re-increase the dose after a dose reduction for 
toxicity (to a maximum of 30 mg once daily) during the study to get an individualized 
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optimal palliative treatment with cediranib. The maximum dose of cediranib was 30 mg 
and not 45 mg because of observed toxicities in other studies12 and the pure palliative 
intention of the study. Patients were scheduled to continue cediranib as long as clinical 
benefit in relation to the malignant effusion was experienced and side effects were 
acceptable, even when progressive disease was observed. 
Patient evaluation and follow-up
Toxicity assessment, hematology, biochemistry and full physical examination and 
Karnofsky performance status were performed at baseline and weekly during the first 2 
cycles of cediranib use, and thereafter once every 8 weeks. VEGF was measured in plasma 
and in ascites or pleural effusion at screening visit and every time a puncture took place. 
Levels of VEGF were measured by a specific enzyme linked immunosorbent assay (ELISA) 
as previously described.13,14 Tumor evaluations with computed tomography (CT) scans 
were performed at baseline, after 1 month and after every 8 weeks. Response was 
evaluated according to the Response Evaluation Criteria of Solid Tumors (RECIST) version 
1.1.15
Statistical analysis
We based our power calculation on the data of the catumaxomab phase II/III study as 
presented during the ASCO Annual Meeting in 2009,16 where a median puncture-free 
survival of 44 days in the catumaxomab group was found compared to 11 days in the 
paracentesis only arm. Assuming a median puncture-free survival time of 44 days for the 
Immediate Cediranib patients and 11 days for the Delayed Cediranib patients, a total of 
16 patients per group was required to obtain a power of 80% for an analysis of puncture 
free survival time using a two-sided alpha of 0.05. If the puncture-free survival in the 
Immediate Cediranib group was >44 days, the treatment of ascites or pleural effusion 
with cediranib was assumed to be effective. 
Kaplan-Meier survival curves were used to analyze the OS of the enrolled patients. The 
duration of OS was defined from the date of study start to the date of death. Differences 
in OS between the two groups were compared using the log-rank test. Analyses were 
done in SPSS version 20.0 and a P value of ≤0.05 was considered significant. 
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Figure 1. CONSORT Flow Diagram
Results
Between April 2010 and January 2012, 12 patients were enrolled in the study; six were 
randomized for immediate starting with cediranib and six for delayed starting (Figure 1). 
Patient characteristics are summarized in Table 1. The study was discontinued prematurely 
after inclusion of 12 patients. Reasons to stop the study prematurely were: (1) a difficult 
accrual and (2) the decision to stop further development of cediranib by AstraZeneca due 
to the disappointing results of two large phase II-III trials17,18 In the Delayed Cediranib 
group, 5 out of 6 patients started cediranib after their first paracentesis or thoracentesis 
Figure 1. CONSORT  Flow Diagram 
Assessed for eligibility n= 12 
Excluded n= 0  
Analysed: n= 6   
Lost to follow-up: n=0 
Discontinued cediranib due to: 
Deterioration with ascites n=1 
Deterioration n=3 
Death due to deterioration n=2 
Group: Immediate treatment with Cediranib n= 6  
On day 0 ascites puncture or thoracentesis 
On day 1 start cediranib 30 mg n=6 
If necessary ascites puncture or thoracentesis: 
n=2  
Lost to follow-up: n=0 
Discontinued cediranib due to: 
Deterioration with pleural effusion n=1 
Deterioration with pleural effusion and ascites n=1 
Deterioration n=3 
Group: Delayed treatment with Cediranib n=6   
On day 0 ascites puncture or thoracentesis 
If necessary ascites puncture or thoracentesis: n=6 
On day 1 after puncture start cediranib 30 mg  
Received cediranib after first puncture n=5   
Did not receive cediranib after first puncture due to 
deterioration of condition n=1 
Analysed: n=6  
  
  
Randomized n=12  
 
 
o 
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(all before day 29). In one patient cediranib was not started due to an ileus. One patient 
in the Delayed Cediranib group only used cediranib for 1 day because of rapid clinical 
deterioration.
Table 1. Baseline patients’ characteristics
Patient 
number
Age 
(years)
Sex PS Tumor Prior lines 
chemotherapy 
Ascites / pleural 
effusion *
Group: Immediate treatment with Cediranib
01 49 M 80 Mixed germ cell carcinoma of the testis 5 Ascites
05 58 F 60 Papillary serous adenocarcinoma of the ovary      3 Pleural effusion
07 79 F 80 M. Paget of the mamma                              1 Ascites
08 49 M 50 Malignant mesothelioma of the tunica vaginalis 2 Ascites
11 58 F 60 Adenocarcinoma of the pancreas                        2 Ascites
12 62 F 50 Papillary serous adenocarcinoma of the ovary      2 Ascites
Group: Delayed teatment with Cediranib
02 56 M 70 Peritonitis carcinomatosa with strong CEA 
expression of the colon
2 Ascites
03 62 F 70 Extra ovary ovarian adenocarcinoma               5 Ascites
04 55 M 80 Sclerosing epitheloid fibrosarcoma of the foot     1 Pleural effusion
06 67 F 60 Papillary serous adenocarcinoma of the ovary     1 Ascites 
09 63 M 80 Adenocarcinoma of the esophagus                        2 Pleural effusion
10 47 F 70 Adenocarcinoma of the mamma and serous 
papillary adenocarcinoma   of the ovary
3 Pleural effusion
M, male; F, female; PS, performance status. * patients with ascites and pleural effusion are categorized in the group 
(ascites or pleural effusion) troubling them most
Puncture-free survival and puncture-free interval 
The two patient groups did not significantly differ in the puncture-free interval before 
start of the study or the amount of fluid removed before the study and on day 0 (Table 2). 
The primary objective of this study was the median puncture-free survival, which was 
longer in the Immediate Cediranib group (45 days) compared to the Delayed Cediranib 
group (7 days: P=0.011) (Figure 2). Furthermore, the change in puncture free-interval 
showed in the Immediate Cediranib patients a median improvement of 31 days, but in the 
Delayed Cediranib group a decline of 3 days (P=0.015) (Table 2.) The median puncture-
free interval after starting cediranib was 45 days in the Immediate Cediranib group versus 
14 days in the Delayed Cediranib group, this was not a significant difference (Table 2). 
One patient with a chemorefractory germ cell tumor used the cediranib for more than 1 
year and never needed an ascites puncture again. After 6 months the cediranib dose was 
reduced to 20 mg because of fatigue, and 4 months later the dose was further decreased 
to 15 mg because of anorexia and fatigue, and patient continued cediranib treatment 
until 2 days before his death. 
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Figure 2. Puncture-free survival
 
 
The puncture free survival defined as the time to first need for paracentesis or thoracentesis or time to death, which-
ever event occurred first after start of the study (in days) in the two study groups (Immediate treatment with Cediranib 
and Delayed treatment with Cediranib) 
VEGF in plasma and ascites or pleural effusion
At baseline, the median plasma VEGF concentration was 1.45 ng/ml (range 0.96 - 2.46 ng/
ml), the median VEGF concentration in pleural effusion was 14.87 ng/ml (range 1.4 - 24.43 
ng/ml), and the median VEGF concentration in ascites was 28.09 ng/ml (range 9.86 - 51 ng/
ml). We found no correlation between the VEGF concentration in plasma and ascites or 
pleural effusion at baseline and the primary and secondary endpoints as puncture-free 
survival, puncture-free interval, puncture-free interval after starting cediranib, or overall 
survival (data not shown).
Safety and tolerability 
Adverse events are shown in Table 3. There were no treatment-related deaths. One 
patient in the Delayed Cediranib group was admitted to the hospital prior to the initiation 
of cediranib treatment and received red blood cell transfusion due to bleeding after 
paracentesis at baseline. Three patients were hospitalized because of an ileus due to Ta
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disease progression. As expected the most common grades 3 and 4 toxic effects included 
fatigue and anorexia, which was in less than half of the cases related to cediranib use: 
most adverse events were strongly related to the underlying disease like anorexia, 
nausea, fatigue, and weight loss.
Table 3. Grade 1 - 4 toxic effects by maximum grade per patient
Toxic effect grade
Group: Immediate treatment with Cediranib 
N=6
Group: Delayed treatment with Cediranib 
N=6
Grade 1 
n (%)
Grade 2 
n (%)
Grade 3 
n (%)
Grade 4 
n (%)
Total
n (%)
Grade 1 
n (%)
Grade 2 
n (%)
Grade 3 
n (%)
Grade 4 
n (%)
Total
n (%)
Fatigue 0 1 (17) 5 (83) 0 6 (100) 0 1 (17) 4 (67) 1 (17) 6 (100)
Anorexia 2 (33) 1 (17) 3 (50) 0 6 (100) 0 1 (17) 4 (67) 0 5 (83)
Pain 4 (67) 1 (17) 0 0 5 (83) 1 (17) 3 (50) 1 (17) 0 5 (83)
Nausea 4 (67) 0 1 (17) 0 5 (83) 1 (17) 11 (17) 3 (50) 0 5 (83)
Vomiting 4 (67) 0 1 (17) 0 5 (83) 0 2 (33) 2 (33) 0 4 (67)
Weight loss 2 (33) 2 (33) 1 (17) 0 5 (83) 1 (17) 2 (33) 1 (17) 0 4 (67)
Dyspnea 2 (33) 1 (17) 1 (17) 1 (17) 5 (83) 0 2 (33) 2 (33) 0 4 (67)
Diarrhea 1 (17) 2 (33) 1 (17) 0 4 (67) 1 (17) 0 0 0 1 (17)
Other 2 (33) 1 (17) 2 (33) 0 4 (67) 1 (17) 0 0 0 1 (17)
Cough 3 (50) 0 0 0 3 (50) 2 (33) 0 1 (17) 0 3 (50)
Edema 1 (17) 1 (17) 0 0 2 (33) 3 (50) 0 0 0 3 (50)
Constipation 1 (17) 0 0 0 1 (17) 2 (33) 0 1 (17) 0 3 (50)
Mucositis 1 (17) 2 (33) 0 0 3 (50) 0 0 0 0 0
Infection 1 (17) 2 (33) 0 0 3 (50) 0 0 0 0 0
Hoarseness 3 (50) 0 0 0 3 (50) 0 0 0 0 0
Hypertension 0 0 2 (33) 0 2 (33) 1 (17) 0 0 0 1 (17)
Fever 2 (33) 0 0 0 2 (33) 1 (17) 0 0 0 1 (17)
Skin rash 2 (33) 0 0 0 2 (33) 1 (17) 0 0 0 1 (17)
Dry skin 2 (33) 0 0 0 2 (33) 1 (17) 0 0 0 1 (17)
Ileus 0 0 0 1 (17) 1 (17) 0 0 1 (17) 1 (17) 2 (33)
Pyrosis 2 (33) 0 0 0 2 (33) 0 0 0 0 0
Hemorrhage 1 (17) 0 0 0 1 (17) 0 0 1 (17) 0 1 (17)
Renal 0 1 (17) 0 0 1 (17) 0 1 (17) 0 0 1 (17)
Dysphagia 1 (17) 0 0 0 1 (17) 1 (17) 0 0 0 1 (17)
Cardial 1 (17) 0 0 0 1 (17) 0 0 0 0 0
 
The maximum severity of each adverse event per patient, after start of the study graded according to National Cancer 
Institute Common Toxicity Criteria version 3.0 (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/
docs/ctcaev3.pd) 
All patients started with Cediranib at a dose of 30 mg. Dose reductions to 20 mg were 
performed in three patients, in two of them due to fatigue and in one because of mucositis 
and diarrhea. Two of these three patients needed a further dose reduced to 15 mg. 
Cediranib was temporarily discontinued for reasons of radiotherapy, a combination of 
adverse event (a so called drug holiday) and hypertension. 
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Tumor response and overall survival
Only three patients were in good enough clinical condition to perform a CT scan for 
evaluation of the tumor response, all three from the Immediate Cediranib group. We 
observed one partial response, one stable disease and one progressive disease. All three 
patients had an improvement in their puncture-free interval after starting cediranib. The 
patient with progressive disease lived for more than 1 year without the need for a new 
puncture. The median overall survival in the Immediate Cediranib group and the Delayed 
Cediranib group was 73 days (range 10-368) and 24 days (range 19-36), respectively 
(P=0.087, Table 2). 
Discussion 
To our knowledge, this is the first phase II study of an oral VEGF inhibitor for the palliative 
treatment of malignant ascites and/or pleural effusion. We showed that it was feasible to 
treat patients with symptomatic malignant ascites and/or pleural effusion with cediranib, 
and although the groups were very small, there is a strong suggestion of clinical benefit 
on ascites or pleural effusion during the use of cediranib. We found a significant and 
meaningful longer median puncture-free survival (primary objective) and an increased 
puncture-free interval in the Immediate Cediranib group (45 days) compared to the 
Delayed Cediranib group (7 days). Cediranib was well tolerated most of the time although 
dose reduction took place in 25% of the patients and short “drug holidays” were sometimes 
necessary.
Our results are in line with the outcomes of the phase II/III trial with catumaxomab for the 
treatment of malignant ascites in epithelial cancer[19]. In this study, catumaxomab was 
administered after paracentesis as a 6 h intraperitoneal infusion on days 0, 3, 7, and 10 
and compared to paracentesis alone. In the catumaxomab arm, the puncture-free survival 
was significantly longer compared to the paracentesis only arm (46 days versus 11 days). 
Catumaxomab has recently been approved in Europe for the intraperitoneal treatment of 
malignant ascites in patients with EpCAM-positive epithelial tumors where standard 
therapy is not available or no longer feasible. Catumaxomab was also tested in a phase I/
II study in patients with malignant pleural effusion.20 The investigators concluded that 
intrapleural catumaxomab was feasible in this group, but considering the substantial 
number of drop-outs and deaths in short proximity to study treatment, there was doubt 
if malignant pleural effusion was the right indication.20 In our study, we only had four 
patients with pleural effusion; after start with cediranib, two of them did not need a new 
thoracentesis. The results of another trial concerning a palliative treatment of malignant 
ascites by blocking VEGF with an intravenous infusion of aflibercept every 2 weeks were 
recently published.21,22. The recombinant fusion protein, aflibercept binds and neutralizes 
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VEGF A, VEGF B, and placental growth factor.23 In the phase II placebo-controlled study, 
the drug showed clinical activity in patients with advanced ovarian cancer and recurrent 
symptomatic malignant ascites. The time to repeat paracentesis and paracentesis-free 
survival were significantly longer with aflibercept than with placebo (55.5 days versus 7.7 
days), and there was a greater mean improvement from baseline in symptoms of ascites. 
However, in the treatment group, three out of 29 patients developed a fatal intestinal 
perforation versus one in the placebo group.22 Gastrointestinal perforation is also a well-
known complication of anti-VEGF treatment with bevacizumab in ovarian carcinoma 
patients.24 No perforation events were observed in our study or in a phase II study with 
46 ovarian carcinoma patients treated with cediranib.12 
Consistent with others, we found that the VEGF levels in ascites and pleural effusions 
were much higher than in matched plasma samples.7 We found no indication that the 
VEGF values at baseline could predict the course of the disease or the reaction on 
cediranib. 
A limitation of our study is the low number of patients participating. We had problems 
with including the 32 patients as was intended. Frequently, this was due to rapid disease 
progression before screening. Our difficulties with the study accrual are a reflection of 
the fragile patient population with malignant ascites or pleural effusion, and this is also 
seen in other studies.22 
Given the palliative setting and the poor prognosis of patients with malignant ascites or 
pleural effusion, cediranib may have the right profile to be an effective and tolerable 
palliative treatment, especially because of its oral administration and the short elimination 
half-life,9 which makes careful titration possible. In this study, we performed a puncture 
at the start of the study, but with the experience we already have with cediranib and other 
oral VEGF TKIs, we presume that a puncture before starting the medication is not 
necessary in the majority of patients. When cediranib is effective, it will reduce the 
malignant effusion rapidly in a non invasive manner. The effects of cediranib on malignant 
effusions are probably a class effect of all VEGF TKIs. 
In conclusion, our data strongly suggest a palliative effect for an oral VEGFR TKI in the 
treatment of malignant ascites or pleural effusion. This palliative effect may even continue 
after formal tumor progression has been documented, and therefore no official tumor 
evaluation by RECIST criteria is warranted. Although confirmation of these results by a 
larger prospective placebo-controlled trial would be preferred, the feasibility in terms of 
patient accrual rate appears low. Our data suggest that an oral anti-VEGFR treatment may 
be considered in patients with malignant effusions. 
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Abstract 
Background
The tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib have efficacy in several types 
of cancer. Recent studies indicate that these agents affect the immune system. Their 
effect on the immune response to influenza vaccination is unknown. The aim of this study 
was to elucidate the specific immune response to seasonal flu vaccination in cancer 
patients treated with sunitinib or sorafenib. 
Methods
Sunitinib or sorafenib treated cancer patients were vaccinated against seasonal influenza 
with inactivated vaccine. Healthy controls and patients with metastatic renal cell cancer 
(mRCC) without systemic treatment (non-treated mRCC controls) were included for 
comparison. Antibody responses were measured at baseline, day 8 and 22 by a standard 
hemagglutination inhibition assay and cellular T cell responses at baseline and day 8 by 
proliferation assay and secretion of cytokines.
Results 
Forty subjects were enrolled, 16 patients treated with sunitinib, 6 patients with sorafenib, 
7 non-treated mRCC controls and 11 healthy controls. All patients treated with sunitinib 
and sorafenib developed seroprotection rates comparable to controls. Functional T cell 
reactivity was observed in all groups, except for patients treated with sorafenib who 
showed a decreased proliferation rate and IFN-y/IL-2 production and increased IL-10 
compared to healthy controls.
Conclusions
We conclude that influenza vaccination should be recommended in cancer patients 
treated with sunitinib or sorafenib. 
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Introduction
Dysfunction of the immune system in cancer patients has been known since long.1-4 This 
is demonstrated by an increased number of regulatory T cells (Treg) in peripheral blood 
and tumors,5,6 an impaired functionality of dendritic cells (DC),3,7,8 and changed T cell 
responses.9,10 In patients with metastatic renal cell carcinoma (mRCC) there is a shift from 
a T helper 1(Th1) mediated CD4+ T cell response, which is critical for the development of 
a cellular antitumor immunity, towards a Th2 response that typically mediates humoral 
immunity.9,10 This immune dysfunction is mediated at least in part by the vascular 
endothelial growth factor (VEGF), that inhibits the differentiation and maturation of 
dendritic cells (DC)11,12 as well as the egress of thymic precursors from the bone marrow.13 
Anti-VEGF treatment can restore DC function11,12 and can increase the influx of T cells into 
the tumor.14
Sunitinib and sorafenib are tyrosine kinase inhibitors (TKIs) of the VEGF receptor (VGFR), 
platelet-derived growth factor receptor (PDGFR) and other receptors.15,16 Both sunitinib 
and sorafenib modulate the innate and adaptive immune responses, with varying clinical 
consequences.6,11,17-23 The immunological effects of sunitinib and sorafenib have been 
studied in humans as well as in murine models. It was shown that sorafenib, but not 
sunitinib, had a detrimental effect on DC phenotype and inhibited cytokine secretion, 
migration ability, and T cell stimulatory capacity in a murine model. The proliferation rate 
and phenotype of T cells were not affected by sorafenib. Vaccination of mice treated with 
sorafenib resulted in a severe, but reversible, inhibition of CD8 T cell mediated immune 
responses.17 Others found that sorafenib decreased the proliferation of human T cells 
and induced T cell apoptosis in vitro. Sorafenib also inhibits T cell mediated immune 
responses.18 In contrast, mice treated with sub-toxic doses of sunitinib did not show an 
impaired CD8 T cell response, however a decrease in peripheral Treg numbers was 
observed.17 
 
Sunitinib and sorafenib are used for the treatment of mRCC.24,25 Sunitinib is also approved 
for second line treatment of gastrointestinal stromal tumors (GIST) (26) and sorafenib for 
treatment of hepatocellular cancer and differentiated thyroid cancer.27,28 
These agents increase the life expectancy of mRCC and GIST patients.24,26 In these patients 
efforts should be made to maintain quality of life and to reduce co-morbidities whenever 
possible. This includes the prevention of influenza. Influenza vaccination is indicated in 
individuals of elderly age or with underlying health problems, since they are at increased 
risk of complications or decline in physical functioning, and even death.29-31 The mortality 
rate of influenza infection can reach 9% in patients treated in oncology.32 In cancer 
patients treated with chemotherapy, vaccination has shown to be safe,31,33-36 but during 
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chemotherapy suboptimal antibody responses and in some studies even an absence of 
responsiveness have been reported.31,34,35 However the majority of patients with 
malignancies respond normally after a treatment-free interval of >30 days.31 Currently no 
data are available about the safety and efficacy of influenza vaccination in cancer patients 
treated with sunitinib or sorafenib.
We conducted a prospective study on influenza vaccination in patients with mRCC and 
GIST on sunitinib or sorafenib treatment who were vaccinated for influenza. The patients 
in this study fulfill the criteria for yearly influenza vaccination as recommended by the 
Advisory Committee on Immunization Practices.37 The primary aim of this study was to 
investigate the antibody response upon influenza vaccination in this group of patients. 
Secondary aims were to investigate cellular immune responses and tolerability of 
vaccination in patients treated with sorafenib and sunitinib. 
Patients and methods 
Patients and controls
The study population consisted of four groups: mRCC or GIST patients treated with 
sunitinib for ≥4 weeks, mRCC patients treated with sorafenib for ≥4 weeks, mRCC patients 
without systemic treatment for ≥1 year (the non-treated mRCC controls), and healthy 
controls aged ≥60 yrs. Patients (age ≥18 years) and controls, who received an invitation 
for influenza vaccination by the Dutch Health Care Organization, were asked to participate 
in this study. Subjects were excluded from participation if they used corticosteroids 
during the previous 2 weeks, had received immunotherapy or other targeted therapy in 
the previous year (previous imatinib use was allowed in patients with GIST), were known 
with an immune disorder or allergy to chicken eggs, or had symptoms of an influenza-like 
illness on the day of vaccination. Baseline evaluations included a medical history including 
previous influenza vaccinations, drug use and a full blood count. The study was approved 
by the institutional review board and all participants gave written informed consent.
Study design and vaccination
This was an open-label, single centre study. In the autumn of 2008, all subjects in the four 
groups were vaccinated intramuscularly with a single dose inactivated trivalent split 
influenza vaccine (InfluvacR Solvay Pharmaceuticals S.A. or VaxigripR Sanofi Pasteur MSD 
nv), that contained hemagglutinin for each of the following three influenza strains: A/
Brisbane/59/07 (H1N1), A/Brisbane/10/07 (H3N2), and B/Florida/4/06. Sunitinib and 
sorafenib were administered according to standard practice. Patients treated with 
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sunitinib at a schedule of 4 weeks on 2 weeks off were vaccinated in the 3th or 4th week of 
the sunitinib use. Peripheral blood mononuclear cells (PBMC) and serum were collected 
at baseline and on days 8 after influenza vaccination. Serum samples were stored at – 
80oC until analysis. PBMC were isolated from heparinised venous blood by density-gradient 
centrifugation on lymphoprep. Cells were frozen using a cryo 1o C freezing container 
(Nalgen, Rochester, NY, USA) which was put in -80oC for 24h, in freezing medium consisting 
of 45% RPMI 1640 (Cambrex Bio Science, Verviers, Belgium), 5% HS, 40% human serum 
albumin and 10% DMSO (final concentration, Sigma). Vials were stored in liquid nitrogen 
until use.
Antibody response on influenza vaccination
The antibody response upon vaccination was measured by the hemagglutination 
inhibition (HI) test with the three influenza strains of the vaccine as described previously.38 
Antibody titers were determined at baseline, on day 8 and day 22 after vaccination. 
Seroprotection was defined as antibody titer of >40.31,28 Subjects were considered fully 
protected if they had protective titres to all three viral strains, partially protected when 
having protective titers only to one or two serotypes and non-protected when titers were 
<40. Post-vaccination seroresponses were defined as a significant (≥4-fold) increase in 
titers.31 The results of the tests were compared between all four groups as well as 
between patients treated with sunitinib or sorafenib and the two control groups. 
Cellular immune response on influenza vaccination
Analytical assays to measure the full range of T cell responses against influenza virus have 
been extensively documented.39 For our study, PBMC samples collected at baseline and 
post-vaccination (day 8) were simultaneously thawed and batch-processed to test 
lymphocyte proliferation, lymphocyte activation and cytokine secretion. For analysis of 
lymphocyte proliferation and cytokine secretion, 1.5 x 105 PBMC were added per well in 
200 µl culture medium (RPMI 1640 supplemented with 7% pooled human serum) and 
incubated with the virus strains (H3N2, H1N1 and B) at a final concentration of 5 µg viral 
protein per ml. Phytohemagglutinin (PHA) stimulation at a final concentration of 1 µg/ml, 
was used as a positive control and a negative control consisted of cells in culture medium 
alone. Stimulation tests were performed in triplicate. After 48 hours supernatant was 
harvested to analyse cytokine production. We used the Th1/Th2 11plex kit (eBioscience, 
San Diego, CA) according to the manufacturer’s protocol to measure the following 
cytokines: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12 (p70), TNF-α, TNF-β, IFN-γ. To measure 
cell proliferation, 3[H]thymidine was added after four days for overnight incubation. 
3[H]thymidine incorporation was measured using a β-counter. Both cytokine production 
and proliferation were calculated as an index in which the outcome with stimulus (PHA or 
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virus) was calculated relative to culture medium alone. For flow cytometric analyses, the 
same conditions were applied with the exception that 1x106 PBMCs were cultured in 1 ml 
of culture medium and cells were harvested after 24 hours. Multi-colour flow cytometric 
analysis was performed with a FACS-Calibur (BD Biosciences, San Jose, CA) using directly 
labeled mAbs against the early activation marker CD69, CD3, CD4 and CD8 (BD Pharmingen, 
San Diego, CA), all according to the manufacturers protocol.
The results of the mean logarithmic lymphocyte proliferation, CD69 expression by CD4+ 
cells and CD8+ cells and the cytokine secretion of PBMC of the patients groups (at 
baseline, on day 8 and the increase from baseline to day 8) were compared to the results 
of the healthy controls.
Tolerability 
The tolerability of the influenza vaccination in patients treated with sunitinib or sorafenib 
and in controls was evaluated using a questionnaire at baseline and on day 22. 
Statistical methods
Given the exploratory nature of this study, group sizes were not based on power 
calculations. Data analysis was performed with the use of SPSS version 16.0. The ANOVA 
and Kruskal-Wallis test were used to compare the four groups on numerical variables and 
simultaneous 95%-confidence intervals for all pair wise differences were estimated using 
Sheffé’s method. The two tailed Fisher’s exact test and the Chi-square test were used to 
compare groups on categorical variables. The increase in titer over time for each group 
and type of virus was analyzed using a linear mixed model with patient as random effect 
to account for the fact that each patient was measured several days (i.e. baseline, day 8 
and day 22). Pearson Correlation Coefficients were used to assess correlations if a 
sufficiently linear association was present. For each type of virus, the t-test was used to 
compare between each patient group and the healthy controls: the baseline values, the 
day 8 values and the change from baseline to day 8 of proliferation of lymphocytes and 
cytokine production (after log-transformation). The baseline values, the day 8 values and 
the change from baseline to day 8 of cytokine production were compared over all three 
types of virus (after log-transformation) between each patient group and the healthy 
controls. To this end, a linear mixed model was used with patient as random effect to 
account for the fact that each patient was measured for these three types of viruses. All 
statistical tests were two-sided and a P value ≤ 0.05 was considered significant. 
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Results 
Patients and controls characteristics
From October 2008 to December 2008, a total of 40 patients and controls were included 
in the study. Twenty-six patients had a diagnosis of mRCC, and 3 of GIST. Sixteen patients 
were treated with sunitinib and 6 patients with sorafenib. Seven non-treated mRCC 
patients and 11 healthy controls were included. At baseline, there were no significant 
differences between the four groups in gender, age, tumor type, hemoglobin concentration, 
and history of influenza vaccination (Table 1). In the sunitinib group, the neutrophil and 
monocyte numbers were significantly lower than in the non-treated mRCC controls. The 
median duration of treatment with sunitinib or sorafenib at the time of vaccination was 
10 months (range 1 – 24) and 4 months (range 1 - 24), respectively. 
Thirty participants (75%) received VaxigripR and 10 (25%) InfluvacR. Serious side effects of 
the vaccinations were not reported by any of the study participants. During a follow-up of 
4 months, none of the participants were admitted to the hospital for influenza-related 
complications. 
Antibody response on influenza vaccination
Vaccination induced a significant increase in HI antibody titers in all four study groups 
(Figure 1, P=0.0001). No significant differences between the groups were observed (Table 
2.). As expected prior to vaccination protective titers were already observed in all four 
study groups. Compared to the controls, the sunitinib- and sorafenib group demonstrated 
similar seroprotection rates against all three virus strains, at baseline and after 
vaccination. Participants who had previously been vaccinated had a significantly higher 
seroprotection rate (P= 0.031) after vaccination. Three sunitinib treated patients had high 
HI titers for the H1N1 virus after vaccination (2560 – 5120, data not shown). There was no 
difference in the duration of sunitinib treatment between those three patients and the 
other sunitinib treated patients. Furthermore, no correlation was observed between the 
duration of sunitinib or sorafenib treatment and the level of the HI antibodies, the 
response rate for each individual virus strain, or the increase in titer from baseline to day 
22 for each virus. As expected, there was no difference in antibody response between the 
InfluvacR and the VaxigripR vaccine.
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Influenza vaccination during VEGFR TKI treatment
Figure 1. Antibody responses to influenza-vaccination. 
Mean antibody titers by hemagglutination inhibition before (day 1) and after vaccination (day 8 and day 22). Antibody 
responses against all three vaccine strains are shown. The dotted line indicates the protective titer cut off value. Error 
bars represent 95% confidence intervals. A significant increase in titers after vaccination is observed in all four studied 
groups (P<0.0001)
Table 2. Hemagglutination inhibition (HI) antibody response 
Healthy 
Controls
Non-treated 
mRCC controls
Sunitinib 
treated patients
Sorafenib 
treated patients
P-value *
N=11 N=7 N=16 N=6
Seroprotection rate 
pre-vaccination 
Frequency % Frequency % Frequency % Frequency %
H3N2 1 9 1 14 4 25 3 50 0.255
H1N1 4 36 3 42 8 50 3 50 0.904
B 6 55 5 71 11 69 4 67 0.859
Protected (all 3 viruses) 1 9 1 14 2 13 2 33 0.580
Seroprotection rate 
post-vaccination
H3N2 7 64 6 86 13 81 4 67 0.628
H1N1 9 82 5 71 14 88 4 67 0.666
B 11 100 6 86 16 100 6 100 0.184
Protected (all 3 viruses) 6 55 3 42 12 75 3 50 0.604
Seroresponse rate 
post-vaccination
H3N2 2 18 4 57 4 25 1 17 0.265
H1N1 4 36 1 14 4 25 1 17 0.704
B 4 36 2 29 5 31 2 33 0.987
Hemagglutination inhibition (HI) antibody response upon vaccination. Values at baseline (before vaccination) and on day 
22 after vaccination. Seroprotection was defined as an antibody titer of ≥40. Subjects were considered fully protected 
if they had protective titres to all three viral strains, partially protected when having protected titers only to one or two 
virus types and non-protected when titers were <40. Post-vaccination seroresponses were defined as a significant (≥ 
four-fold) increase in titer. The results were compared between the groups with the Chi-square test (*)
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Figure 1. Antibody responses after vaccination 
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Chapter 9
Cellular immune responses upon influenza vaccination
In addition to B cell mediated responses as measured by HI antibody titers, vaccination 
also results in a T cell response. Therefore, the proliferative capacity, cytokine secretion 
and the expression of the early activation marker CD69 on T cells were investigated. 
Baseline
Before vaccination, T cells proliferated upon PHA and virus stimulation in all patient 
groups and healthy controls, indicating functional T cells in all study participants 
(Supplementary data Figure 1, PHA data not shown).This proliferation coincided with the 
expression of CD69 on both CD4+ cells and CD8+ cells (Supplementary data Figure 2, 
CD8+ data not shown) and the production of cytokines upon PHA and virus stimulation. 
No differences in PHA- or virus-induced T cell proliferation and CD69 expression on T cells 
were observed between healthy controls and the patients groups (untreated mRCC 
patients and patients treated with sunitinib or sorafenib). However, patients treated with 
sorafenib showed a trend towards lower mean proliferation values in all measurements 
compared to healthy controls (Table 3 and supplementary data Figures 1, PHA data not 
shown).This trend coincided with a lower production of IFN-γ and IL-2 in response to PHA 
in this group of patients (P=0.011, P=0.024, respectively). In addition the baseline mean 
IFN-γ production to all viruses (H3N2,H1N1 and B) showed a significant lower value in the 
sorafenib treated group compared to healthy controls (P=0.004). Unstimulated IFN-γ 
production was also lower in patients treated with sorafenib (P=0.024) (Figure 2).
 
Day 8
After vaccination on day 8 a lower T cell proliferation rate was observed after stimulation 
with PHA (P=0.035), virus H3N2 and virus B in patients treated with sorafenib compared 
to healthy controls (Table 3). Furthermore, the patients treated with sorafenib showed a 
trend towards decreased proliferation values in all measurements compared to healthy 
controls (Table 3 and supplementary data Figure 1) as well as a significantly decreased 
expression of CD69 on CD4+ cells after stimulation with virus H1N1, H3N2 and B (P=0.008, 
P=0.026, and P=0.023, respectively). Compared to healthy controls, patients treated with 
sunitinib also showed a lower mean CD69 expression on CD4+ cells after stimulation with 
virus H3N2 and B on day 8 (P=0.010 and P=0.012, respectively). In all four groups an 
increased IFN-γ secretion of PBMC was observed upon influenza virus exposure in vitro 
(Figure 2). The mean INF-γ production of PBMC in response to all viruses (H3N2, H1N1 and 
B) on day 8 in the sunitinib and the sorafenib treated group showed a significant lower 
value compared to the healthy controls (P=0.023, P=0.002, respectively). The mean IL-10 
production was significantly higher (P=0.044) in the sorafenib treated group (Supplementary 
data Figure 3, PHA data not shown). 
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Chapter 9
Production of IL-4, IL-5, IL-12, and TNF-β after in vitro exposure of PBMC to PHA or virus 
strains was absent or minimal. Results for the secretion of IL-1β, IL-6, IL-8 and TNF-α by 
PBMC following stimulation did not significantly differ between the four groups (data not 
shown). 
After vaccination, a clear positive correlation between the humoral response and 
lymphocyte proliferation upon virus stimulation was observed (Figure 3).
Figure 2. IFN-γ secretion
IFN-γ secretion in supernatants of virus-stimulated PBMC cultures shown for all three vaccine strains before (closed circles) 
and 1 week after vaccination (open circles). Mean IFN-y secretion is indicated by horizontal lines. 
Figure 2. IFN-γ secretion 
H3N2 H1N1 B H3N2 H1N1 B 
H3N2 H1N1 B H3N2 H1N1 B 
Before vaccination 
After vaccination 
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Figure 3. Correlation between humoral and cellular immune responses
 
Correlation between humoral and cellular immune responses within patients. Vaccine specific Antibody-titer (fold increase 
after vaccination) is correlated to the corresponding virus-stimulated PBMC proliferation (fold increase after vaccination). 
Each symbol represents the responses of one patient to a single vaccine specific strain. A significant correlation between 
humoral and cellular immune responses within patients was observed (P=0.009).
Discussion
This is the first study that explores the antibody and cellular immune responses after 
influenza vaccination in cancer patients treated with sunitinib or sorafenib. Our data 
support the use of influenza vaccination in these patients. 
There is evidence that patients with cancer receiving chemotherapy are able to respond 
to influenza vaccination, and because this intervention is safe, inexpensive, and widely 
available, vaccination for seasonal influenza is indicated.31 Prevention of viral infections 
by influenza vaccination in cancer patients adds to the maintenance of quality of life. 
However, very few data are available on the clinical efficacy of influenza vaccination in 
cancer patients; in one study a trend toward decreased morbidity and mortality upon 
vaccination has been observed.31 No data have been reported on the efficacy of influenza 
vaccination in cancer patients receiving tyrosine kinase inhibitors, such as sunitinib and 
sorafenib. This appears relevant since these agents are being used with increased 
frequency and are known to have immunosuppressive effects that are different from 
chemotherapy.
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Figure 3. Correlation of humoral and cellular immune responses 
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We show that cancer patients treated with sunitinib or sorafenib are able to mount an 
antibody response upon a single shot of influenza vaccine which is comparable to healthy 
controls and non-treated mRCC controls. The cellular immune responses on influenza 
vaccination were decreased in patients treated with sorafenib. However, in the sunitinib 
treated group we observed a cellular immune response mainly comparable to healthy 
controls. Controls and patients who showed a good antibody response on vaccination 
also demonstrated a good cellular response and vice-versa, which illustrates the 
consistency of our findings.
Some differences in our results between the immune responses in patients treated with 
sunitinib versus sorafenib warrant further discussion.
First, the cellular data showed lowest proliferative capacity in patients treated with 
sorafenib. This coincides with inhibition of CD69 expression and is in line with the data 
described previously.18 In contrast, we observed normal PBMC proliferation in patients 
treated with sunitinib. Our findings of a normal T cell proliferative capacity in sunitinib 
treated patients differs from the results of an earlier study in which a decreased 
proliferation was observed.19 A possible explanation is that in that study the assays were 
performed in the presence of sunitinib while we used pooled human donor serum which 
was free of TKI inhibitor.
Second, PMBC from patients treated with sorafenib produced less IFN-γ and more IL-10 
compared to healthy controls, suggestive for a shift towards a Th2 response. In contrast, 
we observed that PBMC from patients treated with sunitinib before vaccination produced 
IFN-γ levels comparable to healthy controls suggesting a shift to a Th1 response. One of 
the reasons to include the non-treated mRCC patients is that mRCC patients have a shift 
from a Th1 to a Th2 response.9,10 Previous studies suggest a modulating role for sorafenib 
and sunitinib on the Th1/Th2 balance. For sunitinib, a shift towards a Th1 immune 
response after treatment has been reported,6,22,23 while for sorafenib the data are more 
in line with a shift to a Th2 immune response.17,18,21 In this study after in vivo stimulation 
of the immune system with an influenza vaccination, we obviously confirmed a more 
pronounced Th2 response in patients treated with sorafenib whereas we observed some 
clues for a more prominent Th1 response in the sunitinib treated patients. 
A possible explanation for the difference in the immune-modulating effects of sorafenib 
and sunitinib is that although these agents both inhibit VEGFR and PDGFR, only sorafenib 
inhibits the RAF/MEK/ERK pathway.15 ERK1/2 plays a central role in natural killer (NK) cell 
cytotoxicity and cytokine release.40 In vitro pharmacological concentrations of sorafenib 
but not of sunitinib inhibited cytotoxicity and cytokine production of resting and IL-2 
activated PMBC, resulting in lower IFN-y production from NK cells due to impaired P13K 
and ERK phosphorylation.21 
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In summary based on our findings, a single shot of influenza vaccine is safe and effective 
in mounting a protective antibody response in patients treated with sunitinib or sorafenib 
and comparable to that in healthy controls. Therefore, standard influenza vaccination can 
be recommended in these patients. More studies are needed to examine the efficacy and 
safety of other vaccines like hepatitis A, B or yellow fever in these patients and to explore 
the effects of sunitinib and sorafenib on the immune response.  
 
Supplementary data Figure 1. Cellular proliferation
Proliferation of virus-stimulated PBMC cultures shown for all three vaccine strains before (closed circles) and 1 week 
after vaccination (open circles). 
 
Before vaccination 
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Supplementary data Figure 2. CD69 expression on CD4+ cells
CD69 expression on CD4+ cells derived from virus-stimulated PBMC cultures shown for all three vaccine strains before 
(closed circles) and 1 week after vaccination (open circles). Mean percentage of CD4+ cells that express CD69 is indicated 
by horizontal lines. 
 
Supplementary data Figure 3. IL-10 secretion
IL-10 secretion in supernatants of virus-stimulated PBMC cultures shown for all three vaccine strains before (closed circles) 
and 1 week after vaccination (open circles). Mean IL-10 secretion is indicated by horizontal lines. 
Before vaccination 
After vaccination 
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Summary
Targeted therapies are a relatively new class of drugs that are specifically directed against 
one or more well-defined molecular targets that are relevant for tumor growth and 
metastasis. One of the most successful drugs in this class is directed against the vascular 
endothelial growth factor (VEGF) or its receptor (VEGFR). 
Although their mechanism of action is more tumor-specific compared to standard 
chemotherapy, treatment with targeted drugs is still associated with adverse events (AEs). 
The etiology of many of these AEs has not been clarified, which complicates their 
treatment. AEs may have a negative impact on the quality of life (QoL) of a patient. Since 
targeted drugs may be indicated for a prolonged period of time, i.e., sometimes for years, 
in patients, which cannot be cured, increased knowledge on this topic is urgently required. 
In this thesis we investigated three oral targeted drugs sunitinib, sorafenib and cediranib. 
These three tyrosine kinase inhibitors (TKIs) are directed against the VEGF receptor (VEGF 
TKIs). 
The aim of this thesis was to provide better insight in treatment-related aspects of VEGFR 
TKIs like, diarrhea, cognitive- and immune functioning and to assess the effects of these 
drugs on patient-reported outcomes as fatigue, QoL and depression. Additionally, the 
palliative effects of a VEGFR TKI on malignant effusions were explored (Chapter 1). 
In Chapter 2 an introduction on targeted therapy is presented. Targeted therapies can be 
divided into two groups: the monoclonal antibodies, binding to the extracellular part of 
the receptor or their ligand, and the small molecules, which inhibit the tyrosine kinase 
activity of the intracellular part of the receptor. An overview of the most common toxicities 
of the targeted agents is given. In order to minimize side effects, one should be aware 
that many agents are metabolised in the liver by the CYP3A4 cytochrome P450 enzyme 
system. Several other drugs are substrates (metabolized in the liver by CYP3A4), inducers 
or inhibitors or mixed inhibitors/inducers of the CYP3A4 enzyme. Drugs metabolized by 
the CYP3A4 enzyme system may compete with each other, leading to increased plasma 
concentrations of one or both drugs. Drugs known to induce CYP3A4 levels may decrease 
therapeutic levels of the targeted therapy. Since the publication of the paper in 2007, 
many news drugs have been registered with different targets and side effects, an overview 
of current registered drugs in The Netherlands is also presented. 
Fatigue depression and QoL 
In Chapter 3 we explored the incidence, cause and course of self-reported fatigue in 
patients treated with the VEGFR TKIs sunitinib and sorafenib, its relation with QoL and 
depression, and its possible predictive value for treatment outcome. A prospective trial 
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was conducted in 74 patients with metastatic renal cell carcinoma (mRCC), gastro 
intestinal stromal tumors (GIST ) or hepatocellular cancer (HPC) starting treatment with 
sunitinib or sorafenib. Fatigue was measured by the Checklist Individual Strength (CIS20r), 
the European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire (EORTC-QLQ-C30) for QoL and the Beck’s depression inventory for primary 
care (BDI-PC) for depression. During the study the three questionnaires were repeatedly 
send to the patients. We found that even before start of the VEGFR TKIs treatment, 36% 
of the patients were severely fatigued and 18% depressed. Compared to non-severely 
fatigued patients, severely fatigued patients reported a lower QoL, more cancer related 
symptoms, more feelings of depression, were less physical active and had more problems 
with role- emotional- and social functioning. The severely fatigued patients were younger, 
had signs of more disease activity (higher CRP and calcium and lower Hb) and had a 
shorter time from diagnosis and metastasis to start of the treatment. We also found that 
severe fatigue, depression and a low global QoL at baseline were predictive for the time 
on VEGFR TKI treatment. Severe fatigue and depression were also predictive for a worse 
overall survival. At 4 and 16 weeks of treatment, a significant increase in fatigue was 
observed. In patients still on treatment at 28 weeks, the prevalence of severe fatigue 
(19%) and depression (5%) was low and the global QoL above median, probably because 
these are selection of the fit and responding patients. In conclusion, the results of our 
study suggest that VEGFR TKIs have a small but significant negative impact on fatigue 
mostly during the first months of treatment, but the activity of the cancer self seems to 
have the most important negative influence on fatigue, QoL and depression. 
Cognitive functioning
In Chapter 4, two patients are described with psychotic symptoms during treatment with 
sunitinib. These symptoms were interpreted as a neuropsychiatric adverse reaction to 
sunitinib. All psychotic features disappeared within 1 week after discontinuation of 
sunitinib, which is in line with the half-life elimination time of sunitinib. Studies have 
shown that VEGF levels are decreased in the prefrontal cortex of schizophrenia patients 
and that antipsychotics increase brain VEGF levels. Our cases show that sunitinib may 
cause psychosis in ways similar to those observed in schizophrenia namely by inhibition 
of the VEGF receptors.
In Chapter 5 we present the results of a cross-sectional study on the objective and 
subjective cognitive function of patients during treatment with the VEGFR TKIs sunitinib 
and sorafenib. Three groups of participants, matched on age, sex and education, were 
enrolled: mRCC or GIST patients treated with sunitinib or sorafenib (VEGFR TKI patients n= 
30); patients with mRCC not receiving systemic treatment (patient controls n=20); healthy 
controls (n=30). Sixteen neuropsychological tests examining the main cognitive domains 
(intelligence, memory, attention and concentration, executive functions and abstract 
132
Chapter 10
reasoning) were administered by a neuropsychologist. Four questionnaires were used to 
assess subjective cognitive complaints, mood, fatigue and psychological well-being. We 
found that both patient groups performed significantly worse on the cognitive domains 
Learning & Memory and Executive Functions compared to healthy controls. However only 
the VEGFR TKI patients showed impairments on the Executive subdomain Response 
Generation. On self-reported psychological well-being, subjective cognitive complaints, 
depressive symptoms and fatigue, both patient groups reported significantly more 
complaints compared to the healthy controls. Our data suggest that effect sizes of 
cognitive dysfunction in patients using VEGFR TKIs are larger on the Domains Memory & 
Learning and Executive Functions, compared to patient controls. We found no differences 
in the results of the neuropsychological tests or the questionnaires between the VEGFR 
TKI patients and the patient controls. This result may have been affected by the smaller 
size of the patient control group. Longer duration of treatment with VEGFR TKI was 
associated with a worse score on Working Memory tasks. We also examined factors that 
may influence cognitive function in these patients by analyzing blood samples. In the 
VEGFR TKI patients higher levels of ESR, CRP and neutrophils were associated with worse 
objective cognitive functioning, and higher levels of ESR, CRP en LDH with depressive 
symptoms. Our results show that treatment with VEGFR TKIs has a negative impact on 
cognitive functioning, and that subjective complaints can be corroborated by objective 
neuropsychological testing. For clinical practice it is important that physicians, nurses and 
patients are aware of the possibility of cognitive changes during treatment with VEGF 
TKIs, in order to monitor patients and adjust doses when necessitated by symptoms of 
cognitive impairment.
Diarrhea
In Chapter 6 we describe a patient with a clear cell mRCC and a history of Crohn’s disease 
treated with sunitinib, who developed a severe exacerbation of Crohn’s disease. After a 
rechallenge with sunitinib a second exacerbation occurred. Although the exact 
pathogenesis of Crohn’s disease remains unknown, the involvement of angiogenesis is 
acknowledged. We conclude that angiogenesis inhibitors should be administered with 
care in patients with a history of Crohn’s disease. 
In Chapter 7 we report the results of an explorative cross-sectional study. The aim of this 
study was to gain insight in the underlying pathophysiological mechanism of diarrhea 
during VEGFR TKIs treatment. We therefore performed an endoscopy of the upper and 
lower gastrointestinal (GI) tract with biopsies in ten patients with mRCC who developed 
diarrhea during treatment with VEGFR TKIs. 
During endoscopy normal mucosa in the lower GI tract was seen in seven patients without 
signs of ischemic colitis or inflammation. Gastroduodenoscopy revealed gastro-esophageal 
reflux disease, bulbitis and/or duodenitis with ulcers in eight patients. In three selected 
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patients with bulbitis/duodenitis additional video capsule endoscopy was performed but 
revealed no additional intestinal abnormalities. In conclusion, this study did not result in 
the definitive explanation of the pathophysiological mechanism underlying the diarrhea 
in patients treated with VEGFR TKIs. However as unexpected results, we found mucosal 
abnormalities such as erosions and ulcers in esophagus, stomach and duodenum in the 
majority of patients. Based on these results, we recommend routine gastroduodenoscopy 
in patients treated with VEGFR TKIs who report gastrointestinal symptoms, in order to 
timely diagnose and treat these abnormalities.
Malignant ascites and pleural effusion
We conducted an open label, randomized investigator-initiated phase II trial to determine 
the effect and safety of the oral VEGR TKI cediranib as palliative treatment of malignant 
ascites or pleural effusion. The results of this study are presented in Chapter 8. After a 
baseline paracentesis or thoracentesis (day 0), patients with symptomatic malignant 
ascites and/or pleural effusion were randomized between immediate treatment with 
cediranib (ITC) or delayed treatment with cediranib (DTC) on day 29, or any earlier if a new 
puncture was required prior to day 29. The starting dose of cediranib was 30 mg orally 
once daily. The primary objective of the study was the puncture-free survival, defined as 
the time from study start (day 1) to the first indication for paracentesis or thoracentesis, 
or time to death, which event occurred first. Secondary objectives of the study were the 
change in puncture-free interval, defined as the difference between the puncture-free 
survival and the puncture-free interval before start of the study in days) and the tolerability 
of cediranib. Twelve patients were enrolled. The median puncture-free survival was 45 
days (range 10 - 368 days) in the ITC patients and 7 days (range 4 - 13) in the DTC patients 
(P=0.011). The puncture-free interval increased with a median of 31 days in the ITC 
patients and shortened with a median of 3 days in the DTC patients (P=0.015). Cediranib 
was well tolerated in this group of terminally ill patients; the most common observed 
adverse events were fatigue and anorexia. We planned to enroll 32 patients but the study 
was prematurely discontinued due to slow accrual. We conclude that the oral VEGF TKI 
cediranib increased the puncture-free survival and puncture-free interval in patients with 
malignant ascites or pleural effusion with an acceptable toxicity and that an oral anti-
VEGFR treatment may be considered as palliative treatment in patients with malignant 
effusions.
Influenza vaccination
In Chapter 9 the results are presented of an open-label, single center study in which 
sunitinib- or sorafenib-treated cancer patients were vaccinated against seasonal influenza 
with an inactivated vaccine. The primary objective of this study was to investigate the 
antibody response upon influenza vaccination. Secondary objectives were to investigate 
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cellular immune responses and tolerability of vaccination. Antibody responses were 
measured at baseline, day 8, and day 22 by a standard hemagglutination inhibition assay 
and cellular T-cell responses at baseline and day 8 by a proliferation assay and secretion 
of cytokines. Forty subjects were enrolled: 16 mRCC patients treated with sunitinib, 6 
patients with sorafenib (22 VEGFR treated patients), 7 nontreated mRCC controls, and 11 
healthy controls. All patients treated with sunitinib and sorafenib achieved seroprotection 
rates comparable with controls. Functional T-cell reactivity was observed in all groups, 
except for patients treated with sorafenib who showed a decreased proliferation rate and 
IFN-gamma/IL-2 production and increased IL-10 compared with healthy controls. We 
conclude that a single influenza vaccination is safe and effective in mounting an antibody 
and cellular immune response in patients treated with sunitinib or sorafenib, and the 
induced immune response is comparable with healthy controls. Standard influenza 
vaccination can be recommended for these patients. 
General discussion and future perspectives 
In this thesis we investigate several aspects of the treatment of the VEGFR TKIs sunitinib, 
sorafenib and cediranib. Since these agents are relatively new the knowledge about their 
side effects is still incomplete. We focused on fatigue, depression, QoL, cognitive 
functioning and diarrhea. Furthermore we investigated the safety and efficacy of influenza 
vaccination in patients during treatment with sunitinib and sorafenib. Lastly, we explored 
the use of VEGFR TKIs in the symptomatic treatment of malignant ascites and pleural 
effusion. 
Fatigue depression and QoL
Our own observations are that treatment with VEGFR TKIs is better tolerated and have 
better outcomes in patients with a good performance status without clinical symptoms of 
disease, and that most side effects usually occur during the first 3 treatment cycles and 
improves after that. These observations are confirmed in the study. The results of our 
study suggest that severe fatigue, a low global QoL and depression mainly reflect disease 
activity. This is supported by the findings that severe fatigue, depression, and low global 
QoL at baseline were predictive for a shorter time on treatment and severe fatigue and 
depression were predictive for a shorter overall survival. This is in accordance with other 
studies, in which self-reported QoL in several advanced solid tumors and in mRCC patients 
on sorafenib and sunitinib appeared to be predictive for progression free survival1,2 and 
even overall survival.3,4 No data are available about the predictive value of the CIS-fatigue 
and BDI. 
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We observed an increase in fatigue at 4 and 16 weeks of treatment, but at 28 weeks the 
percentage of severely fatigued and depressed patients was low. Results of a retrospective 
analysis of a phase III trial (sunitinib versus interferon-α as first line treatment in mRCC 
patients) showed a comparable pattern on fatigue.5 In our own trial on cognitive 
functioning a prolonged treatment on VEGFR TKIs was also associated with less complaints 
of fatigue.6 
The results of our study contribute to further knowledge on the mechanism of fatigue and 
its relation to QoL, disease-related symptoms and depression in cancer patients treated 
with VEGFR TKIs. Assessment of all patients before start of VEGFR TKI treatment with the 
CIS20r, BDI and EORTC QlQ-C30 should be considered to identify severely fatigued and 
depressed patients. This may allow the selection of patients suitable for physical activity 
programs and evidence-based psychological interventions for fatigue and depression to 
improve QoL. Additionally, these baseline values might help to predict OS and the 
duration of time patients will stay on treatment and therefore may be helpful to inform 
and select patients before start of a VEGFR TKI treatment to set realistic expectations. 
New studies, preferably large multicentre trials in mRCC patients only, are warranted to 
confirm these findings and to investigate the cause of fatigue, and the value of baseline 
CIS-fatigue, global QoL and BDI values compared to acknowledged predictive tools 
(Database Consortium model7,8, MSKCC model9).
Cognitive functioning
Our study is the first to examine cognitive functioning and subjective cognitive complaints 
in cancer patients during treatment with VEGFR TKIs. No other studies have been 
published on this topic, a French longitudinal study on fatigue, QoL and cognitive functions 
in mRCC patients with antiangiogenic treatment was closed prematurely due to poor 
accrual.10 Our results indicate that treatment with VEGFR TKIs has a negative impact on 
cognitive functioning. Furthermore, our data suggest that markers of systemic 
inflammatory response, which probably reflect tumor activity, are correlated with worse 
cognitive performance and more depressive feelings in patients treated with VEGFR TKI. 
This is consistent with the work of others who found that higher CRP levels were associated 
with depression and worse cognitive functioning,11,12 and consistent with our own findings 
that depression is predictive for overall survival and time on treatment (Chapter 3). The 
role of VEGF in cognitive functioning is still unclear. The results of our study should be 
confirmed in a longitudinal study. Our findings warrant further studies on the underlying 
mechanism of the impairment of cognitive functioning during VEGF TKI therapy, for 
example with functional imaging such as dynamic MRI imaging. 
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Diarrhea
Data on the pathophysiology of VEGFR TKIs-induced diarrhea are lacking. We hypothesized 
that the diarrhea might be due to ischemia in bowel mucosa or inflammation but neither 
endoscopic evaluation showed macroscopic signs of ischemia, nor did (immune)
histological examination. Additionally, the results of this study did not give any indication 
that inflammation is involved in the pathogenesis of the diarrhea. As far as we know, no 
other prospective studies in which endoscopy was performed have been published. A few 
case reports have been published on ischemic colitis and perforation after treatment with 
bevacizumab and VEGFR TKIs.13-17 Another study, in eight patients treated with sorafenib, 
showed that the diarrhea and hypophosphatemia was due to a pancreatic exocrine 
dysfunction.18 Pancreatic exocrine dysfunction leads to malabsorption, as well as other 
disorders such as celiac disease, lactose intolerance and short bowel syndrome. A 
malabsorption syndrome could explain the macrocytosis, vitamin B12 deficit19 and weight 
loss despite a normal caloric intake, which often develops in patients who are treated 
with VEGFR TKIs. Because of the nature of this study, we were not able to investigate non-
mucosal diseases such as pancreatic exocrine dysfunction. Further research is necessary 
and should be aimed at the cause of diarrhea (non-mucosal disease), treatment modalities 
and the possible relation with acid related abnormalities. 
Malignant ascites and pleural effusion
The effect of VEGFR TKI treatment on ascites and pleural effusion has not been investigated 
before. We show a beneficial palliative effect of VEGFR TKI treatment on malignant ascites 
and pleural effusion. Although the number of patients was limited we observed that 
cediranib treatment resulted in a significant and clinically relevant prolonged time to 
paracentesis of malignant effusions. Our results are in line with the outcomes of the 
phase II/III trial with intraperitoneal infusions with catumaxomab, a trifunctional bispecific 
antibody directed against the epithelial cell adhesion molecule (EpCAM),  for the treatment 
of malignant ascites in epithelial cancer.20 Given the palliative setting and the poor 
prognosis of patients with malignant effusions, cediranib may have the proper 
characteristics of an effective and tolerable palliative treatment, especially because of its 
oral administration and the short elimination half-life which allows careful titration. The 
effects of cediranib on malignant effusions are probably a class effect of all VEGF TKIs. 
Although confirmation of our results by a larger prospective placebo-controlled trial 
would be preferred, in our experience the feasibility in terms of patient accrual rate is 
low. Our data suggest that an oral anti-VEGFR treatment may be considered as palliative 
treatment in patients with malignant effusions. 
137
Summary, general discussion and future perspectives
Influenza vaccination
Prevention of viral infections by influenza vaccination in cancer patients adds to the 
maintenance of QoL.  However, the safety and efficacy of vaccination in cancer patients 
treated with VEGFR TKIs is unknown, and these agents are known to have 
immunosuppressive effects that are different from chemotherapy. We show that cancer 
patients treated with sunitinib or sorafenib are able to mount an antibody response upon 
a single shot of influenza vaccine, which is comparable with healthy controls and non-
treated mRCC controls. Only one other trial investigated the effects of influenza 
vaccination in patients on targeted therapy and confirmed our results.21 In this trial 65 
patients on cytotoxic agents and/or targeted therapies were included and received two 
doses of the influenza A H1N1v vaccine, 9 patients were on targeted therapies only 
(bevacizumab, trastuzumab, erlotinib or sunitinib). Targeted therapies associated with 
cytotoxic drugs did not seem to affect immunogenicity. Patients on targeted therapy 
alone, especially multikinase inhibitors have better results than other groups. Therefore, 
standard influenza vaccination can be recommended for these patients. More studies are 
needed to explore the specific and different effects of sunitinib and sorafenib on the 
immune response.
In conclusion
The availability of targeted agents as a new class of anticancer drugs requires a novel 
approach compared to the use of classic chemotherapy. Targeted drugs have different 
dynamics and a different mode of action and toxicity profile. Moreover, since these drugs 
are used in the palliative setting often for prolonged periods of time, any adverse event, 
including those of low grade (i.e., grade 1-2 AE (CTC)), do require attention, and maximal 
efforts should be made to minimise adverse events that influence QoL. Our studies 
contribute to a better understanding of the prevalence and aetiology of VEGFR TKI-
induced side effects, and should result in a more optimal selection, monitoring and 
guiding of patients. 
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Als genezing niet meer mogelijk is, komen patiënten met kanker in de palliatieve fase van 
hun ziekte. Het doel van een behandeling in deze fase is het nastreven van een zo hoog 
mogelijke kwaliteit van leven voor de patiënt. In de palliatieve fase zijn vaak nog 
verschillende antikankerbehandelingen mogelijk die het leven kunnen verlengen met 
behoud, of soms zelfs verbetering van kwaliteit van leven. Wanneer er geen 
antikankerbehandeling meer voorhanden is, kan behandeling van klachten en 
ondersteuning van de patiënt en zijn naasten bijdragen aan de kwaliteit van leven. 
Systemische antikankerbehandelingen kunnen onderverdeeld worden in verschillende 
groepen zoals chemotherapie, hormonale therapie, immunotherapie en de zo genoemde 
doelgerichte therapie (Engels: targeted therapy). Doelgerichte therapie is een relatief 
nieuwe vorm van behandeling met medicijnen die de celdeling van kankercellen remt of 
kankercellen doodt. Doelgerichte therapie maakt gebruik van specifieke groeimechanismen 
van de kankercellen. Een van de mechanismen is het vermogen van de kankercel om 
nieuwe bloedvaten te laten groeien naar de tumor toe, dit proces wordt angiogenese 
genoemd. Deze bloedvaten zijn nodig om zuurstof en bouwstoffen naar de cel te 
vervoeren en afvalstoffen af te voeren, zonder bloedtoevoer kunnen de cellen niet 
groeien en/of delen. De kankercel kan een stofje aanmaken (groeifactor) wat vasculaire 
endotheliale groei factor (VEGF) heet. Wanneer dit VEGF zich hecht aan zijn specifieke 
receptor, de VEGFreceptor (VEGFR) dat zich op het oppervlakte van een bloedvatcel 
bevindt, gaat er een signaal naar de bloedvatcel dat er nieuwe bloedvaten aangemaakt 
moeten worden. Een aantal van de doelgerichte therapieën kan er voor zorgen dat 
bloedvaten in de buurt van de tumor geen signaal krijgen om nieuwe bloedvaten te 
maken, doordat ze de werking van VEGF of de VEGFreceptor blokkeren. Deze doelgerichte 
therapieën worden daarom ook wel VEGF(R)- of angiogeneseremmers, genoemd. 
Tumoren kunnen door doelgerichte therapie stoppen met groeien of zelfs kleiner worden, 
maar ze verdwijnen meestal niet helemaal. Hoewel de doelgerichte therapie gezonde 
cellen minder beschadigt dan bijvoorbeeld chemotherapie, gaat behandeling met 
doelgerichte therapie nog steeds gepaard met bijwerkingen. De oorsprong van veel van 
deze bijwerkingen is nog niet opgehelderd, waardoor de behandeling ervan bemoeilijkt 
wordt. Bijwerkingen kunnen een negatieve invloed hebben op de kwaliteit van leven van 
een patiënt, zeker omdat doelgerichte therapieën vaak gedurende een langere periode, 
soms zelfs jaren, worden gebruikt. Meer kennis over deze bijwerkingen is daarom 
essentieel. 
In Hoofdstuk 1 wordt een inleiding gegeven op het proefschrift en wordt beschreven 
welke onderwerpen in de verschillende hoofdstukken aan bod komen. In dit proefschrift 
hebben we drie medicijnen onderzocht die vallen onder doelgerichte therapie, namelijk 
sunitinib, sorafenib en cediranib. De familie waartoe deze middelen behoren, wordt ook 
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wel de tyrosine kinase remmers (TKIs) genoemd. Binnen de tyrosine kinase remmers 
worden weer verschillende groepen onderscheiden. Sunitinib, sorafenib en cediranib 
vallen daarbij onder de VEGFR remmers, daarom worden deze drie middelen in het 
proefschrift aangeduid met VEGFR TKIs. Het zijn alle drie middelen die in capsule of 
tabletvorm gebruikt worden. 
Bij kankeronderzoek wordt het optreden en de ernst van bijwerkingen van een behandeling 
normaal gesproken door de behandelend oncoloog ingeschat en gerapporteerd. Dit 
gebeurt met behulp van een internationaal scorings systeem (NCI CTCAE). De ernst van de 
bijwerking krijgt een score van I nauwelijks klachten, II milde klachten met een lichte 
hinder in algemene dagelijkse levensverrichtingen (ADL), III ernstige bijwerking maar niet 
levensbedreigend, met een duidelijk negatief effect op de ADL, IV levensbedreigende 
bijwerking, V overlijden ten gevolge van de bijwerking. Het nadeel van het laten scoren 
van de bijwerkingen door de oncoloog, in plaats van door de patiënt, is dat daarbij het 
volledige effect van de bijwerking op de patiënt niet tot zijn recht komt in de score. Dit 
effect is vooral van belang bij bijwerkingen die subjectief zijn zoals moeheid, misselijkheid 
en pijn. Door patiënten zelf gerapporteerde bijwerkingen kunnen ook een meer 
gedetailleerd beeld geven van de bijwerking en het effect op het functioneren en 
welbevinden van de patiënt. 
Het doel van dit proefschrift is om meer inzicht te krijgen in de verschillende aspecten van 
de behandeling met VEGFR TKIs zoals diarree, moeheid, cognitief- en immuun 
functioneren. We onderzoeken wat het effect van deze middelen is op door patiënten 
gerapporteerde uitkomsten over moeheid, kwaliteit van leven en depressie. Daarnaast 
exploreren we wat het palliatieve effect is van een behandeling met een VEGFR TKI op 
vocht veroorzaakt door kanker in de buikholte of in de borstholte. 
In Hoofdstuk 2 wordt een introductie gegeven over doelgerichte therapieën. Doelgericht 
therapieën kunnen worden verdeeld in twee groepen, de eerste groep bestaat uit de 
monoclonale antilichamen die zich binden aan een groeifactor zoals VEGF waardoor deze 
zijn werking niet kan uitoefenen. De tweede groep omvat de kleine moleculen, waartoe de 
TKIs ook behoren, die in de kankercel de activiteit van specifieke eiwitten remmen. Er 
wordt een overzicht gegeven van de meest voorkomende bijwerkingen van deze middelen. 
Moeheid, depressie en kwaliteit van leven 
Moeheid is een van de meest frequent gerapporteerde bijwerkingen van VEGFR TKIs. Zelfs 
een milde moeheid kan een grote impact hebben op de kwaliteit van leven van een 
palliatieve patiënt. De oorzaak van moeheid bij patiënten met kanker en bij patiënten 
onder behandeling met een VEGFR TKIs is nog niet precies bekend, al lijkt het multifactorieel 
te zijn. In Hoofdstuk 3 worden de resultaten van het onderzoek naar moeheid, depressie 
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en kwaliteit van leven beschreven. In deze studie onderzochten we het vóórkomen, de 
oorzaak en het beloop van door patiënten gerapporteerde moeheid, wanneer zij 
behandeld worden met de VEGFR TKIs sunitinib en sorafenib. Daarnaast werd ook gekeken 
wat de relatie was tussen vermoeidheid, depressie en kwaliteit van leven, en de mogelijk 
voorspellende waarde van vermoeidheid op de behandelresultaten. Aan dit onderzoek 
deden 74 patiënten mee die gingen starten met een behandeling met sunitinib of 
sorafenib. Patiënten hadden een uitgezaaide vorm van nierkanker (mRCC), een gastro 
intestinale stromale tumor (GIST) of leverkanker (HPC). Er werden vragenlijsten gebruikt 
om moeheid, kwaliteit van leven en depressie te meten. Vóór start van de behandeling, 
tijdens en na afloop van de behandeling, werden de vragenlijsten op gezette tijden door 
de patiënten ingevuld. 
Onze studie laat zien dat zelfs vóór start van de behandeling met VEGFR TKIs, 36% van de 
patiënten ernstig vermoeid was en 18% depressief. Vergeleken met de niet-ernstig 
vermoeide patiënten, rapporteerden ernstig vermoeide patiënten een lagere kwaliteit 
van leven, meer kankergerelateerde klachten en meer gevoelens van depressie. Daarnaast 
waren ze minder lichamelijk actief en hadden ze meer problemen bij hun emotioneel- en 
sociaal- en maatschappelijk functioneren. De ernstig vermoeide patiënten waren jonger, 
hadden meer tekenen van ziekteactiviteit (hogere ontstekingswaarden en calcium gehalte 
in het bloed, en een lager bloedgehalte) en er zat minder tijd tussen de diagnose van 
uitzaaiingen en het starten van de behandeling met VEGFR TKIs. Verder zagen we dat 
patiënten die vóór start van de behandeling ernstig vermoeid of depressief waren, of 
aangaven dat ze een lage kwaliteit van leven hadden, korter behandeld werden met 
VEGFR TKIs. Patiënten die vóór start van de behandeling ernstig vermoeid of depressief 
waren, hadden ook een slechtere overleving in vergelijking met de niet ernstig vermoeide 
of de niet depressieve patiënten. Na 4 en 16 weken behandeling werd, ten opzichte van 
de meting vóór start, een significante toename in moeheid geobserveerd. In de groep 
patiënten die na 28 weken nog behandeld werd met de VEGFR TKI, was het vóórkomen 
van ernstige vermoeidheid (19%) en depressie (5%) laag, en de ervaren kwaliteit van leven 
hoger dan de mediaan. Waarschijnlijk is dit veroorzaakt doordat het een selectie van fitte 
patiënten betreft waarbij de behandeling aanslaat. Concluderend: de resultaten van deze 
studie suggereren dat VEGFR TKIs een kleine maar significante toename van vermoeidheid 
geven, vooral gedurende de eerste maanden van behandeling, maar dat de activiteit van 
de kanker zelf de meest belangrijke negatieve invloed heeft op moeheid, kwaliteit van 
leven en depressie. 
Cognitief functioneren
Het is bekend dat patiënten die behandeld zijn met chemotherapie problemen kunnen 
ervaren met denken, ook wel cognitieve problemen genoemd. Cognitie betreft de 
hersenfuncties die nodig zijn voor waarnemen, denken, het onthouden van kennis en 
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deze kennis op een goede manier toepassen dan wel begrijpen. De effecten van middelen 
als VEGFR TKIs op het cognitief functioneren waren tot op heden niet onderzocht. Wel 
weten we dat VEGF een belangrijke rol speelt in de hersenen voor aanmaak en herstel van 
hersenweefsel, en ook bij een aantal ziektes van de hersenen zoals een infarct, en de 
ziekte van Alzheimer. 
In Hoofdstuk 4 worden twee patiënten beschreven die, verward raakten met psychotische 
symptomen gedurende de behandeling met sunitinib. De verwardheid verdween binnen 
1 week na stoppen van de sunitinib, wat past bij de tijd die sunitinib nodig heeft om 
afgebroken te worden in het lichaam. We hebben deze verwardheid dan ook 
geïnterpreteerd als een bijwerking van de sunitinib. Studies hebben laten zien dat in een 
bepaald deel van de hersenen van patiënten met schizofrenie de hoeveelheid van de 
groeistof VEGF lager is dan bij gezonde personen en dat medicijnen tegen schizofrenie de 
VEGF hoeveelheid weer kunnen verhogen. De patiënten die wij hebben beschreven, laten 
zien dat sunitinib, op dezelfde manier als bij schizofrenie, een psychose kan veroorzaken, 
namelijk door remming van de VEGF receptoren in de hersenen.
In Hoofdstuk 5 presenteren we de resultaten van een onderzoek naar het cognitief 
functioneren van patiënten die sunitinib of sorafenib gebruiken. De verschillende 
aspecten van het cognitief functioneren worden gegroepeerd in cognitieve domeinen. 
Drie van de belangrijkste hiervan zijn Leren & Geheugen, Attentie & Concentratie en 
Executief functioneren. Onder executief functioneren worden die functies verstaan die 
ervoor zorgen dat andere cognitieve functies gestuurd en gecontroleerd worden, maar 
ook plannen en probleem oplossen. Aan de studie deden drie groepen deelnemers mee 
die gelijk waren wat betreft leeftijd, geslacht en opleidingsniveau. De eerste groep 
bestond uit 30 patiënten met uitgezaaide nierkanker of een gastro intestinale stromale 
tumor die behandeld werden met sunitinib of sorafenib (VEGFR TKI patiënten); de tweede 
groep bestond uit 20 patiënten met uitgezaaide nierkanker die nog geen behandeling 
nodig hadden (de controle patiënten); de derde groep uit 30 gezonde vrijwilligers. De 
deelnemers werden uitgebreid door een neuropsycholoog getest, en vulden een aantal 
vragenlijsten in. Een neuropsycholoog is een psycholoog die gespecialiseerd is in de 
relatie tussen gedrag en de werking van de hersenen. Het doel van de testen en de 
vragenlijsten was om vast te stellen of een deelnemer problemen ervoer met het 
geheugen, concentratievermogen en het verwerken van kennis en in welke mate hij of zij 
er last van had. Wij vonden in onze studie, dat beide patiëntengroepen significant slechter 
presteerden op het gebied van Leren & Geheugen, en Executieve functies, ten opzichte 
van gezonde vrijwilligers. Daarnaast hadden beide patiëntengroepen meer subjectieve 
cognitieve klachten, meer depressieve symptomen en meer last van vermoeidheid, in 
vergelijking met de gezonde vrijwilligers. 
Onze studie uitkomsten suggereren ook dat er in de domeinen Leren & Geheugen en in 
de Executieve functies meer cognitief disfunctioneren wordt gezien in de VEGFR TKI 
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patiënten dan in de controle patiënten, al waren de verschillen niet significant. Ook 
werden er geen significante verschillen gevonden in de uitkomsten van de vragenlijsten 
naar subjectieve klachten tussen de twee patiënten groepen. Dit zou veroorzaakt kunnen 
zijn doordat de groep van de controle patiënten kleiner was dan die van de VEGFR TKI 
patiënten. 
Verder vonden we dat hoe langer patiënten behandeld werden met een VEGFR TKI, hoe 
slechter de score op de testen van het werkgeheugen. Tevens hebben we in dit onderzoek 
gekeken naar factoren in het bloed die mogelijk invloed konden hebben op het cognitief 
functioneren. Bij de VEGFR TKI patiënten vonden we dat waarden passend bij een 
verhoogde ziekte- of ontstekingsactiviteit geassocieerd waren met een slechter cognitief 
functioneren en meer depressieve symptomen. 
Concluderend laten onze uitkomsten zien dat behandeling met VEGFR TKIs een 
verslechtering van het cognitief functioneren geeft. Daarnaast laten we zien dat door de 
patiënt zelf gerapporteerde (subjectieve) klachten bevestigd kunnen worden met 
objectieve neuropsychologische testen. Voor de praktijk is het belangrijk dat artsen, 
verpleegkundigen en patiënten zich bewust zijn van mogelijk veranderingen van cognitief 
functioneren tijdens de behandeling met VEGFR TKIs, zodat patiënten goed gevolgd 
kunnen worden en bij klachten eventueel de medicatie aangepast kan worden. 
Diarree
Alle VEGFR TKIs kunnen als bijwerking diarree geven. Diarree kan een negatief effect 
hebben op de kwaliteit van leven van een patiënt en het kan een reden zijn om de dosis 
van de VEGFR TKI te verlagen of zelfs te onderbreken waardoor de behandeling minder 
effectief is. Adequate behandeling en preventie van diarree is daarom uitermate 
belangrijk. In Hoofdstuk 6 beschrijven we een patiënt met een uitgezaaide vorm van 
nierkanker die bekend is met de ziekte van Crohn (een chronische ontstekingsziekte van 
het spijsverteringskanaal). Deze patiënt werd behandeld met sunitinib. Tijdens deze 
behandeling ontstond er een zeer forse verergering van de ziekte van Crohn. Na een 
periode zonder sunitinib en een tot rust komen van de ontsteking in de darm, werd 
opnieuw de sunitinib herstart. Er ontstond opnieuw een forse verergering van de ziekte 
van Crohn. Hoewel het niet helemaal duidelijk is waardoor de ziekte van Crohn ontstaat, 
wordt aangenomen dat bloedvatnieuwvorming een rol speelt. We concluderen dat 
wanneer een patiënt bekend is met de ziekte van Crohn, voorzichtigheid geboden is bij 
het toepassen van VEGFR TKIs. 
In Hoofdstuk 7 rapporteren we de resultaten van een kleine exploratieve studie bij 10 
patiënten met uitgezaaide nierkanker die tijdens het gebruik van een VEGFR TKI diarree 
ontwikkelden. Het doel van deze studie was om meer inzicht te krijgen in de oorzaak en 
het ontstaan van diarree bij VEGFR TKIs. Bij deze patiënten werd een aantal onderzoeken 
verricht waaronder een onderzoek van de maag en de dunne darm (gastroduodenoscopie) 
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en van een deel van de dikke darm (sigmoidoscopie) waarbij ook weefselhapjes werden 
genomen. Tijdens deze onderzoeken werd bij 7 van de 10 patiënten een normaal slijmvlies 
gezien in de dikke darm zonder tekenen van ontsteking of zuurstoftekort. Wel werd er bij 
8 van de 10 patiënten in de slokdarm, maag, of twaalfvingerige darm een ontsteking 
gezien met ook zweertjes. Concluderend hebben we in deze studie geen definitieve 
verklaring gevonden hoe en waarom de diarree ontstaat bij patiënten onder behandeling 
met een VEGFR TKI. Op basis van de slijmvliesafwijkingen in de slokdarm, maag of 
twaalfvingerige darm die we in een groot deel van de patiënten vonden, adviseren we wel 
om bij patiënten die behandeld (gaan) worden met VEGFR TKIs en maag/slokdarm of 
bovenbuiksklachten hebben een gastroduodenoscopie te verrichten. Dit om tijdig 
slijmvliesafwijkingen te diagnosticeren en te kunnen behandelen. 
Maligne ascites en pleuravocht
Bij sommige patiënten met kanker zitten er ook kankercellen in de buikholte of in de 
longvliezen. Hierdoor kan het zo zijn dat er veel vocht wordt aangemaakt in de buikholte 
of tussen de longvliezen. Wanneer er vocht in de buikholte zit (maligne ascites) kan dit 
klachten geven van een opgezette buik, pijn in de buik, minder eetlust, moeheid, een 
opgeblazen gevoel en soms ook benauwdheid. Wanneer het vocht tussen de longbladen 
zit (maligne pleuravocht) kan dit klachten geven van benauwdheid, pijn op de borst en 
hoesten. Vooral wanneer er geen antikankerbehandeling meer mogelijk of voorhanden is, 
kan dit een vervelend probleem zijn met veel impact op de kwaliteit van leven van de 
patiënt. Hoewel het aftappen van het vocht (puncteren) of plasmedicatie veel toegepast 
wordt in deze situatie, is er geen hard bewijs dat dit ook echt effectieve behandelingen 
zijn. Er is dan ook een grote behoefte aan een effectievere palliatieve behandeling. Bij een 
aantal van onze eigen patiënten hebben we gezien dat tijdens de behandeling met een 
VEGFR TKI maligne vocht verdween. Tevens zijn er bij patiënten met maligne vocht hoge 
waarden van VEGF gevonden in het bloed en in het maligne vocht. Dit heeft ons doen 
besluiten om een studie op te zetten om zo uit te zoeken of het remmen van VEGF met 
een VEGFR TKI een goed palliatief effect heeft op maligne ascites en pleuravocht. De 
resultaten van deze studie worden beschreven in Hoofdstuk 8. Twaalf patiënten met 
maligne ascites of pleuravocht deden mee aan de studie. Bij alle patiënten werd voor 
start van de studie (dag 0) zoveel mogelijk vocht afgetapt. Er werd vervolgens geloot: de 
helft van de patiënten startte meteen met de VEGFR TKI cediranib, terwijl de andere helft 
pas startte met cediranib op dag 29 of eerder, wanneer er een hernieuwde punctie nodig 
was (late start groep) . Het doel van de studie was om de punctievrije overleving te 
bepalen, welke gedefinieerd was als de tijd van dag 1 tot de eerste indicatie tot punctie of 
overlijden, afhankelijk van welke gebeurtenis het eerst zou optreden. Daarnaast werd het 
punctievrije interval bekeken (de tijd tussen twee punctie), en of cediranib goed verdragen 
werd. De mediane punctievrije overleving was significant verschillend tussen de twee 
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groepen met 45 dagen (10 - 368 dagen) in de groep die meteen met cediranib startte, en 
7 dagen (4 - 13 dagen) in de groep die later startte met cediranib. Tevens nam het 
punctievrije interval toe met een mediaan van 31 dagen in de patiënten die direct startte 
met cediranib en werd korter tot een mediaan van 3 dagen in de late groep. Cediranib 
werd goed verdragen in deze groep van terminaal ziekte patiënten; de meest voorkomende 
bijwerkingen waren moeheid en een verminderde eetlust. Concluderend: bij patiënten 
met maligne ascites of pleuravocht zorgt de VEGFR TKI cediranib er voor dat de periode 
dat patiënten niet gepuncteerd hoeven te worden verlengd wordt en dat de tijd tussen 
twee puncties langer wordt. Deze behandeling werd goed verdragen. Een anti VEGFR 
behandeling in tabletvorm zou daarom overwogen kunnen worden als palliatieve 
behandeling bij patiënten met maligne ascites of pleuravocht. 
Influenza vaccinatie
Het doel van een palliatieve behandeling met een VEGFR TKI is de overleving te verlengen, 
maar handhaven of zelfs verbeteren van de kwaliteit van leven is net zo belangrijk. 
Preventie van een ernstige griepinfectie (influenza) met behulp van een vaccinatie (de 
griepspuit) draagt bij aan het handhaven van deze kwaliteit van leven. Mensen boven de 
60 jaar, of mensen met een onderliggend gezondheidsprobleem komen in aanmerking 
voor een preventieve vaccinatie tegen de griep. Dit omdat deze personen tijdens een 
influenza infectie een verhoogd risico hebben op complicaties, verminderd fysiek 
functioneren en zelfs overlijden. Bij patiënten met kanker die behandeld worden met 
chemotherapie is vaccinatie veilig gebleken, Tijdens chemotherapie wordt echter een 
minder goede afweerreactie van het lichaam gevonden, met daardoor een minder goede 
bescherming tegen de griep. Gegevens over de effectiviteit en veiligheid van influenza 
vaccinatie tijdens behandeling met VEGFR TKIs ontbraken nog. Dit is de reden waarom we 
dit onderzocht hebben, de uitkomsten worden in Hoofdstuk 9 gepresenteerd. Veertig 
personen deden mee aan het onderzoek, 22 patiënten die behandeld werden met de 
VEGFR TKIs sunitinib of sorafenib, 7 niet behandelde patiënten met uitgezaaide nierkanker 
en 11 gezonde controles. Alle deelnemers werden met het standaard griepvaccin ingeënt. 
Om te kunnen beoordelen of er een goede afweerreactie ontstond na de griepvaccinatie, 
werd er op verschillende tijdstippen bloed afgenomen. Uit ons onderzoek bleek dat een 
standaard griepvaccinatie veilig en effectief is om een beschermende antilichaamreactie 
op te wekken en dat deze reactie vergelijkbaar is met die van gezonde controle personen. 
Daarom kan de griepprik geadviseerd worden voor deze patiënten. In Hoofdstuk 10 
worden de resultaten samengevat, worden conclusies getrokken en wordt vooruitgeblikt 
op de toekomst.
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In conclusie
De beschikbaarheid van doelgerichte therapieën als een nieuwe klasse binnen de 
antikankermedicijnen, vergt een andere aanpak in vergelijking met klassieke 
chemotherapie. Doelgerichte therapieën hebben een andere dynamiek en manier van 
werking en andere bijwerkingen. Maar vooral omdat deze middelen gebruikt worden in 
de palliatieve setting, en meestal voor een langere periode achter elkaar, verdient elke 
bijwerking, ook de milde, alle aandacht. Maximale inspanningen moeten worden verricht 
om bijwerkingen die invloed hebben op kwaliteit van leven, te verminderen. Onze studies 
dragen bij aan een beter begrip van en het vóórkomen en het ontstaan van door VEGFR 
TKIs geïnduceerde bijwerkingen en zouden moeten resulteren in een meer optimale 
selectie, monitoring en begeleiding van patiënten. 
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Promoveren is net als een taart bakken voor een bijzondere gelegenheid. Je hebt van te 
voren een helder idee voor welke gelegenheid de taart zal zijn, hoe de taart eruit gaat zien 
en welke smaken je er in zou willen hebben. Het unieke recept van deze taart stel je 
samen uit eigen ideeën en bestaande recepten. Je gaat op zoek naar de ingrediënten, 
waarvan er altijd wel een aantal blijken te ontbreken, waardoor het recept wat 
aanpassingen vereist. Uiteindelijk heb je veel te veel vulling gemaakt, waardoor er 
geschrapt moet worden. En dan je tijdsplanning, die leek van te voren heel ruim, maar 
blijkt natuurlijk veel te krap te zijn. Maar na vele uren hard werken, is daar dan toch 
ineens DE Taart, opgebouwd uit allemaal laagjes, heel anders dan bedacht of verwacht, 
maar mooi, lekker en vooral ook: af. 
Aan mijn “Promotie Taart” hebben velen een bijdrage geleverd die ik hierbij hartelijk wil 
bedanken: 
Prof. dr. Pieter de Mulder, betrok mij vanaf het eerste moment dat ik op de afdeling 
Medische Oncologie werkte bij de behandeling van patiënten met nierkanker. Hij gaf me 
kansen,  verantwoordelijkheden en leidde me op, zelfs terwijl we in de lange gang liepen 
onderweg naar de tumorwerkgroep urologie. Dankzij hem heb ik de kans gekregen om 
tijdens de eerste studies met targeted therapy voor patiënten met nierkanker in Nederland 
ervaring op te doen met deze middelen. Een opwindende tijd waarin ineens allerlei 
nieuwe behandelingen mogelijk waren voor een patiënten groep waarvoor jarenlang 
alleen interferon-α een behandeloptie was. Met de komst van nieuwe middelen 
ontstonden er ook weer vele nieuwe vragen en mogelijkheden voor nieuw onderzoek. Na 
het overlijden van Pieter de Mulder is zijn onderzoek naar de behandeling van nierkanker 
voortgezet door prof. dr. Peter Mulders en dr. Carla van Herpen. Ik ben blij en trots dat ik 
met de studies in mijn proefschrift hier ook aan heb kunnen bijdragen. 
De basis voor mijn Promotie Taart is gevormd door prof. Kees Punt en prof. Kris Vissers 
die samen de keuken ingingen en met creativiteit en out of the box denken een werk- en 
promotietraject creëerden, waarbinnen palliatieve zorg en oncologie tot een gezamenlijk 
project versmolten. 
Beste Kees hartelijk bedankt voor alle steun, en de kansen die je me geboden hebt. Je 
talent tot focussen en scherp formuleren heeft me enorm geholpen. Waar ik de neiging had 
om te verdwalen op interessante zijpaadjes of me te verliezen in details, wist jij het onderzoek 
steeds weer terug te brengen naar de kern en onze focus. Wanneer ik het einddoel niet 
meer in zicht had gaf jij me vertrouwen dat het zeker tot een taart zou komen. 
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Beste Kris, jouw tomeloze energie en vermogen om de juiste mensen samen te brengen 
en te enthousiasmeren, heeft grote invloed gehad op mijn periode bij de palliatieve zorg 
en mijn promotie traject. Het was een eer om samen met jou en de andere pioniers het 
Team Ondersteunende en Palliatieve Zorg in het Radboudumc op te mogen zetten en ik 
denk met plezier terug aan onze brainstormavonden. Dankzij jou zijn mooie 
samenwerkingsverbanden ontstaan zoals de studie naar cognitief functioneren met de 
afdeling neuropsychologie. Hartelijk dank voor al je steun!
Mijn copromotor dr. Carla van Herpen, beste Carla, jouw enthousiasme, klinisch 
redeneren, kennis over studies en VEGFR TKIs, maar vooral ook over ‘hoe gaan dit soort 
dingen in een ziekenhuis en tijdens een promotie’, heeft me enorm geholpen. Ik kon je 
altijd bellen of mailen voor raad. Jouw optimistische kijk op hoeveel tijd iets kost om te 
realiseren heeft me soms licht wanhopig gemaakt maar heeft ook tot heel mooie dingen 
geleid. Want als je in augustus bedenkt dat het interessant zou zijn om onderzoek te doen 
naar de griepvaccinatie, die in oktober al gaat plaatsvinden, lijkt dat onmogelijk, maar niet 
voor Carla. En je had gelijk het kon. Al waren onze kooktechnieken niet altijd dezelfde, we 
hebben er samen een goed recept van gemaakt en een prachtige taart, dank voor al je 
hulp!
Alle patiënten, partners van patiënten en vrijwilligers die hebben deelgenomen aan de 
studies wil ik hierbij hartelijk bedanken, jullie zijn de smaakmakers van de taart! Ook wil 
ik al mijn patiënten bedanken, voor de gesprekken die we samen voeren en gevoerd 
hebben. Jullie vertellen me wat werkelijk belangrijk is in het leven op het moment dat je 
kanker krijgt, en wat kwaliteit van leven dan betekent. Lukt het nog om het leven te vieren 
als je klachten hebt van je ziekte of de behandeling, en wat zijn dan de kersen op je taart. 
Beste leden van de manuscriptcommissie: prof. Smit, prof. Vernooij-Dassen en prof. 
Gietema, hartelijk dank voor het beoordelen van dit proefschrift. 
Mijn onderzoeksmaatjes op het gebied van nierkanker en VEGFR TKIs: dr. Ingrid Desar en 
drs. Marye Boers-Sonderen. Het was fijn om samen met jullie aan het onderzoek te 
werken. We hebben heel wat afgekletst de afgelopen jaren, om te brainstormen, 
frustraties te delen, samen oplossingen te zoeken maar vooral ook gewoon te bespreken 
wat er zoal gebeurt in het leven. Dank voor jullie bijdrage aan mijn onderzoek en vooral 
ook voor de fijne samenwerking. 
Mijn medeauteurs, jullie hebben allemaal je eigen unieke laagje toegevoegd aan mijn 
promotie taart. Allerlei kleurtjes en smaakjes,  want er hebben veel verschillende 
afdelingen in en buiten het Radboudumc bijgedragen aan de studies: urologie, psychiatrie, 
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medische psychologie, anesthesiologie en palliatieve zorg, laboratorium geneeskunde, 
tumor immunologie, pathologie, maag- darm- en leverziekten, longziekten, klinische 
chemie en medische microbiologie. 
Beste prof. Peter Mulders en dr. Hans Langenhuijsen, onze wekelijkse nierkankerbespreking 
zorgt al jaren voor een goede en leuke samenwerking én inclusie in al onze lopende 
nierstudies. Beste prof. Roy Kessels en dr. Dirk Bertens, dankzij jullie hebben we meer 
inzicht gekregen in het cognitief functioneren van patiënten die VEGFR TKIs gebruiken, 
een enorme klus maar met mooi resultaat. Beste prof. Judith Prins, jouw kritisch inbreng 
in onze studie naar kwaliteit van leven en vermoeidheid was onontbeerlijk, oncologen en 
medisch psychologen blijken op een heel andere manier naar vermoeidheid te kijken. Dr. 
Arnt Schellekens en dr. Philip van Eijndhoven, dank voor jullie analyse bij de patiënt met 
een psychose tijdens behandeling met sunitinib. Beste dr. Hans Jacobs, jij wist de 
ingewikkelde immunologie voor mij begrijpelijk te maken, en hebt bergen werk verricht 
op het lab samen met Michel Olde Nordkamp. Ook bij het berekenen en interpreteren van 
de gegevens heb je me enorm geholpen samen met prof. Jolanda de Vries, dr. Ruurd 
Torensma en prof. Joep Galama. Beste prof. Iris Nagtegaal, dr. Geert Wanten, dr. Frank 
Hoentjes en drs. Lauranne Derikx jullie enthousiaste en kritische commentaar hebben 
bijgedragen aan het onderzoek naar diarree en colitis. Beste dr. Erik van der Heijden, 
hartelijk dank voor je aandeel in de studie naar maligne pleuravocht. Vooral ook bedankt 
voor het altijd snelle en kundige advies wat ik van je krijg als er een patiënt is met een 
endobronchiale tumor. Jouw endoscopische interventies hebben al heel wat patiënten 
een verbetering van hun kwaliteit van leven gegeven. 
De onderzoeken waren niet mogelijk geweest zonder de samenwerking met het klinisch 
chemisch laboratorium en de analyse van de bloeduitslagen door dr. Teun van 
Herwaarden, dank daarvoor. Beste dr. Dick-Johan van Spronsen, als co-assistent zat ik in 
Eindhoven al bij je op de afdeling, en toen je een baan kreeg aangeboden in het CWZ kon 
ik op jouw plaats beginnen in het Radboudumc. Dank voor je bijdrage aan de studies, 
hopelijk kunnen we in de toekomst onze samenwerking verder uitbreiden op het uro-
oncologische gebied. 
Beste dr. Tineke Smilde (of Tineke Smile zoals je heel toepasselijk in mijn telefoon staat), 
in 1999 hadden we samen een weekenddienst voor de interne geneeskunde, jouw 
enthousiasme voor het vak was zo aanstekelijk en droeg bij aan mijn uiteindelijke keuze 
voor de opleiding tot internist. Het is altijd een feest om met je samen te werken. 
Mijn collega’s van de medische oncologie: Stans Verhagen, Nelleke Ottevanger, Carla van 
Herpen, Ingrid Desar, Winald Gerritsen, Suzanne Kaal, Sandra Radema, Rutger Koornstra, 
Winette van de Graaf, Anja Timmer-Bonte, Rene van Hoesel, Eveline Kuip, Koos van der 
Hoeven en alle fellows en onderzoekers. Dank voor jullie collegialiteit en flexibiliteit 
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waardoor ik de gelegenheid heb gekregen om aan mijn onderzoek te werken. En niet te 
vergeten de fijne gesprekken al dan niet over werk. 
Erik Lambeck dank je voor het altijd creatief meedenken op zoek naar tijd en financiën 
voor mijn onderzoek. 
Fred Witjes, Peter Mulders, Toine van der Heijden, Hans Langenhuijsen, Michiel Sedelaar, 
en Inge van Oort,  mijn Uroboys en Girl. Na het overlijden van Pieter hebben jullie mij, een 
net-uit-het-ei gekomen oncoloog, onder de vleugels genomen en mij verder uro-
oncologisch opgeleid, dank daarvoor. Met jullie samenwerken, onderzoek doen of op 
congres gaan is inspirerend, verhelderend, plezierig en altijd met humor en een flinke 
dosis testosteron. 
Oud collega’s van het Team ondersteunende en Palliatieve Zorg: Kris Vissers, Stans 
Verhagen, Jeroen Fokke, Dirk van Diejen, Kees Besse, José Jacobs, Floor Kooymans, Henny 
Rongen-Hesselmans, Nicole Verwaaijen en Anneke Brand-Timmer ten Wolde. Het werken 
binnen het team van de palliatieve zorg voelde als een warm bad, dank voor jullie goede 
zorgen en collegialiteit. Twee banen, twee baby’s én een promotietraject tegelijkertijd had 
wat te veel impact op mijn eigen kwaliteit van leven, ik stopte daarom met het werken bij 
de Palliatieve zorg, maar dat lag zeker niet aan jullie.
Dankzij de hulp van dr. Steven Teerenstra, dr. Rogier Donders, Ria ter Winkel en dr. Dennis 
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